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SUMMARY
Proteoglycan 4 (PRG4) is a mucinous proteoglycan with an apparent molecular weight o f -345 
kDa. It has been detected in a variety of tissues including cartilage, tendon, bone heart and liver, 
and is also known as cartilage superficial zone protein (SZP), lubricin, megakaryocyte 
stimulating factor (MSF) precursor protein and camptodactyly-arthropathy-coxa vara pericarditis 
(CACP) protein. PRG4 has been shown to reduce friction in joints, and immunological studies 
have located PRG4 on the surface of articular cartilage, in synovial fluid, on the surface of 
meniscus and on the surface o f mature compressed tendon. PRG4 is involved in the congenital 
joint pathology known as CACP.
Analyses of the PRG4 sequence reveal a propensity for a diverse number o f functions including 
lubrication, matrix-binding, self-aggregation, cytoprotection and cell proliferation. This study set 
out to investigate the potential functions o f the N- (exons 2-5) and C-terminal (exons 7-12) 
structural domains of human and bovine PRG4, facilitated by recombinant protein expression. 
Preliminary results from solid-phase binding assays showed an interaction between the N- 
terminal domain o f PRG4 and plasminogen activator inhibitor-1 (PAI-1), type II collagen and a 
70kDa fibronectin fragment. Im m unoprecipitaion experim ents dem onstrated a potential 
interaction between the PRG4 C-terminal domain and fibronectin fragments. Both the N- and C- 
terminal contain functional heparin binding sites. The C-terminal domain was shown to interact 
with superficial zone chondrocytes, an interaction that was perturbed by heparin.
The study also used purified full-length PRG4 from three sources: human recombinant, bovine 
articular cartilage and bovine tendon. These PRG4 species bound to heparin and displayed 
similar glycosylation profiles. This study also shows that PRG4 is susceptible to degradation by a 
number of matrix proteinases including elastase, plasmin, matrix metalloproteinase-7 and 
cathepsin B.
Collectively, the data presented in this thesis provides novel information concerning the 
biochemistry, susceptibility to digestion and functional capabilities of PRG4.
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1. INTRODUCTION
1.1 Articular Cartilage Morphology
Hyaline articular cartilage is a tissue that has an important role in the mechanics o f the body. It 
transmits weight-bearing forces between long bones and facilitates diarthrodial joint articulation. 
It is an avascular, aneural, hypocellular tissue that is, at skeletal maturity, comprised o f 70% 
water, 20% collagen and 7% proteoglycan (all w/w). It is supported by one type o f mesenchymal 
cell, the chondrocyte. The surface o f articular cartilage is resistant to wear, and the hydrated 
macromolecular mesh of the cartilage matrix aids the dissipation o f forces involved in the loading 
of joints. The surface o f articular cartilage also provides a remarkably efficient lubrication 
mechanism that limits the amount o f friction and wear. It is not surrounded by a basement 
membrane, and has a low level o f metabolic activity in comparison with other tissues.
1.1.1 The Chondrocyte
Chondrocytes are usually found as single cells within lacunae, surrounded by an extensive 
extracellular matrix. They are long-lived cells that do not divide during the course o f normal 
adult life. In mature cartilage, nutrients are obtained by diffusion from the synovial fluid. 
Chondrocytes maintain the integrity o f the cartilage matrix through normal turnover (biosynthesis 
and degradation) o f its constituent macromolecules. To do this they must be able to sense 
changes in matrix composition, either from matrix degradation or the demands placed on the 
cartilage surface, and com pensate by synthesising the appropriate types and amounts o f 
macromolecules. Chondrocytes from the different zones o f articular cartilage differ in size, shape 
and metabolic activity (Aydelotte et al., 1996).
1.1.2 Articular Cartilage Zones
Mature hyaline articular cartilage is a heterogeneous tissue that can be divided into the four 
distinct layers or zones illustrated in figure 1.1 — superficial, middle, deep and calcified. There 
are physiological differences between each zone, however these are not apparent in developing 
cartilage, where the tissue is unstratified and cells are randomly distributed.
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Figure 1.1 — Schematic representation of adult articular cartilage. The diagram illustrates the 
stratified nature of the tissue and the cellular morphology within each zone. From the website of 
the UK Centre for Tissue Engineering (adapted from http://www.ukcte.org/images/cartilage.ipu. 
accessed July 2002).
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The superficial zone is nearest to the articular surface o f cartilage, and consists o f an acellular 
layer and a deeper, cellular layer. The acellular layer is also known as the lamina splendens 
(MacConaill, 1951) and is a thin layer o f amorphous material overlying a sheet o f fine fibrils, 
described in more detail in section 1.8. It has been suggested that in some instances this area 
contains type I collagen (Eyre et a l.y 1978; Duance, 1983). In the cellular layer chondrocytes are 
flattened and lie parallel to the cartilage surface. Compared to other zones within cartilage, the 
superficial zone contains fewer proteoglycans but is relatively rich in collagen and small 
proteoglycans (Buckwalter & Hunzicker, 1999). Dense collagen fibrils also lie parallel to the 
cartilage surface, giving the zone high strength and tensile stiffness. Recent studies have 
suggested that polymorphonuclear (PMN) leukocyte adhesion is inhibited by macromolecules of 
the cartilage surface (Mitani et al.y 2001).
The middle or intermediate zone lies between the superficial and deep zones. Cells in this zone 
are more spherical than those of the superficial zone and are randomly organised. Collagen fibrils 
are thicker than in the superficial zone, though collagen concentration is lower and proteoglycan 
concentration is higher (Buckwalter & Hunzicker, 1999).
Deep or radial zone cells are aligned in columns o f lacunae perpendicular to the cartilage surface. 
This zone has the thickest collagen fibrils but the lowest concentration o f collagen and the 
highest concentration of proteoglycans. Collagen fibrils from this zone pass into the ‘tidemark’ -  
the boundary between uncalcified and calcified cartilage. The zone o f calcified cartilage is the 
borderline between cartilage and the subchondral bone. Chondrocytes within this region are 
smaller and presumed to be less m etabolically active, and have been implicated in the 
development and progression o f osteoarthritis (Oegema & Thompson, 1995).
1.1.3 Matrix Territorial Regions
Within these cartilage zones there are non-uniform regions in the matrix that correspond to the 
areas surrounding chondrocytes. These are known as matrix territorial regions, of which there are 
three types: pericellular matrix, territorial matrix and interterritorial matrix. Pericellular matrix 
surrounds cells, and one or more chondrocytes surrounded by pericellular matrix and an 
enclosing capsule comprises a structural unit known as a chondron (Poole et al.y 1992; Lee et al.,
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1997). Territorial matrix surrounds the pericellular matrix, and these two regions combined 
appear to protect chondrocytes from tissue deformation involved in joint loading. The remaining 
cartilage is termed interterritorial matrix and provides the overall mechanical properties of 
articular cartilage.
1.2 Articular Cartilage Collagens
Different types o f collagen molecules make up a superfamily of matrix proteins that are the most 
ubiquitous structures in the extracellular spaces o f most connective tissues, such as type I 
collagen in skin, tendon and bone, type II in cartilage and type IV in the basal laminae. They 
form a 3-dimensional network of fibres into which proteoglycans and other matrix components 
are trapped. With respect to cartilage, the architecture of these cross-striated fibrils vanes to meet 
specific biomechanical requirements from the surface to the subchondral bone (Bruckner & van 
der Rest, 1994). All collagens contain a stretch o f at least 20 amino acids o f the repeat sequence 
Gly-X-Y where X and Y are often proline and hydroxyproline, respectively. There are 27 distinct 
types of collagen molecules that have been identified thus far, divided into 3 main groups on the 
basis of their structure: fibril-forming, network-forming and FACIT (Fibril-Associated Collagens 
with Interrupted Triple Helices). These groups and their constituent members are shown in table
1.1, along with the collagen molecules that do not fit into the above categories.
The fibril-forming collagens include types I, II, III V and XI, and form organised fibres and 
fibrils that provide structural support. They are synthesised as large precursors and form 1/4- 
staggered fibrils that are stabilised through covalent inter- and intra-molecular cross-links. The 
network-forming family comprises types IV, X and VIII, and form net-like structures by 
associating at the C-terminus to form dimers and at the N-terminus to form tetramers. The FACIT 
family include collagen types IX, XII, XIV, XVI and XIX, and also the recently described types 
XX, XXI and XXII (Koch et al., 2001; Fitzgerald & Bateman, 2001; Koch et a l , 2004). They 
contain two or more short triple-helical domains connected by non triple-helical sequence, and 
link fibrillar collagens with other matrix macromolecules. These collagens are said to serve as 
molecular bridges that are important for the organization and stability o f extracellular matrices 
(Shaw & Olsen, 1991).
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Table 1 .1 -  The tissue distribution and collagen group o f the 27 known collagens.
Collagen group Type Tissue distribution
Fibril forming I Skin, bone, tendon, intervertebral disc
II Vitreous, cartilage, intervertebral disc
III Skin, blood vessels, cartilage, intervertebral disc
V Skin, bone, tendon, intervertebral disc
XI Skin, bone, tendon, cartilage, intervertebral disc
XXIV Developing bone, eye
XXVII Cartilage, stomach, lung, gonad, skin
Network forming IV Basement membrane, stromal region o f  comea
VIII Descem ents’ membrane, endothelial cells
X Calcifying cartilage
FACITs IX Vitreous, cartilage, intervertebral disc
XII Skin, cartilage, intervertebral disc
XIV Skin, cartilage, intervertebral disc
XVI Skin, lung, arterial smooth muscle cells
XIX Basement membrane
XX Corneal epithelium?
XXI Heart, stomach, kidney, skeletal muscle, blood vessels
XXII Tissue junctions (e.g. cartilage-synovial fluid, hair follicle-skin, 
skeletal muscle-heart muscle)
Beaded filaments VI Most tissues, including cartilage
A nchoring f ib r ils  for  
basement membrane
VII Stroma & basement membrane in skin, com ea
Transmembrane XIII Most tissues, including skin and placenta
XVII Skin, muscle
XXIII Prostate carcinoma
New collagens XV Basement membranes in most tissues, placenta, muscle
XVIII Most tissues, especially liver
XXV Precursor o f  CLAC (collagen-like A lzheim er am yloid plaque 
component)
XXVI Testis, ovary
Most of the collagen within articular cartilage is o f type II (90%), whilst types VI, IX X and XI 
are present in smaller amounts (Duance et al., 1999). The collagens o f articular cartilage are 
reviewed in (Eyre, 2002).
1.2.1 Type II Collagen
Type II collagen forms fibrillar networks in articular cartilage, and the thickness of these fibrils 
decreases towards the surface It is a homotrimer o f the composition [a l(II)]3 that is synthesised 
almost exclusively by chondrocytes (Aydelotte & Kuettner, 1988). The chains are secreted as 
procollagen m olecules with noncollagenous N- and C-terminal segments. The C-terminal 
propeptides o f all the fibril-forming collagens are homologous, and together with the C- 
telopeptide region contains the inform ation required for chain selection, association and 
nucleation involved in triple helix formation (Doege et al., 1987). Along with type IX collagen, 
type II collagen forms the major structural architecture of articular cartilage, which was first 
illustrated by the arcade model of Benninghoff in 1925.
1.2.2 Type IX  Collagen
Type IX collagen belongs to the FACIT group, and is a heterotrimer composed o f 3 distinct 
polypeptide chains, [a l( IX )  a2(IX ) a3(IX )]. The molecule has three triple-helical domains 
(COL1 to 3) and four non triple-helical domains (NCI to NC4) numbered from the C-terminus 
(Duance et al., 1999). The domains are stabilised by inter-chain disulphide bonds. The NC3 
domain o f the a2 (IX ) chain can serve as an attachment point for the glycosam inoglycan 
chondroitin sulphate. This is an unusual feature, and the degree o f glycosylation o f collagen IX 
varies between tissues. Collagen IX is found on the surface o f articular cartilage collagen fibrils, 
covalently bound to type II collagen: cross-linking studies have demonstrated a number o f sites 
where covalent bonds form between type IX collagen and type II collagen, or with other type IX 
collagen molecules. This interaction can be seen in figure 1.2, along with the interactions o f the 
other major cartilage collagens. Cartilage contains fibrils comprising of collagen types II, IX and 
XI (Mendler et al., 1989) and the structure is referred to as the collagen II:IX:XI heteropolymer 
(reviewed in Eyre, 2002).
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Figure 1.2 -  H eterotypic cartilage collagen fibril. Schematic diagram showing the potential 
interactions between collagen types II, III, IX and XI in articular cartilage. NC -  noncollagenous 
domain. Adapted from (Duance, 2001)
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1.2.3 Type X I Collagen
A member of the fibril-forming group o f collagens, type XI is found in developing cartilage as a 
heterotrimer of the composition [a l(X I) a2(X I) a3(X I)]. It has two collagenous (triple-helical) 
domains -  COL1 and 2 - and three noncollagenous (non triple-helical) domains -  N CI, 2 and 3. 
The NC2 domain forms a kink in the molecule between the COL1 and COL2 domains. The 
molecule is thought to be partially buried within the heterotypic cartilage fibril, and interacts with 
collagens II and IX as shown in figure 1.2. It also interacts with glycosaminoglycans -  including 
cell-surface species -  and has been found bound to or in close proximity to the chondrocyte 
membrane, implicating the molecule in cell-matrix interactions (Duance et al., 1999). Recent 
work has demonstrated that collagen XI binds to heparin, heparan sulphate and dermatan 
sulphate, and that the chondrocyte-type XI collagen interaction is reduced significantly by pre­
treatment of cells with heparin or heparanases (Vaughan-Thomas et al., 2001). It is thought that 
collagen XI may form an interconnecting filamentous network that provides links between as 
well as within fibrils (Eyre, 2002), consistent with the concept that the molecule restricts the 
lateral growth of collagen II fibrils (Blaschke et al., 2000).
1.2.4 Other Cartilage Collagens
Type VI collagen is the main constituent o f the beaded filaments that are found in most 
connective tissues, and in cartilage is localised in the pericellular matrix that surrounds cartilage 
cells, but is also found throughout the matrix (Bruckner & van der Rest, 1994). The meshwork it 
forms helps to protect the chondrocyte from mechanical stress. Expression o f type VI collagen 
appears to be upregulated in osteoarthritic cartilage (Chang & Poole, 1996), although degradation 
and/or transformation o f collagen VI in osteoarthritic cartilage might cause a significant loss of 
function of the pericellular microenvironment (Soder et al., 2002).
Type I collagen, a fibril-forming collagen, is abundant in skin, bone and tendon but is only a 
minor part of articular cartilage. It is present in the superficial zone o f avian cartilage, where 
levels decrease with depth (Eyre et al., 1978). It has also been documented in osteoarthritic 
cartilage (Aigner et al., 1993). Type III collagen is another fibril-forming collagen and is found in 
normal and osteoarthritic cartilage co-localised to type II collagen as a minor but regular 
component (Wu et al., 1996; Young et al., 2000).
In osteoarthritic cartilage, type III collagen is concentrated in the superficial and middle zones 
(Aigner et a l 1993) and it has been speculated that its synthesis is a damage response akin to the 
wound-healing role o f type III collagen in type I collagen-based tissues (Eyre, 2002). Type V 
collagen displays homology with type XI, both being fibril-forming collagens, though its exact 
role in cartilage is unknown at present. Immunolocalisation studies detecting type V collagen in 
cartilage have shown strong staining in chondrocytes (Furuto et al., 1991). Type X collagen is a 
network-forming collagen synthesised almost exclusively by hypertrophic chondrocytes, and has 
been identified in the zone o f calcified cartilage surrounding the cells (Gannon et al., 1991). 
Collagens XII and XIV are FACIT group members and display partial homology to collagen type 
IX. Both may carry a chondroitin sulphate chain and they are thought to exist in proteoglycan 
form in bovine articular cartilage. They are not covalently polymerised in the cartilage matrix and 
are thought to bind physically to fibril surfaces via their COL1/NC1 domains (Watt et a l 1992). 
Their function is unclear but there may be competition between them and other fibril-binding 
molecules in cartilage such as decorin, biglycan and fibromodulin.
It should be noted that articular cartilage differs in structure and function to other types o f 
cartilage, for example growth plate and meniscal cartilage. Whilst all cartilage types have a major 
fibrillar collagen network, the matrix organisation and its interactive properties are greatly 
influenced by minor components, both collagenous and noncollagenous (Duance et al., 1999). 
Cartilage collagen breakdown is considered to be a critical and irreversible step in the 
progression of osteoarthritis (Eyre, 2002).
1.3 Proteoglycans
Proteoglycans (PGs) are made up o f glycosaminoglycans (GAGs) and protein, with GAG chains 
o f repeating disaccharides covalently linked to a core protein. The core protein is made on 
membrane-bound ribosomes, and GAG chains (see section 1.4) are added within the Golgi 
apparatus. Proteoglycans occur intracellularly (usually in secretory granules), at the cell surface, 
or in the extracellular matrix (Kjellen & Lindahl, 1991). They are a functionally diverse family of 
molecules that have the potential to participate in a number o f biological functions. These include 
cell growth, collagen fibrillogenesis, tumour cell invasion and the maturation o f specialised 
tissues including cartilage (Iozzo, 1998). In hyaline cartilage, the large aggregating proteoglycan
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aggrecan provides osmotic resistance to resist loading, although many other proteoglycans are 
present including decorin, biglycan, fibromodulin, lumican epiphycan, perlecan, syndecans and 
glypican (for a review see Knudson & Knudson, 2001). The protein and carbohydrate domain 
structures of each individual PG gives it its specific functional properties by means of protein- 
protein, protein-carbohydrate and protein-cell interactions. A brief description of the structural 
biology o f the major proteoglycans is given below.
1.3.1 Lecticans
Also known as hyalectans or aggregating proteoglycans, the lectican family o f PGs share a 
tridomain structure comprising of an N-terminal domain that binds hyaluronan, a central domain 
that carries GAG chains and a C-terminal lectin-type domain (Iozzo, 1998). Within these 
domains there are certain motifs that are common to all lecticans. At present there are four 
distinct lectican genes -  versican, neurocan, brevican and aggrecan.
1.3.1.1 Versican
Versican is the largest member o f the lectican family and is a chondroitin sulphate proteoglycan 
(CSPG) (reviewed in W ight, 2002). Its tissue distribution is wider than that o f aggrecan, 
neurocan or brevican and various forms have been found in fibroblasts, liver, intervertebral disc, 
skin and cartilage (Dours-Zimmermann & Zimmermann, 1994). Versican is more abundant in the 
intervertebral disc than in cartilage, suggesting the importance o f its function in this tissue 
(Sztrolovics et al., 2002), though the function o f the molecule remains unclear. Versican 
functions as a structural molecule, creating loose and hydrated matrices during key events in 
development and disease, interacting either directly with cells or indirectly with molecules that 
associate with cells to, in part, regulate extracellular matrix assembly and cell adhesion and 
survival, proliferation, migration and phenotype. As with the other lecticans, versican can be 
divided into 3 domains -  I, II and III -  as illustrated in figure 1.3. Briefly, domain I consists of 
one Ig repeat followed by two link proteins that mediate the binding o f hyaluronan. Domain II 
contains two subdomains, GAGa and GAGp, that have up to 30 GAG attachment points as well 
as several potential binding sites for N- or O-linked oligosaccharides. There are four known 
splice variants o f mammalian versican, all involving variations in domain II structure: V0 
(GAGa and GAGp), VI (GAGp only), V2 (GAGa only) and V3 (neither GAGa or GAGp).
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Figure 1.3 -  Schem atic representation  of the  dom ain s tructu res of the four lecticans.
Abbreviations: Ig -  im m unoglobulin-like domain; LP -  link protein motif; GAG -  
glycosaminoglycan domain; EG -  epidermal growth factor-like domain; lectin -  lectin-like 
domain; CR -  complement-regulatory protein -like  domain. Molecular weights refer to 
unsubstituted protein cores. Adapted from (Iozzo, 1998).
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Domain III contains two EGF-like repeats, a C-type lectin domain and a complement regulatory 
protein segment (Iozzo, 1998). Recent work with recombinant versican has suggested an 
interaction o f cartilage link protein with versican is o f a higher affinity than the interaction 
between link protein and aggrecan (Shi et al., 2004).
1.3.1.2 Neurocan
Neurocan is a CSPG originally cloned from rat brain (Rauch et al., 1992), and is expressed 
during tissue modelling or remodelling. A schematic diagram of neurocan is shown in figure 1.3. 
Domain I, the HA binding domain, is similar in structure to that o f versican. Domain II contains 
seven GAG attachment points, and domain III is similar to the lectin-like domains o f the other 
lecticans: between rat neurocan, and human aggrecan and versican, there is a homology of around 
60% (Iozzo, 1998).
1.3.1.3 Brevican
Brevican is the most recently discovered lectican and as one can gather from its name it is also 
the shortest, due to its relatively short GAG attachment region (Jaworski et al., 1994). It exists as 
a secreted form or as an isoform bound to the plasma membrane via a GPI anchor (Seidenbecher 
et al., 1995). This isoform contains no EGF-like repeat, lectin domain or complement regulatory 
protein-like domain (see figure 1.3). These motifs are replaced by a segment o f hydrophobic 
amino acids that resemble the GPI anchor.
1.3.1.4 Aggrecan
Also known as cartilage proteoglycan, aggrecan is the predominating aggregating proteoglycan 
found in cartilage, and its structure contributes greatly to the biomechanical functionality of the 
tissue. The GAG binding region has attachment points for up to 150 GAGs -  around 50 for 
keratan sulphate and around 100 for chondroitin sulphate -  and this polyanionic region is space­
filling and has a high affinity for water. Aggrecan monomers interact non-covalently with HA to 
form large proteoglycan aggregates (reviewed in Roughley & Lee, 1994), an interaction that is 
stabilised by link protein (Hardingham, 1979). The structural organisation o f aggrecan is similar 
to that of versican but with a few notable exceptions, as seen in figure 1.3. In domain I, the Ig- 
like domain and the four tandem repeat modules form two globular domains termed G1 and G2.
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The G1 domain contains the Ig repeat and the first two tandem repeats and the G2 domain 
contains the other two tandem repeats. The interaction between aggrecan and HA is mediated by 
the G1 domain and is stabilised by a link protein, which is similar in structure to the G1 domain 
(Perkins et al., 1989). The G1 domain and link protein bind to a decasaccharide segment o f HA at 
intervals o f approximately 30nm, and G1 also binds to link protein via its Ig-like repeat. These 
interactions are shown in figure 1.4, along with the domain structure of the rest o f the molecule. 
The HA backbone o f aggrecan-HA polymers can vary in length from several hundred nanometers 
to over ten thousand nanometres, and may have up to 300 associated aggrecan molecules. The 
weight of H A-aggrecan complexes has a mass o f around 2 x 106 Da.
The G3 domain is similar in structure to domain III of the other lecticans. The region o f core 
protein that links the G1 and G2 domains is known as the interglobular domain (IGD). This 
contains amino acid sequences that are susceptible to proteolytic attack by matrix proteases. The 
degradation o f aggrecan by these enzymes, some o f which are described later, is important both 
in normal matrix turnover and in matrix degradation and the associated loss o f function involved 
in pathological conditions such as arthritis. The human aggrecan core protein contains a keratan 
sulphate attachment region and two chondroitin sulphate attachment regions, known as CS-I and 
CS-II, shown in figure 1.4 (Doege et al., 1991). Aggrecan from rat contains another minor CS 
attachment region termed CS-III (Doege et al., 1987). Changes in the number, size, sulphation 
patterns and charge density o f the chondroitin sulphate and keratan sulphate regions of aggrecan 
occur with development and ageing (Hardingham et a l 1994). For example, in ageing cartilage 
there is an increase in the proportion o f keratan sulphate in relation to chondroitin sulphate, and 
the ratio of 6-sulphated to 4-sulphated chondroitin sulphate increases. Catabolism o f aggrecan 
occurs with the onset o f joint diseases such as osteoarthritis (for a review see Caterson et al., 
2000).
1.3.2 Small Leucine-Rich Proteoglycans (SLRPs)
Also known as small interstitial proteoglycans, this family o f proteoglycans are both small - 70- 
120 kDa compared to 2.5 x 103 kDa for an aggrecan monomer -  and leucine-rich (reviewed in 
Iozzo, 1999). They contain a central region o f leucine-rich repeats (LRR) flanked by two 
cysteine-rich regions with highly conserved spacing.
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Figure 1.4 -  Schematic representation of (A) the interaction between hyaluronan and 
aggrecan, stabilised by link protein, and (B) the formation of aggrecan aggregates.
Abbreviations: G l, G2 and G3 -  globular domains o f aggrecan; LP -  link protein; CS-I, CS-II -  
chondroitin sulphate I and II domains; IGD -  interglobular domain.
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SLRPs can be split into three families, classes I, II and III, based on their protein and genomic 
organisation.
1.3.2.1 Class I  SLRPs
This class includes decorin and biglycan. Decorin is the ‘prototype’ SLRP, and is a tetradomain 
protein as shown in figure 1.5. Domain I contains a signal peptide and a propeptide, a feature 
unique to class I SLRPs, both of which are not present in the mature secreted proteoglycan. The 
propeptide may regulate the attachment o f GAG chains -  2 CS or DS chains for biglycan, and 
one for decorin (Iozzo, 1999). Domain II has a cluster o f cysteine residues and contains GAG 
attachment sites. Domain III is the leucine-rich region, which is common to most SLRPs. Most of 
the leucine residues are in conserved positions, with the consensus LxxxLxLxxNxLSxL where x 
is any amino acid, L is leucine, isoleucine or valine, S is serine and N is asparagine. Domain IV 
contains two cysteine residues separated by 32 amino acids that may aid interaction with 
collagen. Decorin ‘decorates’ collagen fibrils and has been found to affect fibrillogenesis: it can 
regulate the diameter o f type I collagen fibrils (Danielson et a l ,  1997), and it may have a similar 
role in type II collagen organisation within the cartilage matrix. Collagen malformations exist in 
Den-/- mice, reviewed in (Reed & Iozzo, 2002). It has been suggested that the interactions 
between decorin and other ECM components such as fibronectin and collagen supports formation 
of a pericellular matrix that stabilises cellular differentiation (Kinsella et al., 2000; Gendelman et 
al., 2003). Biglycan associates with the cell surface or pericellular matrix o f a number o f cells, 
and along with decorin it has been shown to interact with collagen VI (Wiberg et a l ,  2001). It 
also binds to the growth factor TGF-P (Hildebrand et a l ,  1994). Decorin also binds to TGF-(3, 
and prevents it from interacting with its cellular surface receptors, neutralising its effect (Hocking 
et a l ,  1998). It is thought that decorin and biglycan may regulate TGF-P activities by 
sequestering TGF-p in the extracellular matrix.
1.3.2.2 Class IISLRPs
This subfamily includes fibromodulin, lumican, keratocan and osteoadherin, and differ to class I 
SLRPs in that they are not proteolytically processed after the removal o f their signal peptide. 
They contain keratan sulphate GAG chains, and share a cysteine-rich region that occurs just N- 
terminal to the 10 LRRs.
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Figure 1.5 -  Schem atic diagram  of the SLRP decorin, illustrating its dom ain structu re .
Abbreviations: SP -  signal peptide; PP -  propeptide; Cys -  cysteine-rich region; LRR -  leucine- 
rich repeat. Consensus sequences for the leucine-rich repeats and the cysteine-rich regions are 
also shown. Adapted from (Iozzo, 1998).
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Lumican and fibromodulin inhibit fibrillogenesis, and fibromodulin, like decorin, binds to TGF-(3 
(Hildebrand et al., 1994) and prevents ligand-receptor interactions. Keratocan, like lumican, is a 
core protein o f a major comeal proteoglycan (Corpuz et al., 1996). Osteoadherin binds to 
hydroxyapatite and also to osteoblasts, and may promote osteocyte attachment (Wendel et al.,
1998).
1.3.2.3 Class III SLRPs
This group consists o f osteoglycin (PG-LB), epiphycan (mimecan) and opticin (Reardon et al., 
2000). They contain 6 LRRs and a unique cysteine-rich consensus sequence. There are two 
molecules, PRELP (Bengtsson et al., 1995) and chondroadherin, that are members of the leucine- 
rich repeat (LRR) family o f ECM molecules but are not classed as proteoglycans. PRELP 
interacts with perlecan heparan sulphate chains and collagen, and is thought to anchor basement 
membranes to the underlying connective tissue (Bengtsson et al., 2002). Chondroadherin has 
been shown to bind cells (Camper et al., 1997) and type II collagen (Mansson et al., 2001), and 
may be of functional importance in communications between the cell and its surrounding matrix.
1.3.3 Basement Membrane Proteoglycans
The proteoglycans within the basement membrane bind specifically to its other components. 
These include type IV collagen, laminin and cellular receptors. They contribute to the formation 
of a negatively charged barrier that regulates the passage of macromolecules across the basement 
membrane. At present, four o f these proteoglycans have been well characterised: the heparan 
sulphate proteoglycans (HSPGs) perlecan and agrin, and the chondroitin sulphate proteoglycans 
(CSPGs) bamacan and leprecan.
Perlecan was the first basement membrane-associated proteoglycan to be characterised (Murdoch 
et al., 1992). It has a mass o f 850 kDa and is a large component of the basement membrane, 
comparable to laminin at 900 kDa. It is made up o f five distinct domains, and the name arises 
from the appearance o f its N-terminal portion: globular domains are interlinked by rod-like 
segments. Perlecan has particular relevance to cartilage -  studies on mutant mice lacking 
perlecan show severe matrix disorganisation, indicating that perlecan is critical in normal 
articular cartilage (Arikawa-Hirasawa et al., 1999).
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Agrin is a HSPG involved in the developm ent o f the neurom uscular junction during 
embryogenesis, including the aggregation of acetylcholine receptors (Groffen et a l ,  1998). It is a 
multidomain protein with four distinct domains, with at least six sites for GAG attachment. 
Bamacan is structurally dissimilar to other proteoglycan due to the presence of coiled-coil motifs 
in two of its five domains (Wu & Couchman, 1997). Leprecan is a CSPG that has yet to be fully 
characterised, though it is possible that both HS and KS chains are attached to the protein core 
(Wassenhove-McCarthy & McCarthy, 1999).
1.3.4 Cell Surface Proteoglycans
This class o f molecules includes the glypicans and syndecans. Glypicans can contain CSPGs, 
DSPGs or HSPGs whereas syndecans (reviewed in Couchman, 2003) contain HSPGs. Both are 
involved in cell-matrix and cell-cell interactions, and have been implicated in the cell binding of 
growth factors. Four isoforms have been cloned in the syndecan family and six in the glypican 
family. The syndecan core protein contains a single pass transmembrane domain, an extended 
extracellular domain substituted with HS and a short intracellular domain with roles in signal 
transduction. Glypicans are attached to the cell surface through a GPI anchor, and have a more 
globular structure, with HS chains close to the cell surface. Heparan sulphate proteoglycans 
present on the cell surface may participate in many events during cell adhesion, migration, 
proliferation and differentiation (reviewed in Tumova et al., 2000). A recent study suggests that 
the proliferation o f chondrocytes effected by fibroblast growth factor-2 (FGF-2) is mediated by 
syndecan-3 (Kirsch et al., 2002). Syndecan-3 also appears to be expressed by osteoarthritic 
chondrocytes (Pfander et al., 2001).
1.3.5 Cartilage superficial zone proteoglycan (SZP)
This 345 kDa proteoglycan is synthesised by superficial zone chondrocytes and by some cells of 
the synovial lining and accumulates on the surface o f articular cartilage (Schumacher et al., 
1999). It has one CS attachment point, and is also known as lubricin or PRG4. It is the subject of 
this thesis and is described in more detail in section 1.9.
18
1.4 Glycosaminoglycans
Glycosaminoglycans (GAGS) are linear polysaccharides made up o f repeating unbranched 
disaccharide units. These units always consist o f a hexosamine residue that is invariably 
sulphated, and a hexuronic acid or galactose residue. The sulphation of GAGs, together with the 
carbohydrate moiety o f hexuronic acid, gives GAG chains a polyanionic charge and therefore a 
high affinity to water. The functional properties o f proteoglycans depend on this feature: in 
cartilage, aggregated proteoglycans attract water via their hydrophilic GAG side chains and 
resists its flow out o f the cartilage matrix when the tissue is deformed during compression. When 
the load is removed, GAGs are rehydrated and tissue deformation is reversed.
1.4.1 GA G Species
There are six GAG species: chondroitin sulphate (CS), dermatan sulphate (DS), heparan sulphate 
(HS), keratan sulphate (KS), heparin (hep) and hyaluronic acid (hyaluronan or HA). HA is not 
sulphated and is not a constituent o f proteoglycans, though it is a major constituent o f synovial 
joint fluid that provides viscosity. Heparin is a more extensively epimerised and sulphated form 
of HS. HS is found on many cell surfaces and in some matrix proteoglycans. The disaccharide 
repeat units of the six GAG species present in articular cartilage are shown in figure 1.6. HA, HS 
and heparin units com prise o f N -acetylgalactosam ine and uronic acid, KS contains N- 
acetylglucosamine and galactose, CS and DS contain N-acetylgalactosamine with glucuronic and 
iduronic acid, respectively. DS is a modified form o f CS, formed by the conversion of one or 
more glucuronic acid residues to iduronic acid by an epimerase (Roughley & Lee, 1994).
Cartilage GAGs display different chain lengths, and with the exception o f HA, show varying 
degrees of sulphation with respect to quantity and position. For example, CS may be sulphated at 
the 4- or 6-position o f the galactosamine residues, sulphation status being loosely dependant on 
tissue type, age and pathology. CS chains isolated from articular cartilage may vary both in chain 
length and sulphation pattern, depending on the activities o f glycosyl transferases and 
sulphotransferases that function during synthesis, and the availability of precursors (Roughley & 
Lee, 1994). The synthesis o f sulphated GAGs takes place in the Golgi apparatus, and initiation 
requires a protein receptor. In contrast, HA is synthesised at the plasma membrane, the growing 
polysaccharide chain extruding directly into the extracellular space.
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Figure 1.6 -  Disaccharide sequences of the six glycosaminoglycan species found in articular 
cartilage.
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1.4.1.1 GAG Attachment
For attachment o f GAGs to protein, there are specific amino acid consensus sequences (Esko & 
Zhang, 1996). The consensus sequences and their method of attachment are shown in figure 1.7. 
The sequence for CS attachment is a cluster o f two or three acidic amino acids followed by Ser- 
Gly-X-Gly, although there is one exception to this -  in type IX collagen, CS is attached through 
the serine o f a Ser-Ala dipeptide. The consensus sequence for the attachment of HS is a Ser-Ala 
or Ser-Gly dipeptide with nearby clusters o f acidic and hydrophobic residues. KS can either be 
O-linked, as in cartilage, or N-linked as in the cornea. The consensus sequence for N-linked KS 
attachment is Asn-X-Ser/Thr where X is any amino acid except proline, and KS attaches through 
asparagines. The sequence for O-linked KS attachment in aggrecan is Glu-Glu/Lys-Pro-Phe-Pro- 
Ser, with KS being attached through the serine residue (Hering et al., 1997).
l.S Other Components of Articular Cartilage
An overview o f the major macromolecular constituents o f articular cartilage is shown in table
1.2. Some o f the constituents o f the cartilage matrix that are not classed as either collagens or 
proteoglycans are described briefly in this section.
1.5.1 Fibronectin
Fibronectin is an extracellular matrix glycoprotein that is a soluble constituent o f plasma 
(~300pg/m l) and other body fluids, and it is also part o f the insoluble extracellular matrix 
(reviewed in Pankov & Yamada, 2002). Its increased expression is often associated with tissues 
undergoing remodelling or repair. Fibronectin is a rod-like molecule that consists o f two 250 kDa 
subunits linked by a disulphide bond at the C-terminus. It has several globular domains that 
contribute to a number o f interactions including binding to collagen, fibrin, heparin, heparan 
sulphate and cell surface receptors. It has an Arg-Gly-Asp (RGD) tripeptide that mediates the 
binding of cells to the extracellular matrix via integrins. Fibronectin is a minor constituent of 
healthy cartilage although elevated levels are present in arthritis. The predominant form of 
fibronectin in cartilage is the alternatively spliced (V+C)-, which exists as either a homodimer or, 
unusually, as a monomer. Parts o f fibronectin are susceptible to proteolysis, and the resultant 
catabolites may have the potential to regulate cartilage metabolism (reviewed in Homandberg,
1999).
21
xylose fr  galactose x  galactosex glucuronic
GAG 
disaccharidelinkage region tetrasaccharide
Consensus sequences for GAG attachment
CS: Ser-Gly-X-Gly
Ser-Ala in type IV collagen 
HS: Ser-Ala 
Ser-Gly
KS: Glu-Glu/Lys-Pro-Phe-Pro-Ser 
Asn-X-Ser/Thr
Core
protein
Figure 1.7 -A tta c h m e n t of com m on G A G s to a core p ro te in  th ro u g h  a linkage 
te trasaccharide. Attachment consensus sequences are also shown. Residues in bold indicate 
amino acids that directly attach GAG. Adapted from (Alberts et al., 1994).
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Table 1.2 -  Structural matrix molecules of articular cartilage. Adapted from (Poole et al., 2001).
M olecule Com m ents | Function
Collagens
Type II Principle component o f  macrofibril Tensile strength
Type VI Forms microfibrils in pericellular sites Unknown
Type IX Cross-linked to surface o f  macrofibril Tensile properties and/or fibril- 
iterfibrillar connections
Type X Associated with macrofibril and present in 
pericellular latticework. Only synthesised 
by hypertrophic chondrocytes. Only 
usually present in hypertrophic layer
Unclear but may add structural 
support
Type XI Present within and on macrofibrils Nucleates fibril formation
Types XII and XIV Each is homotrimeric Probably part o f  macrofibril
Proteoglycans
Aggrecan Majority proteoglycan by mass. Binds HA 
through G 1 domain. Most concentrated in 
deep zone.
Compressive stiffness
Leucine-rich core proteins
Dcconn Has one CS or DS chain near NH2- 
terminus. Equimolar to aggrecan. 
Concentrated at articular surface and in 
pericellular sites
Regulates formation o f  macrofibrils
Fibromodulin May contain as many as 4 KS chains As for decorin
Lumican Contains KS in immature form As for decorin
Biglycan Has 2 CS or DS chains near NH2-terminus Unclear
Perlecan Located at cell surface Cell-matrix adhesion
Other m olecules
Cartilage oligomeric protein Five-armed molecule o f  thrombospondin 
family
Binds type II collagen; may be 
involved in macrofibril assembly
Link protein Structure homologous to G 1 domains o f  
aggrecan/versican
Stabilises binding o f  
aggrecan/versican G1 domains to 
HA
Matrix-Y-carboxyglutamic 
acid protein
Pericellular location. Also known as 
matrix Gla protein
Inhibits calcification
Fibrilin-1 Forms microfibrillar network Unknown
Hyaluronic acid Forms macromolecular aggregates with 
aggrecan/versican. Interacts with collagen
Retention o f aggrecan and versican 
in the matrix
PRG4 (lubricin) Synthesised by cells o f  the superficial 
zone; not retained in matrix
Joint lubrication
Chondroadherin Leucine-rich protein Cell-matrix binding
CD44 Cell surface receptor for HA Cell-matrix binding
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It has been reported that up to 50% of fibronectin in arthritic synovial fluids is proteolytically 
fragmented, with fragments o f between 30 and 200 kDa present (Griffiths et a l 1989; Xie et al.,
1992). The domain structure of fibronectin and the cleavage point of proteinases is shown in 
figure 1.8. The relevance of proteolytically fragmented fibronectin to cartilage catabolism was 
demonstrated in vivo by Homandberg et al. (1993) who showed that injection o f a 29 kDa N- 
terminal domain fibronectin fragment into rabbit knee joints caused severe depletion of 
proteoglycan within days. More recently it has been reported that stimulation o f cultured 
chondrocytes and cartilage explants with the 45 kDa N-terminal fragment o f fibronectin induces 
MMP-13 synthesis and aggrecan degradation by aggrecanases (Stanton et al., 2002).
In addition to the presence o f proteolytic fragments o f fibronectin in joint pathology, novel 
cartilage-specific splice variants o f fibronectin have been identified that may have specific roles 
in the maintenance o f structural integrity or regulation of ‘outside-in’ signalling in chondrocytes, 
one fibronectin splice variant was found to be specific to arthritic cartilage (Parker et al., 2002).
Other work has investigated the release of collagen-binding molecules from cartilage explant 
cultures treated with fibronectin (Johnson et al., 2004). An interesting hypothesis concerning the 
mechanisms behind these observations is that fibronectin fragments are preferentially active 
towards chondrocytes because they contain reduced numbers of integrin binding sites (Huhtala et 
al., 1995). According to the authors, fibronectin appears to be a virtual ‘keyboard’ o f binding 
sites, upon which various ‘chords’ o f integrins can be played by cells (Peters et al., 2002). 
Therefore, a catabolic response could be elicited by cells hitting ‘bum notes’ on a fibronectin 
fragment ‘keyboard’ that has a reduced number o f integrin-binding sites.
1.5.2 Tenascins
There are five known members o f the tenascin multimeric glycoprotein family, as reviewed in 
(Jones & Jones, 2000): tenascins C, R, W, X and Y, o f which tenascin C is the best characterised. 
Tenascin C has a hexabrachion structure and has been found in cartilage, skin and bone marrow, 
with several different isoforms variably expressed during embryogenesis, tumourogenesis, 
angiogenesis and wound healing.
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Figure 1.8 -  Schematic representation of the domain structure of a fibronectin monomer.
Fragments of fibronectin can be isolated by various proteinases, as illustrated above the diagram. 
The types of ligands each domain can bind are shown below the diagram. Abbreviations: Fib -  
fibulin; Hep -  heparin; Fn -  fibronectin; Coll -  collagen; Bact -  bacterial. Adapted from 
(Homandberg, 1999).
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Tenascins interact with matrix metalloproteinases and can also be cleaved by them. Tenascins C 
and R both bind to a number o f proteins with high affinity including the hyalectan family of 
proteoglycans: aggrecan-tenascin complexes exist in cartilage, where it is thought to have roles in 
extracellular matrix assembly and the modulation o f interactions. The aggrecan-tenascin C 
interaction may be affected by alternative splicing o f the G3 domain o f aggrecan (Day et al., 
2004).
1.5.3 Cartilage Intermediate Layer Protein (CILP)
CILP is a 92 kDa single chain glycoprotein. Ten percent of its observed molecular weight is from 
O-linked oligosaccharides, and there are no N-linked oligosaccharides present (Lorenzo et al 
1998a; Lorenzo et a l 1998b). Its location is restricted to the intermediate or middle zone of 
cartilage. The function of CILP is not yet known, but it could be involved in the early stages of 
osteoarthritis and in ageing, as in both processes its expression is upregulated. Recent work 
suggests that increased CILP expression may be associated with calcium pyrophosphate 
dihydrate crystal deposition disease (CPPDCD), and that CILP might play a role in promoting 
CPPD crystal formation (Yamakawa et al., 1999). O f the two isoforms expressed in cartilage, 
CILP-1 and CILP-2, CILP-1 appears capable o f functioning as an insulin-like growth factor-1 
(IGF-1) antagonist (Johnson et al., 2003).
1.5.4 Cartilage Oligomeric Matrix Protein (COMP)
COMP is a 524 kDa extracellu lar, hom opentam eric glycoprotein belonging to the 
thrombospondin family (Hedbom et al., 1992). An N-terminal cysteine-rich domain facilitates 
the assembly of pentamers from monomers, and a globular C-terminal domain may be involved 
in binding proteins and cells. It is expressed in a variety of tissues including cartilage, tendon, 
ligament, bone, skeletal muscle and heart. Levels o f COMP in serum and synovial fluid have 
been used as a marker for cartilage degradation (Saxne & Heinegard, 1992). Recent reports have 
suggested that COMP can interact in a divalent cation-dependent manner with collagens I, II and 
IX (Rosenberg et a l ,  1998; Holden et al., 2001; Thur et al., 2001) and also with fibronectin 
(DiCesare et a l ,  2002). Mutations in the COMP gene have been implicated in two different 
inherited skeletal dysplasias: pseudochondroplasia (PSACH) and multiple epiphyseal dysplasia 
(MED/EDM 1), although characterisation o f a PSACH-type mutant suggests that the mutation
26
does not affect COMP-collagen binding (Spitznagel et al., 2004). The in vivo function o f the 
protein is not yet fully understood though it may be associated with the elaboration o f a weight­
bearing chondrocyte matrix.
1.5.5 Secreted Protein Acidic and Rich in Cysteine (SPARC)
SPARC, also known as BM-40, 41K protein and osteonectin, is a 34 kDa glycoprotein made up 
of three structural domains, one or more o f which are implicated in the regulation of cell 
adhesion, cell proliferation and matrix turnover (Motamed, 1999). It is expressed by a number of 
cell types, but appears to be upregulated in the superficial and transitional zones o f osteoarthritic 
cartilage. It can bind to collagen & vitronectin, and has also been implicated in the regulation of 
growth factor activity and lens transparency (reviewed by Brekken & Sage, 2000).
1.5.6 Matrilins
There are currently four identified members o f the matrilin family, matrilins 1, 2, 3 and 4. 
Matrilin-1 was initially identified as an abundant proteoglycan-associated cartilage matrix protein 
(Paulsson & Henegard, 1981). All matrilins are modular proteins with two von Willebrand factor 
A (vWFA) domains separated by a varying number o f EGF-like domains. It is thought that 
matrilins connect supramolecular assemblies in cartilage: complexes of matrilin-1 and biglycan 
or decorin have been shown to connect collagen VI microfibrils to both collagen II and aggrecan 
(Wiberg et al., 2003). A recent report has suggested that matrilin-3 expression is enhanced in 
osteoarthritic cartilage and thus may be a cellular response to the modified microenvironment 
during disease (Pullig et al., 2002).
1.6 Cartilage Turnover
Turnover (synthesis versus degradation) o f articular cartilage macromolecules maintains the 
function of the tissue. Matrix constituents are synthesised by chondrocytes and specifically 
degraded by a number o f matrix proteinases. The same proteinases are also thought to be 
responsible for the increased catabolism of matrix molecules in degenerative joint diseases. There 
are four main classes o f matrix proteinase, classified according to the amino acid or chemical 
group at the catalytic centre of the enzyme: aspartate, cysteine, metallo- and serine proteinases.
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The main classes o f proteases are shown in figure 1.9, along with examples from each family and 
pH requirement for activity. The cysteine and aspartate proteinases act at low pH levels and are 
thought to act intracellularly within the lysosomal system. However, these enzymes can also be 
released extracellularly into small pockets near the cell membrane, where they degrade matrix in 
a controlled low pH microenvironment. Some enzymes may not catabolise matrix proteins 
directly but instead are capable o f activating other proteinases that degrade the matrix. 
Membrane-bound proteinases may be involved in cytokine processing, receptor shedding and 
regulation of cell-cell and cell-matrix interactions.
1.6.1 Acidic Proteinases
Intracellular proteolysis by lysosomal proteinases occurs when cleaved matrix components are 
phagocytosed, but the relative contributions o f intra- versus extra-cellular pathways are not 
clearly understood. Papain-like lysosomal cysteine proteases known as cathepsins are ubiquitous 
processive and digestive enzymes. Expression o f cathepsins B, H and L is elevated in antigen- 
induced arthritic cartilage, whilst levels o f cathepsins B and D are elevated in osteoarthritic 
tissues and have been implicated in the degradation o f aggrecan core protein (Fosang et al., 1992; 
Mort et al., 1998; Handley et al.,2001). Cathepsin B (reviewed in Mort & Buttle, 1997) may also 
act as an intracellular activator o f other proteinases that then degrade cartilage components. Acid- 
induced cathepsin K is expressed by phenotypically altered chondrocytes and may cause 
degradation o f the superficial gliding surfaces o f cartilage in osteoarthritis (Konttinen et al.,
2002). Cathepsin K is capable o f degrading aggrecan complexes (Hou et al., 2003).
1.6.2 Matrix metalloproteinases
At present, 23 distinct members o f the human MMP family have been identified (for a review see 
Somerville et al., 2003). They fall into four main groups: collagenases, stromelysins, gelatinases 
and membrane bound (MT-MMPs), as shown in figure 1.9. All members contain a zinc atom at 
their catalytic centre and are secreted as inactive pro-MMPs or zymogens that require activation, 
apart from MT-MMPs, which are active when they reach the plasma membrane. MMP activation 
can be mediated by other factors including other MMPs (particularly MT-MMPs), plasmin and 
reactive oxygen species released by inflammatory cells.
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Figure 1.9 -  The four main classes of matrix proteinases. Examples are given for each family 
along with pH range in relation to enzyme activity. Figure adapted from (Cawston & Rowan, 
2002).
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Most proMMPs have a propeptide domain that contains a unique ‘cysteine switch’ sequence -  
PRCG(V/N)PD -  in which the cysteine residue ligates the catalytic zinc to maintain the inactive 
state o f the zymogen (Nagase & Woessner, 1999). Invertebrate MMPs are referred to based on 
their substrate (e.g. collagenase 1) whereas vertebrate MMPs are assigned a number (e.g. MMP- 
1). All connective tissues contain endogenous Tissue Inhibitors o f MetalloProteinases (TIMPS 1- 
4) that bind to active MMPs. Some MMPs are stored in granules within neutrophils and can be 
released when these cells are stimulated; others are produced by cells as a result o f stimulation by 
cytokines. A brief description of the main MMP families is given below.
• Stromelvsins have a broad substrate specificity that includes proteoglycan, laminin and 
fibronectin. Stromelysin-1 (MMP-3) is not widely expressed but is induced by IL-1.
• Collagenases cleave fibrillar collagens at a single site to produce quarter and three-quarter 
length catabolites that are further degraded by gelatinases. They include MMP-1 
(interstitial collagenase), MMP-8 (neutrophil collagenase) and M M P-13 (collagenase 3). 
M M P-13 appears to be important in cartilage as it preferentially cleaves type II collagen.
• Gelatinases MMP-2 and - 9  cleave degraded collagens, type IV and V collagen and 
elastin.
• MT-MMPs are activated by fiirin in the Golgi vesicles and may activate pro-MMPs.
MMPs play a role in tissue pathologies such as arthritis, cancer and cardiovascular disease. 
Information regarding MMP structure and function has led to the development of synthetic MMP 
inhibitors with a view to treating patients with these conditions. However, although this may be 
beneficial, MMPs also function in vital non-pathological processes such as embryonic 
development, organ morphogenesis, wound healing, nerve growth and bone remodelling, and the 
effect of MMP inhibitors on these processes is not clearly understood (reviewed in Nagase & 
Woessner, 1999).
/. 6.3 ADAM/ADAM- TS proteins
1.6.3.1 ADAM proteinases
ADAMs are enzymes with A Disintegrin And Metalloprotoeinase domain, o f which over 30 have 
been found. ADAMs have cell adhesion and protease activities, and act in a highly diverse set of
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biological processes, including, neurogenesis, myogenesis, embryonic TGF-alpha release and the 
inflammatory response, reviewed in (Primakoff & Miles, 2000).
1.6.3.2 ADAM -TSproteinases
ADAMTS stands for A Disintegrin And Metalloproteinase with ThromboSpondin motifs. These 
include the recently described aggrecanases-1 and -2  (ADAMTS-4 and -5 ), which can cleave 
aggrecan, brevican and versican. The importance of aggrecanase-mediated aggrecan degradation 
in arthritis has been o f considerable interest in recent years (for a review, see Amer, 2001). 
Recombinant ADAMTS-4 and -5  cleave aggrecan at five distinct sites along the core protein, 
and catabolites generated by cleavage at all five sites have been identified in cartilage explants 
undergoing matrix degradation. Aggrecanase activity can be modulated by altered expression, 
activation by cleavage at a furin-sensitive site, binding to aggrecan through the C-terminal 
thrombospondin motif, activation through post-translational modification of a portion of the C- 
terminus and inhibition of activity by tissue inhibitor of metalloproteinase-3 (TIMP-3).
1.6.4 Serine proteinases
Endogenous serine proteinases such as elastase and plasmin are found at low levels within 
cartilage and are thought to be derived from neutrophils. The activation o f pro-MMPs may be 
mediated by plasmin as well as other serine proteinases. Tissue plasminogen activator (tPA) and 
urokinase plasminogen activator (uPA) are both found in cartilage and can convert plasminogen 
to plasmin.
/. 6.5 Neutrophil-dependent proteolysis
Neutrophils store large quantities o f enzymes such as elastase, cathepsin G, neutrophil 
collagenase and gelatinase B. In many inflammatory situations there is an influx of neutrophils 
into the joint, and neutrophil enzymes degrade cartilage if released close to the surface. In most 
synovial fluids there is an excess o f inhibitors such as TIMPS 1 and 2, a2-macroglobulin and a l -  
antiproteinase which can clear the degradative enzymes from the joint. In septic arthritis this 
inhibitory capacity may be exceeded and neutrophil enzymes are able to degrade the cartilage 
surface.
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1.7 Arthritis
The Latin word 'arthritis' is derived from Greek: arthro (joint) and itis (inflammation). There are 
many different types o f arthritis, ranging from mild localised forms such as tendonitis to severe 
systemic forms such as rheumatoid arthritis. However, most arthritides fall into one o f two 
categories -  osteoarthritis (OA) and rheumatoid arthritis (RA). According to the Arthritis 
Research Campaign (UK) website (w w w .arc.oru.uk . July 2003) one in every five visits to a 
general practitioner is arthritis related, and more than seven million people have long-term health 
problems due to arthritis or a related condition. This situation is likely to worsen as the 
population o f the developed world ages due to advances in other areas o f medical research, 
though not only adults are affected - one child in every thousand has arthritis. The unravelling of 
the events during and leading up to degenerative joint disorders is a matter o f considerable 
scientific and commercial interest. Information regarding non-collagenous cartilage matrix 
proteins is fragmentary at present, even though this group o f molecules has proven to be of great 
importance in mediating matrix-matrix and cell-matrix interactions in other tissues. The 
insufficient characterisation o f these presumably important components o f the cartilage matrix is 
a considerable handicap in understanding and treating lesions and diseases o f cartilage.
1.7.1 Osteoarth ritis
OA is a ‘wear-and-tear’ disease, and its onset is usually related to alteration in the mechanical 
stresses applied to articular cartilage. The tissue attempts to repair itself to compensate for these 
changes by altering its biochemical composition, but this attempted remodelling only exacerbates 
the disability o f the cartilage to cope with loading. For example, in the superficial zone there is a 
loss in proteoglycan that results in a change in the way that the tissue holds water, compromising 
performance under load. A feature o f early OA is the increased hydration o f cartilage, possibly 
due to an alteration in the collagen network (Hamerman, 1989). The matrix exhibits a decrease in 
keratan sulphate and a switch to chondroitin-4-sulphate from chondroitin-6-sulphate as the major 
cartilage CSPG (Roughley, 1986). Matrix proteases are activated through cytokines such as IL-1, 
and these degrade the cartilage matrix leading to joint space narrowing. In later stages there is a 
change in chondrocyte phenotype and morphology: cells divide in their lacunae and express type 
X collagen. There is no ‘cure’ for OA, and commonly used treatments only modify the symptoms 
of the disease rather than the underlying process. The ‘old wives tale’ of the use o f cod liver oil
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for the treatment o f OA symptoms has recently been given credence by studies demonstrating 
that n-3 (but not n-6) fatty acids can inhibit the expression and activity o f degradative and 
inflammatory factors such as aggrecanases, cyclooxygenase-2, IL-1 and TN Fa (Curtis et al., 
2000; Curtis et al., 2002). Glucosamine sulphate has recently received attention as a disease- 
modifying agent based upon its role in the metabolic pathway o f GAG production and PG 
assembly. Recent in vitro results have shown that glucosamine sulphate can stimulate mRNA and 
protein levels of aggrecan core protein and inhibit production and enzymatic activity of MMP-3 
in chondrocytes from OA articular cartilage (Dodge & Jimenez, 2003). However, the jury is still 
out in clinical circles as concerns its effectiveness in combating degenerative joint disease when 
used as a dietary supplement.
/. 7.2 Rheumatoid Arthritis
RA is a systemic disease with diverse and fluctuating manifestations, and the mechanisms behind 
it are not fully understood. Viruses or toxins may trigger an autoimmune response in genetically 
susceptible individuals. Immune complexes in the synovial joint cause an influx o f inflammatory 
cells such as macrophages and neutrophils into the synovial cavity, and these cells release 
inflammatory cytokines such as IL-1 and TN F-a, which induce the synthesis, secretion and 
activation of matrix proteases. A major site o f tissue damage resulting from this, the pannus, 
eventually grows over the cartilage surface, invades the cartilage matrix and destroys it. Pannus is 
an invasive granulation tissue com posed o f aggressive macrophage- and fibroblast-like 
mesenchymal cells (Fassbender & Simmling-Annefield, 1983) that contribute to cartilage 
destruction by the release o f collagenolytic enzymes. Pannus-like tissue also exists in advanced 
OA cartilage (Shibakawa et al., 2003). RA symptoms can also include general stiffness, 
inflammation o f other tissues such as blood vessels or the lungs, and fatigue. RA has a variable 
course, with flares and remissions that fluctuate unpredictably, which complicates the task of 
quantifying the effects o f RA therapies (Schiff, 2003).
/. 7.3 Surface zone o f articular cartilage in arthritis
In OA, the surface o f cartilage is altered, such that the normal gliding surface (Mankin grade 0) 
becomes fibrillated (grade 1). During the progression of the disease, superficial fissures (grade 2) 
and deep fissures that penetrate to the subchondral bone (grade 3) develop. This implies that the
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surface o f cartilage is the region to be first affected by OA. Superficial cracks or fissures caused 
by unusual loading are a feature o f post-traumatic osteoarthritis (Kafka, 2002). In late-stage OA 
pannus tissue can also accumulate on the cartilage surface (Shibakawa et al., 2003). The 
biochemical and biomechanical features of the surface of cartilage is described in the following 
section.
1.8 Surface Zone of Articular Cartilage
1.8.1 Introduction - surface o f articular cartilage
Articular cartilages serve to absorb and dissipate load, and provides almost frictionless 
articulation within a diarthrodial joint. The surface zone is important in both these aspects, as its 
position influences both articulation between cartilage surfaces and the tensile and compressive 
properties o f the tissue as a whole (Guilak et al., 1994). The surface zone of articular cartilage 
has been studied since the 18th century, when the surgeon and anatomist William Hunter (1718- 
1783) noted that when ‘viewed with a glass,’ it appeared to be ‘smooth, polished and covered 
with a membrane’ (Hunter, 1743). It is now known that articular cartilage is not covered by a 
membrane, but by a layer o f collagen fibrils that lie tangential to the surface topped with a layer 
o f amorphous, electron-dense material (Ghadially, 1983). It was termed the ‘lamina splendens’ 
by MacConaill in 1951 (MacConaill, 1951), who observed a bright line at the surface of cartilage 
examined by phase contrast microscopy. The term lamina splendens was disputed by Aspden & 
Hukins in 1979, who predicted that its appearance was an artefact of phase contrast microscopy, 
a ‘halo’ effect that is apparent along any incision or scratch made into a section of cartilage 
(Aspden & Hukins, 1979). Since then, studies have confirmed the presence of a specific lamina 
splendens by polarising (Dunham et al., 1988), scanning electron (Teshima et al., 1994) and 
atomic force (Kumar et al., 2001) microscopy. It appears to be comprised o f collagen fibrils 
arranged tangentially to the surface, which is only loosely connected to the underlying fibrous 
structures (Teshima et al., 1994).
1.8.2 Structure & composition o f  the surface o f  articular cartilage
The structure and composition of the articular surface has been the subject of considerable debate 
in the recent past (Ghadially, 1983; Jeffery et al., 1991; Jurvelin et al., 1996; Kumar et al., 2001). 
Viewed by scanning electron microscopy, the surface appears as a tangentially arranged layer of
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collagen fibrils covered by a single layer o f electron dense, amorphous material (Ghadially, 
1983). This is shown in figure 1.10. There are irregularities in the surface coat, and these 
undulations are likely to be a shrinkage artefact o f SEM (Jurvelin et al., 1996). This surface coat 
is proteinic in nature - it can be digested with trypsin and chymopapain but is resistant to 
degradation by testicular and microbial hyaluronidases, keratanase and chondroitinase ABC 
(Stanescu, 1985; Kumar et al., 2001).
1.8.2.1 Proteins at the articular surface o f  cartilage
On the intact articular surface o f cartilage type II collagen is masked from recognition by 
antibodies to collagen. The surface material that protects surface zone type II collagen is thought 
to be mainly proteinic, non-covalently bound to the underlying intercellular matrix and 
synthesised by chondrocytes located in the superficial zone (Noyori et al., 1994a; Jasin et al
1993). It is sensitive to in vivo degradation in a rabbit model of acute inflammatory arthritis, and 
in vitro by activated polymorphonuclear leukocytes and neutrophil elastase (Jasin & Taurog, 
1991). The major proteins o f the articular surface o f cartilage are the collagen-binding small 
proteoglycans fibromodulin and albumin, with fibronectin, decorin and biglycan detected in 
smaller amounts (Noyori et al., 1998). It has been found that the amount o f decorin and biglycan 
in the superficial zone o f intact osteoarthritic cartilage is decreased in comparison to normal 
cartilage (Poole et al., 1996). Other surface zone-specific molecules include clusterin (Khan et 
al., 2001), Dell (Pfister et al., 2001) and superficial zone proteoglycan (SZP) (Schumacher et al.,
1994), which is described in more detail in section 1.9.
1.8.2.2 Phospholipids at the articular surface
In recent years, many studies have championed the hypothesis that surface-active phospholipid 
(SAPL) is a vital lubricant on the surface o f articular cartilage (Schwarz & Hills, 1996; Hills, 
1990; Hills & Monds 1998a). The surface o f articular cartilage is hydrophobic, based on the 
observation that a droplet o f water beads up when placed on a rinsed articular surface, and Hills 
and others propose that SAPL produced by type B synoviocytes and adsorbed to the surface of 
cartilage via synovial fluid is responsible for this hydrophobicity (reviewed in Hills & Crawford,
2003). Water droplets do not appear to bead to the same degree on osteoarthritic cartilage.
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Figure 1.10 -  Scanning electron m icrograph of a section of rabb it a rticu la r cartilage 
processed attached to bone, showing a fairly straight surface. The surface coat, C, presents as 
a layer of electron-dense material lying on the surface. T represents the collagen fibrils arranged 
tangentially to the articular surface. The coat is rarefied or attenuated in places, as shown by 
arrowheads. From (Ghadially, 1983).
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A study to characterise the phospholipid components adsorbed onto the surface of cartilage 
identified phosphatidylcholine, phosphatidylethanolamine and sphingomyelin as the major 
components, with oleic acid as the predominating fatty acid observed with all 3 lipid types 
(Sarma et al., 2001). SAPL has been shown to be deficient on the surface of osteoarthritic hip and 
knee cartilage (Hills & Monds, 1998b). SAPL may be prone to lysis by phospholipase A2, a 
mechanism that may be inhibited by HA present in synovial fluid (Nitzan et al., 2001). It is 
proposed by Hills and others that the protein lubricin (section 1.9) acts as a carrier for SAPL, and 
that SAPL is the true lubricant, as reviewed in (Hills, 2002a). This dispute is described in section 
1.8.3.2. Microscopical studies have identified globular lipid-like structures in the upper surface 
layer of hip and knee cartilage (Watanabe et al., 2000).
1.8.3 Function o f the surface o f articular cartilage
1.8.3.1 Joint lubrication
The surface structure o f articular cartilage provides a highly efficient boundary lubrication 
mechanism with an extremely low coefficient o f friction. Boundary lubrication is a term first 
introduced by Hardy in 1922, when he stated that very thin adsorbed layers were sufficient to 
cause two glass surfaces to slide over each other with very low friction, and that under such 
circumstances the lubrication depended wholly upon the chemical constitution o f the fluid and 
not on its viscosity, and that a good lubricant was a fluid which was adsorbed by the solid 
surfaces (Hardy & Doubleday, 1922). Synovial joints are lubricated and nourished by synovial 
fluid, and in a healthy individual can operate in a wear resistant, frictionless manner for decades. 
In the 1960s two conflicting theories for joint lubrication were proposed, taking into account 
fluid transport across the articular surface. The ‘weeping lubrication’ model o f McCutchen 
(McCutchen, 1959; McCutchen, 1962) proposed that the synovial film is supplied by the 
exudation o f interstitial fluid from compressed cartilage. Conversely, the ‘boosted lubrication’ 
model o f Walker et al. (1968) assumes that viscous accumulations of synovial fluid in the surface 
pores o f articular cartilage separate the two sliding surfaces. A mechanical, ‘biphasic’ model of 
articular cartilage was developed by Mow and co-workers, where the collagen-proteoglycan 
matrix is modelled as an intrinsically incompressible porous permeable solid matrix, and the 
interstitial fluid is modelled as an incompressible fluid (Mow et al., 1980). The triphasic model 
described by Lai et al. (1991) is an extension of the biphasic theory, where proteoglycans are
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modelled as a negative charge density fixed to the solid matrix and monovalent ions in the 
interstitial fluid are modelled as additional phases. A series o f formulas that relate the biphasic 
and triphasic models has recently been described by Ateshian and others (Ateshian et al., 2004). 
Using the development o f these models it has been shown that interstitial fluid pressurisation is 
responsible for increasing the stiffness o f cartilage under dynamic loading, which allows it to 
sustain physiological levels o f stress in the range o f 2-12 MPa. This interstitial pressurisation is 
thought to be the primary mechanism imparting low friction and wear to the surface of cartilage 
(McCutchen, 1962). In 1994, Macirowski and others utilised unique prosthetic instruments to 
collect in situ data regarding cartilage stresses in the human hip joint, the results o f which support 
the ‘weeping’ mechanism of joint lubrication as proposed by McCutchen (Macirowski et al.,
1994). This process has been literally frozen in time by Clark et al., (1999) who have performed 
experiments involving the plunge-freezing o f rabbit joints loaded in vitro followed by sectioning 
and scanning electron microscopy. This reveals a continuous fluid film that separates one 
cartilage surface from the other, avoiding direct contact.
The study o f joint lubrication is a complex area: many different types of lubrication are involved 
(boundary, fluid film, elastohydrodynamic, boosted, weeping), and it is unclear exactly when 
each type o f  lubrication com es into play during the gait cycle. The surface o f  cartilage is 
not un iform , and the types o f  m odels used  to study jo in t lubrication and  the various 
factors that affect it, such as cartilage on glass bearings or latex on glass bearings, are all 
subject to certain lim itations.
1.8.3.2 Lubricin -  a proteoglycan constituent o f  synovial flu id  and the surface o f  articular 
cartilage
Lubricin was first described by Swann et al. (Radin et al., 1970; Swann & Radin, 1972; Swann et 
al., 1973) as a 227.5 kDa mucinous glycoprotein constituent o f synovial fluid that facilitates 
boundary lubrication in diarthrodial joints. It has since been established that lubricin is also 
produced by chondrocytes in the superficial zone of articular cartilage (Schumacher et al., 1994), 
and immunohistochemical analyses have shown that it accumulates at the articulating surface 
(Schumacher et al., 1999; Tudor, 2002). Lubricin has been shown to be a product of PRG4/MSF 
gene expression by synovial fibroblasts (Jay et al., 2000). This molecule is the subject o f this
38
thesis and will be discussed at greater length in section 1.9. Both PRG4 and lubricin contain a 
central domain o f 904 amino acids, 208 o f which are threonine in a repeating sequence of 
K.EPAPTT, putative sites for O-linked glycosylation. Bovine lubricin is 50% (w/w) glycosylated 
with multiple residues of O-linked (3 (1-3) Gal-GalNAc, which are incompletely capped with 
NeuAc to an unknown degree (Swann et al., 1981). Recent digestion studies have found that 
boundary lubrication by lubricin in vitro is provided primarily by extensive O-linked (3 (1-3) Gal- 
GalNAc (Jay et al., 2001a). This indicates that lubricin, by virtue of its extensive glycosylations, 
somehow organizes water to support contact loading. The altered frictional characteristics 
observed in the joints o f PRG4 knockout mice seem to confirm that PRG4/lubricin is critical for 
normal jo in t lubrication (Jay et al., 2003a). PRG4/lubricin is present in tendon (Rees et al., 
2002), and recent preliminary studies have shown that lubricin improves the gliding function of 
extrasynovial tendon in vitro (Kutsumi et al., 2004).
At present, opinions differ as to the true role of lubricin/PRG4 in boundary lubrication. Hills and 
Mond postulate that lubricin is a carrier for surface-active phospholipid, the true lubricant, based 
on the loss o f synovial fluid lubrication following phospholipase digestion and the apparent 
hydrophobicity o f the articular surface (Hills & Mond, 1998a; Hills, 2002a). This would imply a 
similar role for a lubricin/surface active phospholipid complex as for phospholipoprotein in 
alveolar lubrication. Jay and Cha challenged these results by demonstrating trypsin-like activity 
in the phospholipase used by Hills (Jay & Cha, 1999). Hills countered these suggestions by 
stating that removal o f the putative carrier o f surface-active phospholipid, lubricin, would have a 
similarly detrimental effect on lubrication as would removal of surface-active phospholipid 
(Hills, 2002b). Jay responded (Jay, 2002) by questioning the purity o f lubricin obtained in a 
previous study supporting the hypothesis that lubricin is a carrier for surface-active phospholipid 
(Schwarz & Hills, 1998) and drew attention to the results obtained in the study of the removal of 
synovial fluid lubrication by glycosidases (Jay et al., 2001a). According to Jay, resolution of this 
issue will depend on the detection o f elemental phosphorous in purified lubricin. Another view of 
the role o f lubricin in boundary lubrication is provided by a recent biomechanical study: ‘it is 
likely that m  [coefficient o f friction at the articular surface] can be further reduced by a lubricant
such as lubricin, SZP, or phospholipids [but that] the primary mechanism of lubrication is
governed by interstitial fluid pressurisation’ (Park et al., 2003).
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Hyaluronan gives healthy synovial fluid its viscosity and is present at the surface of articular 
cartilage. However, it is thought that it does not directly contribute to the boundary lubrication 
mechanism described above (Tadmor et al., 2002). Joint articulation is an inherently cyclic 
process, and the viscosity of synovial fluid due to hyaluronan could be important in minimising 
the outflow of the fluid film at the surface during the period of time that a particular area of 
cartilage is loaded (reviewed in Simkin, 2000). An interaction between lubricin and hyaluronan 
has been proposed but not conclusively demonstrated (Jay et al., 2003a; Jay et al., 2003b). 
V iscosupplementation (reviewed in Kirwan, 2001) refers to the intra-articular injection of 
hyaluronan, and is purported to increase lubrication as well as having an anti-inflammatory 
effect. However, the large placebo response in viscosupplementation studies makes it hard to 
assess the clinical efficacy of this technique.
1.8.3.3 Barrier function o f  the surface o f  articular cartilage
Recent work has suggested that the mature superficial zone o f articular cartilage can act as a 
barrier against substances that invade from the surface (Takada et al., 1999). However, cartilage 
is an avascular and alymphatic tissue, and the resident cells depend on diffusion o f soluble 
nutrients from the joint cavity and from subchondral bone. It has been found that the superficial 
zone o f articular cartilage does not constitute a barrier to the transport o f macromolecular solutes 
of up to 440 kDa into the deeper zones (Uesugi & Jasin, 2000).
IgG is found in small amounts in normal cartilage, and has been shown to bind to an unspecified 
cartilage component in cartilage homogenates (Alomari et al., 1983). It has been proposed that 
immune complexes found in the superficial zone of articular cartilage in RA (Cooke et al., 1975) 
and in antigen-induced arthritis are formed because pre-existing antibody normally present in 
cartilage irreversibly traps antigen within the tissue (Jasin, 1975).
The intact surface o f articular cartilage is thought to resist the adhesion of inflammatory cells 
(Shiozawa et al., 1992; McCurdy et al., 1995; Mitani et al., 2001). Macromolecules normally 
present on articular cartilage surfaces, such as fibromodulin, decorin and biglycan (Poole et al.,
1996) are thought to act as a barrier to polymorphonuclear neutrophil (PMN) adhesion (Mitani et 
al., 2001). This is in contrast to elastase-treated cartilage explants reconstituted with fibronectin,
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which sustain PMN adhesion (Noyori & Jasin, 1994). PMN make up a significant proportion of 
the synovial fluid cells in rheumatoid arthritis and there is evidence to suggest these cells and 
their products, particularly proteolytic enzymes, are present at the cartilage-pannus junction and 
may be responsible for cartilage damage (Jasin & Taurog, 1991; Edwards & Hallett, 1997). 
Studies concerned with the organisation of the intact surface o f adult articular cartilage should 
yield valuable insights into the pannus-mediated degradation o f cartilage in inflammatory 
arthritis - breakdown o f the surface layer o f articular cartilage could be a preliminary event 
leading to the attachment o f inflammatory cells and the invasion of pannus. The term pannus 
applies to macroscopical cloth-like tissue covering articular cartilage in rheumatoid arthritis, but 
recent studies have shown the presence o f a pannus-like tissue on osteoarthritic cartilage 
(Shibakawa et al., 2003).
1.9 Proteoglycan 4 (PRG4)
A number of surface zone-specific molecules have been found in articular cartilage, and these 
include D ell (Pfister et al., 2001), clusterin (Khan et al., 2001) and PRG4. PRG4 is a 
proteoglycan of 1054 amino acids with a molecular weight o f around 345 kDa. It has a number of 
aliases owing to its different routes of discovery (shown in figure 1.11) including megakaryocyte 
stimulating factor (MSF) precursor protein (Merberg et al., 1993), camptodactyly-coxa-vara- 
pericarditis (CACP) protein (Marcelino et al., 1999), lubricin (Swann et al., 1985) and cartilage 
superficial zone proteoglycan (SZP) (Schumacher et al., 1999). PRG4 is the unifying gene name 
assigned by the Human Genome Organisation (HUGO) Gene Nomenclature Committee 
(HGNC). The molecule is not homologous to p53-responsive gene 4, which is also known as 
PRG4 (Horikoshi et al., 1999).
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F igure 1.11 -  The m any m onikers of PRG 4: clarification of a confusing nomenclatural 
situation. Different names have been given to products o f the PRG4 gene, resulting from different 
routes of discovery.
/. 9.1 Isolation and Location o f  PRG4
PRG4 was first described in articular cartilage synthesised specifically by chondrocytes of the 
superficial zone, and also by some of the surface lining cells present in the villi o f the synovium 
of diarthrodial joints (Schumacher et al., 1994; Schumacher et al., 1999). Cartilage PRG4 was 
first isolated by Schumacher et al. (1994) from the culture medium of thin slices o f bovine 
superficial zone articular cartilage. It was not found to be produced in the middle or deep zones. 
It contains KS and CS chains, but treatment with chondroitinase and keratanase resulted in only a 
minor shift in electrophoretic mobility, suggesting that there are low levels of KS and CS 
substitution. It is not retained in the cartilage matrix, and can be detected in synovial fluid. 
Immunodetection of PRG4 at the surface o f cartilage and tendon is more apparent in mature 
tissues, and this may be due to the maturation o f the collagen architecture at the matrix surface, 
which could form a barrier that entraps PRG4 (Schumacher et al., 1999; Rees et al., 2002).
Studies with monoclonal antibodies raised against bovine PRG4, including 3-A-4 and 6-A -l, 
confirm ed the location o f  PRG4 at the cartilage surface (Schum acher et al., 1999). 
Immunodetection studies also revealed that although PRG4 is not incorporated into the matrix 
per se, it does accumulate in the superficial matrix at the interface between the cartilage surface
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and the synovial cavity. Along with cartilage intermediate layer protein (CILP), PRG4 appears to 
be a phenotypic marker, indicative o f chondrocytes o f a particular morphological zone. Figure 
1.12 shows the location o f PRG4 in bovine articular cartilage as described in the 
immunohistochemical studies o f Tudor (2002).
PRG4 has also been found in other tissues. Further work with the antibodies described above has 
located PRG4 as residing in a distinct layer of the surface of mature compressed tendon (Rees et 
al., 2002). Expression o f human and mouse PRG4 mRNA has been found not only in cartilage 
but also in liver, heart, lung and bone (Ikegawa et al., 2000). Other researchers are involved in 
quantifying PRG4 concentrations in the serum and synovial fluid o f healthy and diseased 
individuals (Schmid et al., 2001), and developing and utilising cross-species PRG4 antibodies 
(Su et al., 2001).
1.9.2 Structure and potential functions o f PRG4
Monoclonal antibodies were also used by Schumacher et al. (Schumacher et al., 1999) to isolate 
a Xgt 11 clone producing a fusion protein corresponding to the C-terminal portion o f PRG4. The 
partial cDNA sequence obtained was subjected to a BLAST search and was shown to display a 
high degree o f homology with human megakaryocyte stimulating factor (MSF) precursor mRNA. 
MSF has been shown to be a complex glycoprotein that displays some homology to vitronectin 
(Merberg et al., 1993). In work from this laboratory, primers were designed specific to N- 
terminal regions o f bovine PRG4 using the previously published sequence for human MSF 
precursor. This study further highlighted the homology between human and bovine PRG4 and 
MSF precursor, and led to the postulation that the two proteins originate from the same 12-exon 
gene (Flannery et al., 1999).
1.9.2.1 PRG4 domain structure
Based on the partial cDNA sequence for bovine PRG4 and the published sequence for MSF 
precursor protein, PRG4 is considered to have a number o f structural motifs, which in turn 
indicate that the molecule has the potential for numerous diverse functions (Merberg et al., 1993; 
Flannery et al., 1999). A schematic representation o f the structure o f PRG4 is shown in figure 
1.13, and a sequence comparison between bovine and human species is shown in figure 1.14.
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Figure 1.12 -  Im m unoloealisation of PRG4 in adult bovine articu lar cartilage using the 
monoclonal antibody 3-A-4. (A) -  Vertical section o f cartilage stained with 3-A-4 and viewed 
by microscopy. (B) -  Similar section viewed by microscopy but with no primary antibody. 
Adapted from (Tudor, 2002).
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Figure 1.13 -  Schematic representation of the structure  of human articular cartilage PRG4.
Functional domains are indicated by coloured boxes. Adapted from Flannery et al., 1999.
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Hum FFKRGGSIQQYIYKQEPVQKCPGRRPALNYPVYGEMTQVRRRRFERAIGPSQTHTIRIQY 1320  
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Figure 1.14 -  Alignment of amino acid sequences for human and bovine PRG4. Sequences 
are from human monocytes and bovine articular cartilage chondrocytes (GenBank Accession 
Nos. NM005807 and AF056218, respectively). The top (numbered) line in each row represents 
the sequence for human PRG4, with exons and boundaries indicated by lines and arrowheads 
above the sequence. Bovine PRG4 sequence identified in this study is shown in bold. Consensus 
sequences for N-glycosylation (NXS/T) and chondroitin sulphate substitution (DEAGSG) are 
underlined. Several o f the mucin-like repeats are included though most o f the exon 6 sequence 
has been omitted for clarity. Heparin binding consensus sequences are shown in red. N-terminal 
and C-terminal domains targeted for cloning and expression in this study are indicated by ‘N- 
temT and ‘C-term’ bold type. Adapted from Flannery et al., 1999.
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At the N- and C-termini there are domains similar to those found in vitronectin, and these may 
impart cell-proliferative and matrix binding properties. The central part o f the molecule contains 
a 940 amino acid stretch o f large and small mucin-like repeats, and this region is likely to be 
heavily substituted with O-linked oligosaccharides indicating that PRG4 has a lubricating role. 
Lubricin is a 228 kDa mucinous glycoprotein responsible for the boundary lubrication of 
synovial joints, and it appears to be the product of PRG4/MSF/SZP gene expression, displaying 
100% homology with exons 6 through 9 (Jay 2000; Jay et al., 2001b). The exact relationship 
between lubricin and PRG4 is still unclear, but based on the assumption that both molecules 
undergo the same post-translational modifications it is likely that PRG4 functions as a boundary 
lubricant in the same way that lubricin does. Jay et al. (2001b) have suggested that PRG4 and 
lubricin occupy a new class o f biomolecules termed tribonectins, a term derived from tribology 
and the Latin nectere, meaning “to bind or connect”. Tribology is the study of sliding surfaces in 
relative motion and the impact o f different factors on the friction between the two surfaces.
Two somatomedin B-type domains at the PRG4 N-terminus could bind plasminogen activator 
inhibitor-1 and inhibit plasmin generation, based on sequence comparisons with vitronectin 
(Merberg et al., 1993). The C-terminal portion of PRG4 contains an uneven number of cysteine 
residues, and this may facilitate self-aggregation, as seen in secretory mucins (Gum, 1995). This 
self-aggregation could explain the accumulation o f PRG4 at the surface of cartilage. Matrix 
binding could also be explained by the putative heparin-binding domain located within the N- 
terminal domain of the molecule (Merberg et al., 1993; Flannery et al., 1999).
1.9.3 Megakaryocyte Stimulating Factor (MSF) precursor
PRG4 was first documented with the cloning o f the homologous MSF precursor protein and the 
subsequent determination o f its genomic and cDNA sequences led to the prediction of its 
multidomain structure (Merberg et al., 1993). MSF was first detected in and subsequently 
purified from the urine of bone marrow patients during the period of acute thrombocytopaenia 
(Ogata et al., 1990; Turner et al., 1991). Purified urinary MSF has a molecular weight o f 28-35 
kDa under reducing conditions, and represents an N-terminal portion o f the PRG4 protein. In 
murine bone marrow fibrin clot cultures, urinary MSF stimulates the growth o f both pure and 
mixed megakaryocyte colonies with a specific activity of greater than 5 x 107 units per milligram
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of protein. The researchers that isolated and cloned the MSF (PRG4) gene performed sequence 
analyses and noticed that several regions were very similar to domains of vitronectin (Merberg et 
a l 1993). Vitronectin is a 75 kDa glycoprotein, and is a member of a group of adhesive plasma 
proteins which includes fibrinogen, fibronectin and von Williebrand factor (for a review see 
Schvartz et al., 1999). It is a multifunctional regulator of both complement and coagulation 
systems, and is also known as serum spreading factor or complement S protein. It is anchored to 
the extracellular matrix via collagen or proteoglycan binding, and promotes cell attachment, 
spreading and migration through specific interactions o f a single RGD peptide with integrins. 
Vitronectin can potentially influence extracellular matrix breakdown by virtue o f its ability to 
bind plasminogen activator inhibitor-1 (PAI-1). Some o f the structural similarities between 
vitronectin and MSF/PRG4 are detailed below. These similarities contribute to the theoretical 
functions o f cartilage PRG4.
1.9.3.1 Somatomedin B domains
There are two somatomedin B (SMB) domains in the N-terminal portion o f PRG4, encoded for 
by exons 2 and 3, and these domains are similar to the SMB domain encoded by exon 2 of 
vitronectin (M erberg et al., 1993). SMB, produced by proteolytic cleavage o f vitronectin, 
circulates in serum and was originally believed to have growth promoting activity, although this 
was later found to result from contamination by EGF (Heldin et al., 1981). The somatomedin B 
domain of vitronectin has been implicated in the binding of plasminogen activator inhibitor-1 
(PAI-1) (Seiffert & Loskutoff, 1991). PAI-1 is a highly specific serine protease inhibitor, and 
regulates the activity o f plasminogen activators that catalyse the conversion o f the zymogen 
plasminogen into plasmin. Plasmin is a protease of broad specificity, and has the capacity to 
degrade many extracellular proteins including proteoglycans, either directly or by the activation 
of procollagenase. PAI-1 in solution is unstable and rapidly decays into an inactive inhibitor, and 
the binding o f PAI-1 to vitronectin appears to stabilise PAI-1 in an active configuration. A 
number o f potential PAI-1 binding sites have been identified within vitronectin, the highest 
affinity being within the SMB domain (Seiffert & Loskutoff, 1991; Royle et al., 2001). There is 
also evidence that cells may bind to vitronectin through urokinase receptor (uPAR) mediated 
attachment to the SMB domain (Okumura et al., 2002). Furthermore, it appears that PAI-1 bound 
to vitronectin sterically hinders cellular attachment to the SMB domain through uPAR (Deng et
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al., 2001), and that urokinase plasminogen activator (uPA) can reverse this process by binding to 
PAI-1 and causing it to be released from vitronectin (Mimuro & Loskutoff, 1989). This would 
suggest that both the fibrinolytic system and cell adhesion and migration are locally modulated 
by the relative balance between vitronectin, uPAR and PAI-1. SMB contains 8 cysteine residues 
that were thought to create 4 disulphide bonds in a linear, uncrossed manner (Kamikubo et al. , 
2002). However, more recent work investigating the crystal structure o f the somatomedin B-PAI- 
1 complex has revealed the presence o f crossed disulphide bonds which constrain the peptide as a 
novel disulphide bonded knot (Zhou et al., 2003), as illustrated in 1.15B. The conservation of 
cysteine residues between SMB and PRG4 shown in figure 1.15A would suggest a similar 
secondary structure for the two SMB domains o f PRG4.
Besides vitronectin and PRG4, three other proteins have been found to contain somatomedin B 
domains: PC-1, a plasma cell membrane glycoprotein (Oda et al., 1991); Tcl-30, a T cell specific 
protein expressed in immature thymocytes (Baughman et al., 1992) and PP11, a human placental- 
specific protein (Grundmann et al., 1990). Between these five molecules, eight cysteine residues 
are conserved in the somatomedin B domains. The presence o f somatomedin B domains in the 
form of MSF/PRG4 that stimulates megakaryocytes implies that this domain has proliferative 
effects, but this has yet to be shown definitively (Merberg et al., 1993).
1.9.3.2 Heparin binding domains
PRG4 contains 2 ‘C ardin-W eintraub’ heparin binding consensus sequences (Cardin & 
Weintraub, 1989) in exons 4 and 10, shown in red in figure 1.14. The heparin binding domain of 
vitronectin has been shown to exhibit conformational flexibility. Vitronectin exists in a native 
form that does not bind heparin and a conformationally altered, heparin binding form. Both forms 
bind to the extracellular matrix, however there is evidence to suggest that only the 
conformationally altered form is cleared from the matrix by receptor-mediated endocytosis for 
subsequent degradation by lysosomes (Panetti & McKeown-Longo, 1993). Vitronectin contains a 
cAMP-dependent protein kinase phosphorylation site at the carboxyl terminus o f the heparin 
binding domain, KKKTK, which has shown to be phosphorylated (McGuire et al., 1988). An 
identical site exists in exon 4 o f PRG4, though its phosphorylation status has not been 
investigated. The heparin binding capability of PRG4 has not been formally documented.
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Figure 1.15 -  Amino acid sequence com parison between human SMB and hum an PRG4 
and predicted disulphide bonds of hum an somatomedin B (SMB). Sequence comparisons 
between somatomedin B and the two somatomedin B-like domains of PRG4 are shown in (A). 
Conserved residues are highlighted in bold. Disulphide bonds in human somatomedin B were 
determined by crystallography (Zhou et al., 2003) and are shown in (B).
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1.9.3.3 Hemopexin domains
Exons 8 and 9 o f PRG4 are homologous to exons 4 and 5 of vitronectin, and are hemopexin-like 
domains, with central hydrophobic motifs and proximal aromatic residues. Hemopexin is a 60 
kDa heme-binding plasma glycoprotein that transports heme to the liver: heme-hemopexin 
complexes are delivered to hepatocytes by receptor-mediated endocytosis after which hemopexin 
is recycled to the circulation (reviewed in Delanghe & Langlois, 2001). It is not only the plasma 
transporter o f heme but also acts as a multifunctional agent in processes including iron 
homeostasis, antioxidant protection and bacteriostatic defence. After haptoglobin, hemopexin 
forms the second line o f defence against haemoglobin-mediated oxidative damage during 
intravascular haemolysis. The C-terminal hemopexin-like domains of matrix metalloproteinases 
have specific roles in the binding o f collagens and TIMPs (reviewed in Murphy & Knauper,
1997).
1.9.3.4 Other PRG4-vitronectin comparisons
Unlike vitronectin, PRG4 does not contain an RGD tripeptide for integrin-mediated cell binding. 
It may however share some o f the adhesive properties o f vitronectin: PRG4 exon 12 contains the 
pentapeptide IDVPS, a similar sequence to the LDVPS m otif found in the CS-1 peptide of a 
fibronectin splice variant. This m otif is responsible for the binding of fibronectin to the VLA-4 
integrin receptor. Exon 7 o f  PRG4 is very similar to the carboxy end of vitronectin exon 3. The 
high proportion of conserved residues suggests a biological property common to both vitronectin 
and PRG4, as these sequences appear to be unique (Merberg et al., 1993).
1.9.4 PRG4 exon 6: mucin domain
In its central region o f around 940 amino acids, encoded by exon 6, PRG4 contains large and 
small mucin-like repeat domains composed o f the sequences KEPAPTTT/P (76-78 repeats) and 
XXTTTX (6-8 repeats) (Flannery et al., 1999). The length of these mucin-like domains may vary 
between species (Ikegawa et al., 2000). The potential o f PRG4 to act as a synovial joint lubricant 
due to its central mucin domain is discussed in section 1.8.3.1.
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1.9.4.1 Mucins
Mucins are the major glycoprotein components o f mucous, a viscous secretion that protects 
epithelial cells from infection, dehydration and physical or chemical injury (Perez-Vilar & Hill 
1999). Members o f the mucin family vary in size but all contain domains rich in proline, 
threonine and/or serine (PTS regions) that are substituted with O-linked oligosaccharides, to a 
degree o f 40-80% [w/w] in a mature mucin (Van Klinken et al., 1995). These glycosylated PTS 
regions consist o f tandem repeat sequences o f serine and/or threonine that contain at least one 
proline residue per repeat (Gum, 1995). The length o f these repeats and their total number vary 
from mucin to mucin. Many individual mucins also show length polymorphisms resulting from 
multiple alleles that encode different numbers o f tandem repeats (Vinall et al., 1998). The 
attached oligosaccharides may contain between one and twenty sugar residues, and these may be 
neutral, sulphated or substituted with sialic acid. The functions o f mucins depend on these 
carbohydrate structures in forming viscous gels by virtue o f their filamentous conformation, large 
volume and charge repulsion in aqueous solution. Because of their large, often negatively 
charged structure, mucins can act as a barrier protecting the cell, although when other cells have 
specific receptors for mucins, adhesion can override the barrier function (Van Klinken et a l ,
1995). They also help to protect against infection by microorganisms that bind to cell surface 
carbohydrates, and mucin genes appear to be upregulated by substances derived from bacteria, 
such as lipopolysaccharides (Dohrman et al., 1998). There are two groups of mucin: membrane- 
bound and secreted. M embrane-bound mucins such as MUC1 form part o f the cell surface 
glycolax and protect against pathogens (Perez-Vilar & Hill, 1999). They can also function as 
anti-cell adhesion molecules, and their overexpression in cancer may be related to tumour 
dissemination. Secreted mucins such as MUC2 are generally larger, with cysteine-rich regions 
flanking the central glycosylated region. These domains have been implicated in the aggregation 
of MUC2 monomers into large polymers, and are thought to be similar in structure to vWF, an 
extracellular molecule that is known to multimerise. For example, the mucin PSM is thought to 
form dimers in the endoplasmic reticulum (ER) through its C-terminal CK domains. These 
dimers then form multimers in the Golgi complex through their N-terminal D-domains (Perez- 
Vilar & Hill, 1999). O-glycosylation is thought to occur in the Golgi complex and N- 
glycosylation occurs in the ER. The role of secretory mucins is to lubricate and protect the tissues 
they line.
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I .9.5 PRG4 in Disease
1.9.5.1 Influence o f  cytokines and growth factors on PRG4 expression in vitro
PRG4 and its associated functionality may be critical in the onset of joint pathology, as it is 
situated at the interface between cartilage and synovium. Superficial zone chondrocytes cultured 
in agarose have been shown to differentially express PRG4 under the influence of cytokines and 
growth factors. IL-1 appears to inhibit PRG4 biosynthesis, whilst TGF-p and IGF-1 upregulate 
levels o f both PRG4 message and protein (Flannery et al., 1999). IL-1 mimics aspects of 
inflam m ation in vitro , so it could be postulated that the inhibition o f PRG4 expression in 
inflamed joints would remove its potential protective proclivity at the cartilage surface. In 
rheumatoid arthritis, this may contribute to the invasion of the articular surface by a proliferating 
synovial pannus. IL-1 also seems to downregulate PRG4 expression in mature compressed and 
young tensional tendon (Rees et al., 2002), and recent studies have described the suppressive 
effect o f IL-1 and the stimulatory effect o f TGF-P on PRG4 expression by chondrocytes in 
cartilage explants (Schmidt et a l ,  2004). However, a conundrum exists: why would the body 
switch off the expression of a protein with potential protective properties during inflammation? 
However, although IL-1 appears to downregulate the expression of PRG4 by chondrocytes in 
vitro, recent work by Schumacher and others has described the presence of PRG4 at the surface 
of osteoarthritic cartilage (Schumacher et al., 2004).
1.9.5.2 Osteoathritis & PRG4
In osteoarthritic cartilage, an alternatively spliced form of PRG4 mRNA exists which lacks exons 
encoding part o f the N-terminal matrix-binding and cell-proliferative domain, including the 
heparin binding site (Flannery et al., 1999). Expression o f this truncated form during 
osteoarthritis and the possible resultant change in structure and function o f PRG4 could 
contribute to joint pathology. Multiple tissue-specific splice variants of the PRG4 gene have been 
detected as mRNAs in healthy cartilage, liver, lung, heart and bone (Ikegawa et al., 2000). As 
well as confirming that PRG4 and splice variants thereof could function in several distinct 
biological processes, this also suggests that PRG4 splice variants are not necessarily inherent to 
disease.
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1.9.5.3 CA CP syndrome
Recently, a study into the autosomal recessive disorder camptodactyly-arthropathy-coxa vara- 
pericarditis (CACP) syndrome discovered that its cause is a result o f mutations in the CACP 
gene, effectively the PRG4 gene (Marcelino et a l , 1999). This disorder affects joints and 
tendons. In affected individuals, flexion contractions of finger joints (camptodactyly) are usually 
present at birth, or noticed within the first year o f life (Athreya & Schumacher, 1978). Swelling 
and stiffness o f large joints (arthropathy) typically develops between 3 and 8 years of age, and is 
associated with a non-inflammatory synovial hyperplasia. Some CACP patients also develop a 
non-inflammatory pericarditis (thickening o f the fibrous sac around the heart) in the first or 
second decades of life). Alternatively, coax-vara deformity (a radiographic change in the angle of 
the hip joint) may occur (Verma et al., 1995; Bahabri et al., 1998). Eight mutations of the CACP 
protein (PRG4) have been found, all o f them truncated at the C-terminus that contains the 
hemopexin-like and possible aggregation domains (see figure 1.12). Analysis o f the frictional 
characteristics o f PRG4/CACP knockout mice joints using a modified Stanton pendulum 
technique has confirmed that the CACP phenotype includes a reduction in diarthrodial lubrication 
(Jay et al., 2003a). This is supported by the observation that synovial fluid from CACP patients 
displays a reduced boundary lubricating ability (Jay et al., 2003b). Jay and co-workers postulate 
that a potential interaction between HA with the C-terminal o f PRG4 is central to the lubricating 
function o f PRG4, and that this interaction may be interrupted by the C-terminal truncating 
mutations of CACP syndrome.
1.9.5.4 Tissue engineering and PRG4
Articular cartilage can degenerate over time, and has a minimal capacity for self-repair. Tissue 
engineering approaches to repair cartilage defects are under active investigation, and recent 
efforts have focussed on fabricating cartilaginous tissue in vitro for transplantation into patient 
tissue, reviewed in (Risbud & Sittinger, 2002). Most attempts have been based around the 
seeding o f cultured cells into an artificial, degradable scaffold, although new approaches are 
being developed. For example, the alginate-recovered-chondrocyte (ARC) method retains certain 
properties of immature cartilage, which has the capacity for repair, by culturing cells in a three- 
dimensional gel to generate a pericellular matrix. These cells and their newly formed matrix can 
then be released from the gel and seeded onto cell culture inserts at a high density, which
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produces a de novo cartilaginous matrix (Masuda et al., 2003). A recent study has utilised this 
method with the intention of engineering cartilage constructs that include features o f normal 
stratification by culturing subpopulations o f chondrocytes from different cartilage zones (Klein et 
a l 2003). By culturing superficial and middle zone chondrocytes, a cartilage construct has been 
produced that displays some aspects o f normal physiological stratification, including the 
expression o f PRG4 at the superficial surface. This ‘biomimetic’ approach o f engineering 
cartilage tissue with zonal stratification may be useful within a variety of methods for forming 
cartilaginous tissue in vivo.
1.9.5.5 PRG4 and prosthesis loosening
Approximately 10% of hip endoprostheses loosen after 10 years, caused by either septic or 
aseptic loosening. A recent study investigating the differences in gene expression in these two 
pathomechanisms found a strong upregulation (from 20- to 323-fold) o f MSF/PRG4 gene 
expression in all aseptic and some septic cases (Morawietz et al., 2003), leading to the hypothesis 
that the lubricating property o f PRG4 may disturb the tight interaction between bone and 
prosthesis. Further investigation of this phenomenon is ongoing.
1.9.5.6 Other studies relating to PRG4 in disease
A subtractive suppressive hybridisation study into the differential gene expression in the 
synovium o f rheumatoid and osteoarthritic joints has found PRG4 to be constitutively over­
expressed in rheumatoid synovium (Jiisten et al., 2000). Along with the other genes identified, 
this suggests that different matrix proteins and cell-matrix interactions are relevant for 
rheumatoid arthritis and osteoarthritis, and that some of these interactions could involve PRG4. 
Suppression subtractive hybridisation studies into immune-relevant genes affected by hepatic 
acute phase response in the livers o f rainbow trout have documented the upregulation of a 
vitronectin-like protein very similar to MSF. The tentative conclusion drawn by the authors was 
that the molecule could boost thrombocyte production, a useful activity during an acute phase 
response (Bayne et al., 2001). Megakaryocyte stimulating factor (PRG4) has also been identified 
as a viral-induced gene of Japanese flounder (Aoki et a l, 1999).
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1.10 Project Aims
PRG4 is a relatively newly identified extracellular matrix component that is secreted by 
chondrocytes of the superficial zone of articular cartilage and by synoviocytes. Primary sequence 
information and experimental data from a number of studies indicate that the molecule is a 
multidomain glycoprotein/proteoglycan that has the potential for a number of functions including 
cell proliferation and adhesion, cytoprotection, self-aggregation and lubrication These functions 
may be compromised during arthritic disease. However, at present there is little information 
regarding the potential biological activities that can be mediated by different domains of PRG4.
The aims o f this project were:
• To obtain the non-mucinous N- and C-terminal domains o f human and bovine PRG4 by 
means of recombinant protein expression.
• To investigate the potential multifunctionality of PRG4 by characterising the functions of 
its different structural domains. This is to be achieved by utilising recombinant proteins in 
binding/interaction assays with extracellular and cellular components o f the synovial 
joint.
• To determine the susceptibility o f PRG4 to degradation by matrix proteinases using 
recom binant domains and purified full-length PRG4 as substrates in digestion 
experiments.
• To determine the biological role or roles o f PRG4 and its different structural domains in 
the synovial joint.
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2. PURIFICATION AND BIOCHEMICAL CHARACTERISATION OF PRG4
2.1 Introduction
The objective of this section was to develop methods for the purification of PRG4 from the 
conditioned culture medium of (a) superficial zone chondrocytes isolated from bovine articular 
cartilage, (b) bovine tendon explant cultures, and (c) a stable, human PRG4-expressing Chinese 
hamster ovary (CHO) cell line. This material could then be used for biochemical characterisation 
studies and analyses o f PRG4 domain biological fimction(s). Purified PRG4 could also then be 
used for in vitro proteinase digestion experiments as described in Chapter 5 of this study.
2.2 Materials and Methods
2.2.1 Materials
All chemicals were of analytical grade and were purchased from Sigma-Aldrich (UK) unless 
indicated otherwise. A detailed list o f the materials used in this research project and their 
suppliers is listed in Appendix A. Tissue culture plastics were purchased from Coming, and all 
water used was drawn from a MilliQ Plus 185 purification unit (Millipore). Pipette tips and 
glassware were autoclaved prior to use in tissue culture.
2.2.1.1 Stock solutions
Stock solutions and their components are listed in table 2.1. Non-sterile solutions for tissue 
culture were autoclaved or filtered before use (0.22p,m filters, Millipore). Hydrochloric acid, 
acetic acid, sodium hydroxide, methanol and ethanol were all purchased from Fisher Scientific, 
UK. Phosphate buffered saline (PBS) was purchased as tablets from Oxoid, UK (Dublecco A 
formula.).
2.2.1.2 Origin o f  PRG4-expressing CHO cell line (CHO-MegK)
The CHO-MegK stable cell line, expressing full-length human PRG4, was a gift from Dr. Lori 
Fitz of Wyeth Research (formerly Genetics Institute, Cambridge, MA, US). In the generation of 
this cell line, the plasmid used to transfect CHO DUKX cells utilised the dihydrofolate reductase 
(DHFR)/methotrexate selection and amplification system (Alt et al., 1978).
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Table 2.1 -  Stock solutions and their components.
Solution Components
2X SDS-PAGE sample buffer 0 .125M Tris-HCl, pH 6.8, 4% [w/v] SDS, 20% [w/v] glycerol, 
0.01% fw/v] bromophenol blue
SDS-PAGE running buffer 25mM Tris-HCl, 192mM glycine, 0.1% fw/v] SDS
Western blot transfer buffer 25mM Tris-HCl, pH 8.1-8.4, 192mM glycine, 20% [v/v] methanol
Tris-buffered saline with azide (TSA) 50mM Tris-HCl, pH 7.4, 0.2M NaCl, 0.02% [w/v] NaN3
AP buffer for BC1P/NBT substrate lOOmM Tris-HCl, pH 9.55, lOOmM NaCl, 5mM MgCl2
BC1P (5-bromo-4-chloro-3-indoyl phosphate) 50mg/ml in dimethylamide
NBT (nitro blue tetrazolium) 50mg/ml in 70% [v/v] dimethylformamide
D issociative buffer for CsCl density gradient 
centrifugation
8M Guanidine-HCl, pH 6.8, 0.1M  sodium acetate, protease 
inhibitors 0.02M EDTA, 0.2M 6-AHA, lOmM benzamidine and 
ImM PMSF
Heparin agarose equilibration buffer lOOmM Tris-HCl, pH 7.5, 50mM NaCl.
Heparin agarose elution buffer (stock) lOOmM Tris-HCl, pH 7.5, 2M NaCl
PNA lectin agarose equilibration buffer lOmM Tris-HCl, pH 7.8, 0.15M NaCl
PNA lectin agarose elution buffer lOmM Tris-HCl, pH 7.8, 0.15M NaCl, 0.1-1M D-galactose
Tris-buffered saline for HA affinity blotting 20mM Tris-HCl, pH 7.4, 0.5M NaCl
Phosphate buffered saline (PBS) Dulbecco A
0.16M NaCl, 3mM KC1, 8mM Na2H P 04, KH2P 0 4, pH 7.3
Briefly, methotrexate is a folate analogue and binds to and inhibits DHFR, an enzyme that 
catalyses the regeneration of tetrahydrofolate, a versatile carrier of activated one-carbon units that 
are needed for the de novo synthesis of purines and pyrimidines. CHO DUKX cells are deficient 
in DHFR, so cells transfected with a vector containing a DHFR gene and a target protein gene 
will be resistant to methotrexate (Kaufman, 1989). The heat-inactivated FCS used to culture the 
CHO cells was dialysed against PBS using 12-14,000 molecular weight cut-off dialysis 
membrane (Spectrapor) to remove nucleosides. For expansion of cell culture, cells were grown in 
medium containing 0.5mM methotrexate. Methotrexate was purchased from Sigma as (+)- 
Amethopterin. A stock solution was prepared by dissolving lg  methotrexate in 20ml of 0.1 M 
NaOH, followed by the addition of lOpl volumes o f 10M NaOH until the solution became clear. 
This yielded a stock with a methotrexate concentration of approximately 0.1M, and molarity was 
calculated by reading absorbance at 370nm, based on the assumption that a 1M solution has an 
absorbency value of 8100. Methotrexate stock solutions were wrapped in foil and stored at -20°C.
2.2.1.3 Tissue culture
All cell culture plates and 0.2pm  filter units were from Corning Costar and Millipore 
respectively. Bovine metacarpophalangeal joints from animals aged 2-3 years were obtained from 
a local abattoir. Pronase (Streptomyces griseus) was from Boehringer-Mannheim (Roche
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Diagnostics). Type 2 collagenase (Clostridium histolyticum) was from Worthington Biochemical 
Corporation, New Jersey, USA. D ulbecco’s ’ Modified Eagle Medium (DMEM), M EM a 
medium, chemically defined (CD) CHO medium, L-Glutamine, penicillin, streptomycin, 
gentamicin, trypsin and foetal calf serum were obtained from Invitrogen. All media, serum, 
antibiotics and other supplements were filtered before use. Low melting temperature agarose 
(SeaPlaque GTG) was obtained from FlowGen, Staffordshire, UK. Formulations o f the culture 
media used are detailed in table 2.2.
Table 2.2 -  Formulation o f cell and tissue culture media
Function of culture medium Culture medium Supplements
Pronase digestion o f  bovine cartilage DMEM (Dublecco’s modified 
eagle medium)
10% [v/v] FCS, 50pg/ml gentamicin, 
0.1% [v/v] pronase
Collagenase digestion o f  bovine 
cartilage
DMEM 10% [v/v] FCS, 50pg/ml gentamicin, 
0.04% [v/v] type 11 collagenase
Agarose culture o f  bovine 
chondrocytes
DMEM 5% [v/v] FCS, 50pg/ml gentamicin, 
25pg/ml phosphotin C
Bovine tendon explant preculture DMEM 10% [v/v] FCS, 50pg/ml gentamicin
Bovine tendon explant culture DMEM 50pg/ml gentamicin
CHO cell expansion MEMa 10% [v/v] heat inactivated FCS 
(dialysed against PBS), ImM L- 
glutamine, lOOU/ml penicillin G, 
lOOpg/ml streptomycin, 0.5mM  
methotrexate
CHO cell expression CD (chemically defined) CHO 
medium
ImM L-glutamine, lOOU/ml penicillin 
G, 1 OOpg/ml streptomycin
2.2.1.4 Protein purification
Heparin-agarose and PNA lectin-agarose was obtained from Sigma-Aldrich Co. The matrix in 
each case was cross-linked 4% beaded agarose.
2.2.1.5 SDS-PAGE
Pre-cast gradient SDS-PAGE gels (4-12%) and gel running apparatus were from Invitrogen. Slab 
gels were poured using acrylagel and bisacrylagel from National Diagnostics. Molecular weight 
standards were from BioRad. Protran BA 83 pure nitrocellulose (0.2 pM ) designed for high 
binding capacity and low background noise was from Schleicher and Schuell. Transfer tanks and 
power packs for the electro-elution o f SDS-PAGE gels onto nitrocellulose were from BioRad.
59
2.2.1.6 Proteinase inhibitors
Proteinase inhibitors were added to the conditioned culture medium of CHO cells, tendon 
explants and chondrocytes, and also to purification products, but not if the products were to be 
used in in vitro proteinase digestion experiments (see chapter 5). The inhibitors used are listed in 
table 2.3, along with their concentration and specificity.
Table 2.3 -  Proteinase inhibitors used in this study
Inhibitor Concentration Specificity o f inhibitor
Na:EDTA lOmM Metalloproteinases
Benzamidine HC1 5mM Thrombin and trypsin
Phenylmethyl sulphonyl fluoride (PMSF) 0.5mM Serine proteases, papain
e-Aminocaproic acid (6-AHA) 0.1M Fibrinolysin, chymotrypsin
2.2.1.7 Western blotting
The origin and specificities of the monoclonal and polyclonal antibodies used for detection of 
PRG4 are described in table 2.4. All were used at a dilution of 1:1000. For use with monoclonal 
antibodies, the anti-mouse IgG (H+L) alkaline phosphatase secondary antibody (affinity purified 
goat anti-mouse) was purchased from Promega, UK. A similar anti-rabbit secondary antibody 
from Promega was used in conjunction with the polyclonal antibodies. For all blots the alkaline 
phosphatase substrate was 0.33mg/ml nitro blue tetrazoleum (NBT) and 0.165mg/ml 5-bromo-4- 
chloro-3-indolyl phosphate (BCIP) from Promega, made up in the AP substrate buffer as detailed 
in table 2.1.
2.2.1.8 Affinity blotting
For detection o f the carbohydrate structures on PRG4, a DIG Glycan Differentiation kit was used 
according to the manufacturers instructions (Boehringer Mannheim). The lectins used and their 
specificities for different carbohydrate structures are listed in table 2.5. For HA affinity blotting, 
biotinylated HA and avidin-AP conjugate were purchased from Sigma.
2.2.2 Isolation and agarose culture o f bovine superficial zone chondrocytes 
The superficial layer o f bovine articular cartilage was aseptically harvested from the 
metacarpophalangeal joints of 2-3 year old cows as previously described (Tudor, 2002). For the 
isolation of superficial zone chondrocytes, tissue slices were washed in DMEM and subjected to
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digestion with 0.1% pronase [w/v] in DMEM containing 10% [v/v] FCS for 1-2 hours. After this 
time the pronase solution was removed and tissue was digested with 0,04% collagenase [w/v] in 
DMEM containing 10% [v/v] FCS overnight (14-16 hours). Isolated chondrocytes were then 
washed out of collagenase and into DMEM by centrifugation (1800rpm for 8 minutes) and 
aspiration. All DMEM used contained 50pg/ml gentamicin. Agarose culture plates were 
established by preparing a 2% [w/v] solution o f SeaPlaque GTG agarose in DMEM. 60mm plates 
were coated with 2 ml o f 1% agarose and placed at 4°C for 15 minutes to set, followed by 15 
minutes at 37°C. Chondrocytes were resuspended at a concentration of 12 x 106 cells/ml. This 
suspension was diluted with an equal volume o f 2% agarose, and 1ml of the resultant 1% [w/v] 
agarose cell suspension was laid over the agarose plug (6 x 106 cells/plate). Plates were placed at 
4°C for 15 minutes to set. Experimental medium was then added to the plates which were 
maintained at 37°C in 5% CO2. The medium consisted o f DMEM, 5% [v/v] FCS and 25pg/ml 
phosphotin C. Phosphotin C is an ascorbate analogue, and ascorbate functions as a cofactor in the 
proline hydroxylation of collagen. Culture media was harvested and replaced every 4-6 days. The 
conditioned media o f agarose cultures was centrifuged at 3200 x g for 30 minutes at 4°C to 
remove agarose, and was passed through a 0.22pm filter after the optional addition of proteinase 
inhibitors (table 2.3) and stored at -20°C prior to processing.
2.2.3 Explant culture o f bovine deep digital flexor tendon
Bovine deep digital flexor tendon (DDFT) explant cultures were established by cutting diced 
tendon pieces (10-50mg) from 2-3 year old bovine DDFT and pre-culturing them at 1 explant/ml 
in 100mm dishes with DMEM supplemented with 10% [v/v] FCS, at 37°C, 5% CO2 for two days 
(Rees et al., 2002). At this time explants were washed 3 times in DMEM (without FCS) and 
placed in serum free DMEM. Conditioned media was harvested every 3 days, and was filtered 
after the optional addition of proteinase inhibitors (table 2.3) and stored at -20°C until use.
2.2.4 CHO cell culture
2.2.4.1 Initiation o f  cell culture and preparation offrozen stocks
For the preparation o f frozen CHO cell stocks, confluent plates were washed with PBS, removed 
from the plastic by trypsinization and re-suspended at a density o f 2 x 106 cells/ml in M EM a 
medium containing 10% [v/v] heat inactivated FCS and 10% [v/v] DMSO. Cells were placed in
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Nalgene cryovials (1ml cell suspension/vial) and frozen to -80°C in Styrofoam containers. Stocks 
were transferred to liquid nitrogen for long term storage. For the initiation of cell culture from 
frozen stocks, a single vial was thawed by warming in a 37°C water bath and added to 9ml of 
CHO expansion medium (table 2.2) in a lOOmM plate. Cells were allowed to attach for 24 hours 
before the aspiration o f the DMSO-containing medium and the addition of fresh expansion 
medium.
2.2.4.2 Expansion o f  cultures and collection o f  conditioned medium
The human PRG4-expressing cell line CHO-MegK (Wyeth) was grown in M EM a with 10% 
[v/v] heat-inactivated FCS (dialysed against PBS), ImM L-Glutamine, lOOU/ml penicillin G, 
lOO^g/ml streptomycin and 0.5mM methotrexate (see section 2.2.1.2 for more information on the 
use o f methotrexate). Cells were grown on 100mm plates with 10ml of media at 37°C in 5% CO2 
until visibly confluent and were split following trypsinisation. Cells were pelleted by 
centrifugation at 450 x g for 5 minutes. Following three washes with PBS, cells were then plated 
in serum free CD CHO medium (with glutamine and antibiotics) and conditioned media was 
harvested at 48 hours with replacement and again at 96 hours. Conditioned media was stored at - 
20°C  either with or without protease inhibitors (table 2.3) depending on the different 
experimental applications used -  if  PRG4 was to be used in proteinase digestion experiments, 
enzyme inhibitors were omitted.
2.2.5 Heparin-agarose affinity chromatography
In general, a 0.5-2.0ml bed volume o f heparin-agarose was used in a 10ml plastic gravity flow 
chromatography column (BioRad), which was equilibrated with 10 column volumes of heparin- 
agarose equilibration buffer (lOOmM Tris-HCl, pH 7.5, 50mM NaCl) and pre-eluted with 10 
column volumes o f 2M NaCl in lOOmM Tris-HCl, pH 7.5 before re-equilibration. Heparin- 
agarose was then mixed with the sample in a 50ml tube (Corning) and agitated at room 
temperature for 30 minutes. The affinity gel was re-packed by passing the agarose-sample 
suspension over a 10ml BioRad column, and unbound proteins were removed with 20 column 
volumes o f equilibration buffer. Heparin-binding proteins were eluted with 0.1-2M NaCl in 
equilibration buffer in stepwise aliquots o f 1 column volume unless otherwise stated. After
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elution, columns were re-equilibrated and stored at 4°C in heparin-agarose equilibration buffer 
supplemented with 0.02% [w/v] sodium azide.
2.2.6 PNA lectin-agarose affinity chromatography
Samples were applied to a PNA lectin-agarose column with a bed volume of 1ml in a 10ml 
BioRad chromatography column. Before use the agarose was equilibrated in 10 column volumes 
of PNA agarose equilibration buffer (lOmM Tris-HCl, pH 7.8, 0.15M NaCl), pre-eluted with 10 
column volumes o f 1M D-galactose in equilibration buffer and re-equilibrated. PNA-agarose was 
then mixed with the sample and agitated at room temperature for 30 minutes. The suspension of 
sample and agarose was then passed over the BioRad column to collect the agarose. Following a 
wash step of 20 column volumes of equilibration buffer to remove unbound proteins, PNA lectin- 
bound glycoproteins were eluted with aliquots o f 0.1-1M D-galactose (Lotan et al., 1977) in 
equilibration buffer. After elution, columns were re-equilibrated and stored at 4°C in PNA- 
agarose equilibration buffer supplemented with 0.02% [w/v] sodium azide.
2.2.7 CsCl density gradient centrifugation
Briefly, an equal volume of CsCl dissociative buffer was added (table 2.1), and this solution was 
made up to a density o f 1.47-1.48g/ml by addition o f solid CsCl. The sample was then 
centrifuged at 100,000 x g for 40 hours at 10°C in a Beckman L-60 ultracentrifuge. The gradient 
was fractionated into five fractions (see figure 2.1) and the PRG4-containing D5 fraction (density 
of approximately 1.3g/ml) was dialysed exhaustively against MilliQ water before freezing.
D5_ 
D4 
D3 
D2 
D1
1.3g/ml
1.6g/ml
Figure 2.1 -  Fractionation o f a sample into 5 x 5ml fractions after CsCl density gradient 
centrifugation under dissociative conditions, with an overall starting density of 1.47-1.48g/ml.
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2.2.8 Procedures for the purification o f PRG4
Full-length PRG4 was purified from a number of sources. The protein concentration o f eluents 
was calculated by reading absorbancy values at 280nm in an Ultrospec 2000 spectrophotometer 
(Pharmacia).
2.2.8.1 Purification o f  human recombinant PRG4 from  conditioned media o f  the CHO-MegK cell 
line
Conditioned CHO cell media was centrifuged at 600 x g for 10 minutes and supernatant was 
passed through a 0.22pM filter to remove cellular debris. Heparin affinity chromatography was 
performed as described in section 2.2.5 (40ml conditioned media/lml heparin agarose). Heparin 
column eluents were further purified by PNA lectin agarose affinity chromatography (section 
2.2.6). Fractions were separated by SDS-PAGE and analysed by Western blotting (section 2.2.9), 
lectin affinity blotting (section 2.2.10), HA affinity blotting (section 2.2.11) and silver staining 
(section 2.2.12).
2.2.8.2 Purification o f  bovine cartilage PRG4 from  the conditioned media o f  superficial zone 
chondrocyte agarose cultures
The conditioned medium from bovine superficial zone chondrocyte agarose cultures was 
collected and centrifuged to remove agarose (section 2.2.4.1), and CHAPS was added to a final 
concentration o f 0.5% [w/v]. Bovine cartilage PRG4 was partially purified from conditioned 
medium by heparin agarose affinity chromatography (section 2.2.5), PNA lectin affinity 
chromatography (section 2.2.6) and dissociative density gradient centrifugation (section 2.2.7). 
These fractions were then used in proteinase digests and Western/affinity blotting experiments 
(sections 2.2.9-11).
2.2.8.3 Purification o f  bovine tendon PRG4
Tendon PRG4 was partially purified by directly applying the conditioned media of bovine DDFT 
explant cultures to heparin agarose. Prior to this, media was passed through 0.22pM filters to 
remove debris. A lml bed volume o f heparin beaded agarose was pre-eluted and added to 40ml 
of conditioned media, and mixed at room temperature for 30 minutes before the elution of 
heparin bound proteins with a NaCl gradient (section 2.2.5).
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2.2.9 SDS-PAGE and Western blotting
For SDS-PAGE, the Laemmli buffer system was used (Laemmli, 1970), and experimental 
samples were diluted (1:1) with 2X SDS-PAGE sample buffer (table 2.1). (3-mercaptoethanol was 
added to 10% [v/v] if samples were to be reduced. Samples were routinely run under reducing 
conditions. Samples were boiled for 3-5 minutes prior to loading, and were separated on either 4- 
12% pre-cast gradient gels or slab gels o f 10% or 15% depending on target protein size, using 
vertical Novex gel apparatus (Invitrogen). The SDS-PAGE running buffer used is listed in table 
2.1, and gels were run at 120-150V for 1.5 hours or until the bromophenol blue in the SDS- 
PAGE sample buffer reached the heel o f the gel. Samples were electrophoretically transferred 
onto nitrocellulose membrane using transfer buffer (table 2.1) formulated with a Towbin recipe 
(Towbin et al., 1979), in BioRad apparatus for 1 hour at 100 volts. For Western blotting, transfer 
membranes were blocked for 1 hour at room temperature or overnight at 4°C in 5% [w/v] BSA in 
TSA (see table 2.1). Membranes were probed with antibodies (see table 2.4) in 1% [w/v] BSA in 
TSA for a minimum of 1 hour at the dilutions listed in table 2.4. Primary antibody was removed 
with 3 x 10 minute washes in TSA before incubation with an anti-mouse (dilution o f 1:7500) or 
anti-rabbit (dilution o f 1:3000) secondary antibody diluted in 1% [w/v] BSA/TSA for one hour at 
room temperature. After 3 x 10 minute washes in TSA, the immunoblots were incubated with 
alkaline phosphatase substrate (section 2.2.1.7) for 5-60 minutes at room temperature to achieve 
optimum colour development. Membranes were washed with MilliQ water. If a comparison 
between Western blots was required, all incubation times were kept consistent.
Table 2.4 -  PRG4-specific antibodies
Antibody nam e O rigin and PRG4 specificity Source Dilution
6-A-l Monoclonal against purified bovine PRG4 Prof. B. Caterson 
(Schumacher et al., 1999)
1:1000 (ascites) 
1:100 (media)
3-A-4 Monoclonal against purified bovine PRG4 
Epitope disrupted by reduction
Prof. B. Caterson 
(Schumacher et al., 1999)
1:1000 (ascites) 
1:100 (media)
5-B-6 Monoclonal against purified bovine PRG4 Prof. B. Caterson 1:1000 (ascites) 
1:100 (media)
5-D-l Monoclonal against purified bovine PRG4 Prof. B. Caterson 1:1000 (ascites) 
1:100 (media)
06A10 Polyclonal -  purified human recombinant 
(G in1-Leu924)
Wyeth Research 1:1000
378 Polyclonal -  human exon 3 peptide (Gly - 
Asp85)
Wyeth Research 1:1000
01B-10 Polyclonal -  human exon 12 peptide 
(Gln,374-Ala1387)
Wyeth Research 1:1000
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2.2.10 Lectin affinity blotting
A DIG glycan differentiation kit (Roche) was used according to the manufacturers instructions. 
The specificities o f the lectins in the kit are listed in table 2.5. Blots were developed with 
NBT/BCIP in AP substrate buffer (section 2.2.1.7).
Table 2.5 -  Lectins o f the DIG Glycan Differentiation kit (Roche) and their specificity. Lectins 
that recognise PRG4 are indicated with an asterix.
Lectin name Specificity
Peanut agglutinin 
(PNA)*
Core disaccharide galactose P( 1 -3) N-acetylgalactosamine. Identifies O- 
linked oligosaccharides
Maackia amurensis agglutinin (MAA)* Sialic acid linked a(2-6) to galactose. Identifies complex, sialylated chains
Galanthus nivalis agglutinin (GNA) Terminal mannose a ( l-3 ) , a ( l-6 )  or a ( l-2 )  linked to mannose. Identifies 
high mannose N-glycan chains
Sambucus nigra agglutinin (SNA) Sialic acid linked a(2-6) to galactose. Identifies complex, sialylated N- 
glycan chains
Datura stamonium agglutinin (DSA) Galactose linked P (l-4 ) to N-acetyl glucosamine.
2.2.11 Affinity blotting with biotinylated hyaluronan
Preparations of purified or partially purified PRG4 were separated by SDS-PAGE under reducing 
and non-reducing conditions and transferred to nitrocellulose. As a positive control for HA 
binding, 5p.g of a preparation o f link protein was used that runs at 45 kDa and binds HA under 
non-reducing conditions (bovine nasal cartilage A1D4 fraction, prepared by Dr. C. R. Flannery). 
Membranes were blocked for 16 hours at 4°C in TBS (20mM Tris-HCl, pH 7.4, 0.5M NaCl) with 
0.1% [v/v] Tween-20, without rocking. Membranes were subjected to 3 x 10 minute washes with 
TBS/0.05% [v/v] Tween-20 prior to incubation with biotinylated HA at a concentration of 
5pg/ml in TBS/0.05% Tween-20 for 1 hour at room temperature with rocking. Biotinylated HA 
was removed with 6 x 5  minute washes with TBS/0.05% Tween-20 prior to the addition of 
0.5^g/ml avidin-alkaline phosphatase (in TBS/0.05% Tween 20), which was incubated for 1 hour 
at room temperature. Membranes were washed six times as previously described before 
incubation with NBT/BCIP substrate (section 2.2.1.7) as for Western blotting experiments.
2.2.12 Silver staining
For detection o f total protein, SDS-PAGE gels were silver stained using a method adapted from 
(Morrisey, 1981). Briefly, gels were pre-fixed for 1.5-16 hours in 30% [v/v] ethanol and 10%
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[v/v] acetic acid. After 2 x 10 minute washes in 10% [v/v] ethanol and 3 x 1 0  minute washes in 
MilliQ H2O, gels were placed in 5pg/ml DTT for 30 minutes then 0.1% [w/v] silver nitrate for 30 
minutes. Gels were developed with 3% [w/v] sodium carbonate containing 0.05% [v/v] 
formaldehyde solution. A small amount of this solution was added and incubated with the gel, 
and was removed when it became cloudy before adding fresh solution for full development. The 
developing solution was neutralised with 5ml of 5M citric acid for 10 minutes. Following 
neutralisation, gels were washed with repeated changes of H2O.
2.3 Results
2.3.1 Purification o f  human recombinant PRG4 from the culture medium o f  a PRG4- 
secreting CHO cell line
2.3.1.1 Purification o f  human recombinant PRG4 by heparin-agarose affinity chromatography 
Previous reports have indicated that PRG4 may be capable of binding to heparin through an 
arginine/lysine-rich sequence present in exon 4 (Merberg et al., 1993). Therefore, it was decided 
to investigate this potential interaction with respect to the affinity purification of human 
recombinant PRG4 from the conditioned media of the CHO-MegK polyclonal cell line (obtained 
as a gift from Wyeth, MA), which expresses and secretes full-length human PRG4. The results of 
utilising this procedure are shown in figure 2.2, which shows the results of applying 40mls of 
CHO serum free conditioned medium to a lm l heparin agarose column. Heparin-binding proteins 
were sequentially eluted with 2ml volumes of 0.1-1.0M NaCl in 0.1 M increments. Proteins were 
visualised by silver staining (figure 2.2A) and Western blotting with the polyclonal antibody 
06A10 (figure 2.2B). The majority o f the PRG4 present in 40mls of conditioned CHO medium 
was bound by lm l o f heparin-agarose, as assessed by comparing the staining seen with the 
starting material (lane 1) and the flowthrough (lane 2), and PRG4 was eluted at a salt 
concentration o f between 0.2M and 0.4M NaCl (lanes 4-6). The Western blot with antibody 
06A10 seen in figure 2.2B verifies that the eluted protein present in lanes 4-6 running at >250 
kDa is human PRG4. Other proteins eluted from the column may be contaminants or catabolites 
of full-length PRG4 lacking the 06A10 epitope.
67
JSCD3o
•S NaCl elutions (M)
c3 2
8  «  0.1 0.2 0.3 0.4 0.6 0.8 1.0
Mhlu
250kDa—
150kDa
Silver stain
250kDa—
Western blot 
(06A10)
150kDa—
2 3 4 5 6 7 8 91
Figure 2.2 -  Purification of hum an recom binant PRG4 (hrPRG4) by heparin-agarose 
affinity chrom atography. Starting material was 40mls of conditioned culture medium from the 
CHO-MK cell line, which was applied to heparin-agarose (1ml bed volume). Bound proteins 
were eluted from the column using a stepwise NaCl gradient (lanes 2-9, 2mls per fraction) 
Fractions were separated by SDS-PAGE and hrPRG4 was visualised by (A) silver staining and 
(B) Western blot probed with polyclonal antibody 06A10. Migration o f molecular weight 
standards (kDa) is shown to the left.
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2.3.1.2 P urifica tion  o f  human recom binant PRG4 by PNA lectin-agarose a ffin ity  
chromatography
The O-linked oligosaccharide substitution of PRG4 from bovine cartilage has previously been 
characterised by affinity blotting using a panel of lectins, with positive reactions occurring with 
the lectins PNA and MAA (Tudor, 2002). The lectin PNA recognises the core disaccharide 
galactose (3(1-3) N-acetylgalactosamine (Carter & Sharon, 1977) and the lectin MAA recognises 
sialic acid linked a(2-6) to galactose (Wang & Cummings, 1988). These glycosylation features of 
the molecule were used in the further purification of heparin-purified human recombinant PRG4. 
Although studies with a MAA-agarose affinity column were unsuccessful (data not shown), 
purification o f PRG4 was successful with PNA-agarose affinity chromatography. This was 
achieved by adding samples obtained during heparin-agarose affinity chromatography to a 1ml 
PNA-agarose column and eluting bound protein with 1ml aliquots of D-galactose (Lotan et al., 
1977) in a stepwise manner, using a concentration range of 0.1-0.7M. Figure 2.3 shows fractions 
from this purification after separation by SDS-PAGE, visualised by silver stain. Not all PRG4 
from the heparin-agarose column eluent was bound by the column, as observed by comparing the 
start and flowthrough fractions (lanes 1 & 2). The inability of the flow through material to bind to 
the PNA-agarose column when passed over the column for a second time (data not shown) 
suggests that the PRG4 sample may contain differentially glycosylated sub-populations. PRG4 
bound to the column was eluted with 0.2-0.3M D-galactose in two apparently homogenous 
fractions (lane 4 & 5). Therefore, this data describes a two-step procedure for the purification of 
human recombinant PRG4 from the culture medium of a PRG4-expressing CHO cell line. Protein 
concentrations o f purified preparations were calculated by reading absorbance at 280nm, and 
purified protein was used in Western and affinity blotting experiments as shown later in this 
chapter, and also in proteinase digestion experiments described in Chapter 5.
2.3.2 Partial purification o f bovine articular cartilage PRG4 from the culture medium o f  
superficial zone chondrocytes
2.3.2.1 Purification o f  bovine cartilage PRG4 by heparin-agarose affinity chromatography 
Following the success of the heparin- and PNA-agarose affinity chromatography methods used 
for the purification of hrPRG4, the potential o f these methods for purifying native bovine PRG4 
was investigated.
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Figure 2.3 -  Purification of hum an recom binant PRG4 (hrPR G 4) by PNA lectin-agarose 
affinity chrom atography. Starting material was 6mls o f heparin-agarose affinity column eluent 
(start, see figure 2.2), which was applied to PNA lectin-agarose (1ml bed volume). HrPRG4 was 
eluted from the column with a stepwise gradient of D-galactose (lanes 2-9), with elution volumes 
of 1 column volume (1ml). Fractions were separated by SDS-PAGE (30pl/lane) and total protein 
was visualised by silver staining. Migration of molecular weight standards is shown to the left.
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Bovine articular cartilage PRG4 (bcPRG4) obtained from the conditioned medium o f agarose 
cultures of superficial zone chondrocytes was concentrated and partially purified using heparin- 
agarose affinity chromatography. Figure 2.4 shows the result o f applying 40mls o f conditioned 
medium to 0.5ml o f heparin-agarose, eluting proteins with sequential 5ml volumes of 0.1-1.0M 
NaCl. A Western blot o f the starting material (conditioned medium) with the antibody 6-A-l is 
shown in lane 1 to confirm the presence o f bovine PRG4 at -345 kDa. Eluted proteins were 
detected using silver staining, and PRG4 is apparent as a strongly stained band of around 345 
kDa and was eluted from the heparin-agarose column with 0.2-0.3M NaCl (figure 2.4, lanes 5 &
6). It can therefore be concluded that bovine cartilage PRG4 is capable of binding to heparin- 
agarose, an interaction that is disrupted by 0.2-0.3M NaCl. Human recombinant PRG4 is also 
eluted from heparin-agarose with similar NaCl concentrations as shown in figure 2.3. However, 
the silver stain shown in figure 2.4 (lanes 5 & 6) shows that the eluents are heterogeneous, which 
would suggest that endogenous bovine PRG4 is only partially purified from the conditioned 
media o f superficial zone chondrocyte agarose cultures by a heparin-agarose affinity 
chromatography step.
23.2.2 Purification o f  bovine articular cartilage PRG4 heparin-agarose column eluents by CsCl 
density gradient centrifugation
Further purification o f bovine cartilage PRG4 from heparin-agarose column eluents was 
performed using dissociative CsCl density gradient centrifugation (section 2.2.7), a process that 
has previously been used in the purification of bovine PRG4 (Tudor, 2002). The results o f this 
procedure can be seen in figure 2.5, which shows a silver stain analysis of the 5 fractions. PRG4 
(-345 kDa) appeared in the D5 fraction (figure 2.5, lane 4), but only in a slightly purer mixture 
than the starting material figure 2.5, lane 1). A contaminant o f around 275 kDa can be clearly 
seen in the D5 fraction (lane 6). This may well be fibronectin, a component o f FCS that has a 
heparin-binding domain. A Western blot o f the D5 fraction with mAb 6-A-l is shown in figure 
2.5, lane 7, confirming the presence of PRG4 at -345 kDa.
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150kDa 
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blot (6-A-l)
Figure 2.4 -  Purification of bovine articu lar cartilage PRG4 (bcPRG4) by heparin-agarose 
affinity chrom atography. Starting material was 40mls of conditioned culture medium from 
superficial zone chondrocyte agarose cultures Figure 2.4 -  Analysis of fractions (30pl/lane) 
Conditioned medium from bovine superficial zone chondrocyte agarose cultures (40ml) was 
applied to 0.5ml heparin-agarose. Bound proteins were eluted using a stepwise NaCl gradient 
(lanes 3-10, 5ml per fraction) and fractions were separated by SDS-PAGE under reducing 
conditions (30pl/lane). The starting material is shown as a Western blot probed with mAb 
antibody 6-A-l (lane 1), heparin-agarose column eluents were silver stained. Migration o f  
molecular weight standards (kDa) is shown to the left.
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Figure 2.5 -  Purification of bovine articu la r cartilage PRG4 by heparin-agarose affinity 
chrom atography followed by CsCl density gradient centrifugation. Heparin column eluent 
(5ml, lane 1) was subjected to cesium chloride density gradient centrifugation under dissociative 
conditions (total volume 32.4ml). Following fractionation of the sample into 5 parts (D1-D5), 
fractions were separated by SDS-PAGE (25pl/lane) under reducing conditions and visualised by 
silver stain. A Western blot of the D5 fraction using mAb 6-A-l is shown on the far right (lane
7), and an arrow marks the position of PRG4. Migration of molecular weight standards is shown 
to the left.
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23.2.3 Purification o f  bovine articular cartilage PRG4 by PNA lectin affinity chromatography 
Heparin column eluents were applied to a PNA lectin-agarose column in a similar manner to the 
purification method described for human recombinant PRG4 (section 2.3.1.1). Similarly to 
human recombinant PRG4, bovine cartilage PRG4 bound to the column and was eluted with 
-0.2M  D-galactose, as seen in an analysis of purification fractions by SDS-PAGE followed by 
silver staining (figure 2.6A). However, the fraction is heterogeneous, and the same ~275 kDa 
contaminant is present in PRG4 purified by PNA lectin-agarose affinity chromatography as that 
seen with PRG4 purified by CsCl density gradient centrifugation. The contaminant of around 
75kDa is removed by PNA lectin-agarose affinity chromatography (figure 2.6A & B). The PNA 
affinity purification step proved to be inefficient -  the binding capacity o f the PNA-agarose 
seemed to be low, based on the observation that a considerable amount o f PRG4 was present in 
flowthrough material (data not shown). A Western blot of the heparin affinity/CsCl density 
gradient centrifugation-purified fraction is shown in figure 2.6C, probed with mAb 6-A-l to 
verify the presence of bovine PRG4. For the later applications in this study (Western and affinity 
blot analyses, in vitro proteinase digests), bovine articular cartilage PRG4 was partially purified 
by heparin agarose affinity chromatography followed by density gradient centrifugation. The 
purity could be improved by utilising other previously reported PRG4 purification methods such 
as ion exchange chromatography (Tudor, 2002), anti-fibronectin immunoaffinity chromatography 
(Jay et al., 2000) and size exclusion chromatography. Size exclusion column chromatography 
and immunoaffinity chromatography (using mAbs 6-A-l and 3-A-4) were utilised in an attempt 
to further purify bovine cartilage PRG 4, but the experimental approaches proved to be 
unsuccessful (data not shown).
2 3 3  Partial purification o f bovine tendon PRG4
Recently, PRG4 has been immunolocated on the surface of bovine compressed deep digital flexor 
tendon, and is also found to be expressed by tenocytes at the mRNA level (Rees et al., 2002). 
Bovine tendon PRG4 was partially purified from the conditioned medium of bovine deep digital 
flexor tendon (DDFT) explant cultures using heparin-agarose affinity chromatography.
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Figure 2.6 -  Purification of bovine articu lar cartilage PRG4 by heparin-agarose affinity 
chrom atography followed by PNA lectin-agarose affinity chrom atography. Conditioned 
medium from superficial zone chondrocyte agarose cultures was subjected to (A) heparin and 
PNA affinity chromatography, and (B) heparin affinity chromatography and CsCl density 
gradient centrifugation. Fractions were separated by SDS-PAGE (30pl/lane) and were visualised 
by silver stain. Material shown in (B) is also shown as a Western blot in (C), probed with 
monoclonal antibody 6-A-l to show the presence of bovine PRG4. Migration of molecular 
weight standards is shown to the left.
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Figure 2.7 shows fractions from this purification after separation by SDS-PAGE, which were 
visualised by (A) a silver stain and (B) Western blot probed with monoclonal antibody (mAb) 3- 
A-4. PRG4 eluted from the column at a salt concentration of between 0.2 and 0.6M NaCl (figure 
2.7, lanes 2-6), and was identified by mAb 3-A-4 as a protein running at around 345 kDa. This 
demonstrates that bovine tendon PRG4 exhibits the same heparin-binding characteristics as 
human recombinant and bovine cartilage PRG4. Purification of tendon PRG4 from this source 
was facilitated by the use of serum free medium within the culture system, and the conditioned 
media o f bovine DDFT explant cultures may be a useful source of tendon PRG4 for functional 
analyses when coupled with other purification strategies.
2.3.4 Characterisation o f  anti-PRG4 antibodies using human recombinant, bovine cartilage 
and bovine tendon PRG4
Purified human recombinant PRG4 (hrPRG4) and partially purified bovine articular cartilage 
PRG4 (bcPRG4) and bovine tendon PRG4 (btPRG4) were used in Western blotting analyses to 
determine the cross-species reactivity of a number of antibodies to epitopes present in human and 
bovine PRG4. HrPRG4 was purified to homogeneity by heparin-agarose and PNA lectin-agarose 
affinity chromatography (section 2.3.1), bcPRG4 was partially purified by heparin affinity 
chromatography and CsCl density gradient centrifugation (section 2.3.2) and btPRG4 was 
partially purified by heparin-agarose affinity chromatography (section 2.3.3).
Figure 2.8 shows W estern blots o f hrPRG4, bcPRG4 and btPRG4 probed with polyclonal 
antibodies raised against purified human recombinant PRG4 (Gln'-Leu924, 06A10) and a synthetic 
peptide from exon 3 o f human PRG4 (G ly 72-Asp85, Ex3). Both antibodies recognise epitopes of 
hrPRG4, but showed no cross-species reactivity with PRG4 from bovine tendon and articular 
cartilage.
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Figure 2.7 -  H eparin-agarose affinity purification of bovine tendon PRG4. The starting 
material was 80mls o f conditioned culture medium from bovine DDFT explant cultures, which 
was applied to heparin-agarose (1ml bed volume). Bound proteins were eluted from the column 
with a stepwise NaCl gradient (lanes 2-6, 1ml per fraction) Eluent fractions were separated by 
SDS-PAGE (30pl/lane) under non-reducing conditions and were visualised by (A) silver stain 
showing total protein and (B) Western blot probed with mouse anti-bovine mAb 3-A-4, which 
recognises an non-reduced epitope o f native bovine PRG4 (Schumacher, et al., 1999). Migration 
o f molecular weight standards (kDa) is shown to the left.
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Figure 2.8 -  W estern blot analysis of purified  hum an recom binant PRG4 (hrPRG4), 
partially purified bovine cartilage (bcPRG4) and tendon PRG4 (btPRG4) with polyclonal 
an tibodies raised  against h rP R G 4. Proteins were run under reducing conditions at a 
concentration of 5pg total protein/lane. Western blots were probed with (A) 06A10, a polyclonal 
antibody raised against purified human recombinant PRG4 and (B) anti-exon 3 (Ex3), a 
polyclonal antibody raised against a synthetic peptide in exon 3 of human PRG4. The migration 
of molecular weight standards is shown to the left.
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Figure 2.9 shows W estern blot analysis o f hrPRG4, bcPRG4 and btPRG4 (5pg total 
protein/lane), using a panel o f monoclonal antibodies (mAbs) raised against purified bovine 
PRG4: 6 -A -l, 3-A-4, 5-B-6 and 5-D -l. Antibodies 6-A-l and 3-A-4 have been used to 
immunolocalise PRG4 in bovine articular cartilage (Flannery et a l ,  1999; Schumacher et al., 
1999; Tudor, 2002), tendon (Rees et a l , 2002), synovial fluid (Schumacher et a l , 1999; Tudor, 
2002) and meniscus (Schumacher et a l ,  2003). For Western blotting analyses the samples were 
separated under reducing (figure 2.9A) and non-reducing (figure 2.9B) conditions, as previous 
studies have indicated that the 3-A-4 epitope is lost under reducing conditions whilst the 6-A-l 
epitope is better exposed under reducing conditions (Tudor, 2002; Schumacher et a l ,  1999). As 
expected, bcPRG4 was immunostained with 6-A-l under reducing conditions (figure 2.9A) and 
3-A-4 under native conditions (figure 2.9B). There appeared to be weak staining of bcPRG4 by 
mAbs 5-B-6 and 5-D-l under non-reducing conditions (figure 2.9b) but not under reducing 
conditions. A btPRG4 band of -345 kDa, representing full-length tendon PRG4, was apparent 
with 3-A-4 under non-reducing conditions (figure 2.9b). Interestingly, 5-B-6 immunostained a 
number o f btPRG4 bands under reducing and non-reducing conditions that could represent 
degradation fragments. These fragments are not recognised by the other antibodies, and 
surprisingly, 6-A-l does not recognise btPRG4 under reducing or non-reducing conditions. 
Disappointingly, there appeared to be no strong staining o f hrPRG4 by any of the mAbs to 
bovine PRG4, suggesting that these antibodies may not cross-react between bovine and human 
PRG4.
2.3.5 Characterisation o f carbohydrate moieties on recombinant human and native bovine 
PRG4 by lectin affinity blotting
Lectins are proteins that recognise and bind to different carbohydrate moieties, and this feature 
allows the carbohydrate moieties o f glycoproteins to be characterised using lectin affinity blot 
analysis (reviewed in Vijayan & Chandra, 1999). The procedure in this study involved 
immobilising the target glycoprotein onto a nitrocellulose membrane after separation by SDS- 
PAGE followed by affinity blotting with lectins conjugated with the steroid hapten digoxigenin. 
This enables a secondary immunological detection o f the digoxigenin hapten on the bound 
lectins. Previous work has demonstrated the reactivity of bovine PRG4 with the lectins peanut 
agglutinin (PNA) and Maackia amurensis agglutinin (MAA) (Tudor, 2002).
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Figure 2.9 -  W estern blot analysis of purified hum an recom binant PRG4 (hrPRG 4), 
partially purified bovine articu lar cartilage PRG4 (bcPRG4) and partially purified bovine 
tendon PRG4 (btPRG4) with monoclonal antibodies raised to bcPRG4. Proteins were run 
under reducing (A) and native (B) conditions at a concentration of 5pg total protein/lane. 
Western blots were probed with mAbs 6 -A-l, 3-A-4, 5-B-6 and 5-D-l which were raised against 
purified PRG4 from bovine cartilage. (Schumacher et al., 1999). Migration of molecular weight 
standards (kDa) is shown to the left.
8 0
PNA recognises the core disaccharide galactose linked p(l-3) to N-acetylgalactosamine; MAA 
identifies sialic acid linked a(2-6) to galactose. Lectin affinity blotting experiments with hrPRG4, 
bcPRG4 and btPRG4 are shown in figure 2.10, along with a control blot performed without 
primary lectin (no 1°). Western blots with polyclonal antibodies (pAbs) specific to human and 
bovine PRG4 (anti exon 3 and mAb 3-A-4) are shown underneath to illustrate the migration 
position of PRG4. The specificities o f the lectins used are listed in table 2.5, and all proteins were 
separated under reducing conditions with the exception o f the 3-A-4 Western blot. These 
experiments demonstrated that the human and bovine PRG4 molecules both react with PNA and 
MAA (figure 2.10, lanes 1-6) and thus share a similar glycosylation pattern. This pattern also 
shows that the glycosylation o f hrPRG4 is not adversely affected by the different post- 
translational machinery in the CHO-cell expression system. The btPRG4 preparation contained a 
number o f degraded PRG4 species as shown in figure 2.9, although there was positive staining 
for PNA (figure 2.10, lane 3) and MAA (figure 2.10, lane 6 ). HrPRG4 was not recognised by the 
lectins DSA, SNA or GNA, as seen in figure 2.10, lanes 7, 10 and 13, respectively. DSA and 
SNA recognise some species in bcPRG4 and btPRG4, but it must be borne in mind that these are 
partially purified preparations, and there is little, if any, staining at the migration position of 
PRG4 as assessed by Western blot, 345 kDa. These bands may therefore represent contaminants 
in the protein preparations used.
2.3.6 Analysis o f  PRG4-hyaluronan interactions by affinity blotting
Previous work has proposed a physical interaction between a synovial lubricating factor (PSLF), 
thought to be part o f the lubricin/PRG4 gene, and HA (hyaluronic acid), and that this interaction 
contributes to the lubricating function o f lubricin/PRG4 (Jay et al., 1992). Exons 8-9 of PRG4 
contain haemopexin-like domains similar to vitronectin, and haemopexin is a serum haeme- 
scavenging protein that has been shown to interact with HA (Hrkal et al., 1996). At present there 
have been no biochemical studies demonstrating the potential interaction between PRG4 and HA. 
This study investigated this potential interaction by means of affinity blotting experiments using 
the purified PRG4 molecules described earlier in this chapter along with biotinylated HA, and the 
results can be seen in figure 2 .1 1 .
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Figure 2.10 -  Lectin affinity blotting analysis of purified hum an recom binant PRG4 
(hrPRG 4), partially  purified PRG4 from bovine cartilage (lane 2) and partially purified 
PRG4 from bovine tendon (btPRG4). Proteins were run on SDS-PAGE gels under reducing 
conditions at a concentration of 5pg total protein/lane. Membranes were probed with the lectins 
PNA, MAA, DSA, SNA and GNA, the specificities of which are listed in table 2.5. The positive 
controls for human recombinant and bovine cartilage PRG4 are Western blots with anti-Exon 3 
(reduced) and 3-A-4 (non-reduced) antibodies, respectively. A negative control was performed in 
the absence of primary lectin (no 1°). Migration of molecular weight standards (kDa) is shown to 
the left.
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PRG4 was separated under reducing (figure 2.11 A) and non-reducing (figure 2.1 IB) conditions 
and transferred to nitrocellulose, which was then incubated with biotinylated HA. A positive 
control for the procedure was performed using 5pg of a bovine nasal cartilage A1D4 preparation, 
which contains the HA-binding cartilage molecule link protein. Lane 6  o f figure 2.11A shows 
that HA binds to link protein (~40 kDa) under non-reducing conditions, but in this procedure 
there was no visible interaction between HA and hrPRG4 or bcPRG4 (lanes 1& 2, 4& 5).
2.4 Discussion
The results presented in this chapter demonstrate that human recombinant, bovine articular 
cartilage and bovine tendon PRG4 all bind to heparin, and that this is a feature that can be used to 
purify the molecule from conditioned culture media by means o f heparin-agarose affinity 
chromatography. PRG4 contains 2 Cardin-Weintraub heparin-binding consensus sequences 
(Cardin & Weintraub, 1989), as highlighted in the amino acid sequence of PRG4 shown in 
chapter 1 , figure 1.14. These results suggest that one or both of these sites is functionally active 
in PRG4. This chapter also details the use of PNA lectin-agarose affinity chromatography in the 
purification o f human recombinant and bovine cartilage PRG4, a technique that has also been 
used in the purification o f the homologous molecule lubricin from human synovial fluid (Jay et 
al., 2000). In other studies, bovine PRG4 has been shown to be recognised by the lectins PNA 
and MAA (Tudor, 2002), and PNA affinity chromatography has been shown in this study to be a 
useful technique for the purification o f PRG4, although MAA affinity chromatography proved to 
be unsuccessful. This chapter details a two-step protocol for the purification o f human 
recombinant PRG4 from the culture media of a stable, PRG4-expressing CHO cell line, which 
involved heparin-agarose affinity chromatography (figure 2.2) followed by PNA lectin-agarose 
affinity chromatography (figure 2.3). Using these methods, full-length human recombinant PRG4 
of around 345 kDa can be purified to homogeneity, as assessed by SDS-PAGE and silver 
staining, and such a pure fraction was used in later chapters of this study and could conceivably 
be used in further applications such as binding assays and cell biology experiments.
83
3 3
* Ij= -£>
a
<
uzco
A.
reduced
§cu
£
Tf
Q
rr <
S  w
Cu 
-O
z
CQ
non-reduced
B.
TTa06
Cu
J2
au
cu
X)
M u
O
<
UzOQ
reduced
a06
cu
£
a&
CuX
T
Q
<
Uz
OQ
non-reduced
250 kDa 
100 kDa 
75 kDa
50 kDa 
37 kDa
2 3 4 5 6 7 8 9 10 11 12
Affinity blot with Western blot with 6 -A-1
biotinylated HA and 06A10 combined
Figure 2.11 -  HA affinity blotting experim ents with purified human PRG4 and partially 
purified bovine cartilage PRG4. PRG4 preparations were separated under reducing (lanes 1-3) 
and non-reducing (lanes 4-6) conditions (5pg total protein/lane). Membranes were probed with 
biotinylated hyaluronan (HA), shown in (A). A bovine nasal cartilage A1D4 prep containing link 
protein is used as a positive control (5pg, lanes 3 and 6 ). A Western blot probed with antibodies 
to human and bovine PRG4 is shown in (B). Migration of size standards is shown to the right.
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Bovine articular cartilage PRG4 was partially purified from the conditioned medium of 
superficial zone chondrocyte agarose cultures using heparin-agarose affinity chromatography 
(figure 2.4) and CsCl density gradient centrifugation (figure 2.5). PNA lectin-agarose affinity 
chromatography was also used, but despite being successful the step was inefficient and did not 
produce a homogenous PRG4 preparation (figure 2.6). For the purpose o f further experiments, 
bovine cartilage PRG4 was used as purified by heparin affinity chromatography and CsCl density 
gradient centrifugation. The addition o f a further purification step could purify bovine PRG4, and 
understanding o f PRG4 functions could be furthered by the generation o f stable cell lines 
expressing full-length human and bovine PRG4, incorporating a purification/detection tag such as 
the FLAG epitope described in chapter 3, or other protein purification tags as reviewed in (Terpe, 
2003).
Immunohistochemical analyses have demonstrated the presence of PRG4 on the surface of 
mature compressed bovine tendon (Rees et al., 2002). In this study, bovine PRG4 was partially 
purified from the conditioned medium of deep digital flexor tendon explant cultures by heparin- 
agarose affinity chromatography, and PRG4 was detected with mAb 3-A-4 (figure 2.7). Bovine 
tendon PRG4 runs at around 340 kDa on a reduced SDS-PAGE gel, similar to human 
recombinant and bovine articular cartilage PRG4. This culture system and initial chromatography 
step could be useful in the large-scale purification o f tendon PRG4. The culture system is (a) less 
costly and time-consuming than the isolation o f chondrocytes or tenocytes, as there is no need for 
pronase and collagenase, and (b) lends itself better to purification, as no calf serum is present in 
conditioned medium o f the explant cultures. Tendon PRG4 could be used towards the 
determination o f the differences, or lack thereof, between PRG4 molecules present in different 
anatomical sites within the joint, which would contribute to a better characterisation o f the 
overall PRG4 phenotype.
Affinity blotting with biotinylated hyaluronan failed to reveal an interaction between hyaluronan 
and PRG4. However, this does not necessarily disprove the hypothesis that an interaction exists 
between PRG4 and HA (Jay et al., 2003a & b), as there are a number o f methods for studying 
protein-HA interactions. These include column chromatography (Heinegard & Hascall, 1979), 
affinity chromatography, co-precipitation with cetylpyridinium chloride (Acharya et al., 1998;
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W atanabe et al., 1997), ELISA with lipid-conjugated HA, (W atanabe et al., 1997), gel 
electrophoresis with agarose incorporating HA (Hrkal et al., 1996) and BIAcore analyses 
(Watanabe et al., 1997). Jay and others have suggested that the potential HA-PRG4 interaction 
may be interrupted by the C-terminal truncating mutations that are characteristic of CACP 
syndrome, the pathology associated with PRG4, and that this may explain why synovial fluid 
from patients with CACP syndrome displays a decrease in boundary lubricating ability (Jay et a l ,  
2003b). The potential for HA interactions with recombinant PRG4 domains is discussed later in 
this thesis.
Western blot analyses o f human and bovine PRG4 show that the 06A10 and anti-Exon 3 
polyclonal antibodies to human PRG4 do not recognise bovine PRG4 (figure 2.8), and that 
monoclonal antibodies to bovine PRG4 do not detect human PRG4 (figure 2.9). Interestingly, 
mAb 5-B-6 appeared to react with degradation products of bovine tendon PRG4 (figure 2.9). The 
cross-species reactivity o f these antibodies could be further tested by W estern blotting 
experiments with PRG4 from other species. Lectin affinity blotting experiments show that both 
human and bovine PRG4 are recognised by the lectins PNA and MAA, dem onstrating a 
similarity in terms o f post-translational modifications with respect to N- and O-linked 
oligosaccharides. The contribution o f carbohydrates to the lubricating ability o f PRG4 at the 
cartilage surface has been demonstrated by Jay et al. (2001a), who have determ ined that 
boundary lubrication by PRG4 is mediated by O-linked (3(1-3) Gal-GalNAc oligosaccharides. 
MAA recognises complex, sialylated chains (Wang & Cummings, 1988), and the importance of 
these terminal sialic acids in lubrication could be investigated further using sialyltransferase and 
their inhibitors. Sialyltransferases are a family o f enzymes that catalyse the transfer o f sialic 
acids onto terminal positions of complex carbohydrates from glycoproteins and glycolipids. PNA 
recognises galactose linked (3(1-3) to N-acetylgalactosamine, a chain that is elongated by (3(1-3) 
galactosyltransferase. Inhibitors o f sialyltransferases (Kleineidam et al., 1997) and (3(1-3) 
galactosyltransferase (D elannoy et al., 1996) could be applied to specifically inhibit the 
glycosylation o f PRG4, and the implications could be studied by lubrication analyses.
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2.5 Chapter Summary
• Human recombinant PRG4, bovine articular cartilage PRG4 and bovine tendon PRG4 all 
bind to heparin-agarose and were eluted with 0.2-0.4M NaCl.
• Human recombinant and bovine cartilage PRG4 both react with the lectin PNA as 
assessed by affinity blotting. This feature was used in the lectin affinity purification of 
PRG4, which eluted from a PNA-agarose column with 0.2M D-galactose.
• Human recombinant PRG4 was purified to apparent homogeneity from the conditioned 
medium of a stable, PRG4-expressing cell line by a two-step process: heparin-agarose 
affinity chromatography followed by PNA lectin-agarose affinity chromatography.
• Bovine tendon PRG4 was partially purified from the conditioned media of deep digital 
flexor tendon explant cultures, which may be a good source o f tendon PRG4 for 
functional analyses
• The PRG4-specific antibodies available did not display any cross-reactivity between 
human and bovine species
• Bovine cartilage and human recombinant PRG4 are both recognised by the lectins PNA 
and MAA, indicating that the two species of PRG4 incorporate similar post-translational 
modifications.
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3. CLONING, EXPRESSION AND PU RIFICATION O F PRG4 STRUCTURAL
DOMAINS
3.1 Introduction
Sequence analyses of PRG4 have indicated that it is a multifunctional domain protein that has the 
potential for a number o f physiological functions including cell proliferation, cytoprotection, 
lubrication and self-aggregation/matrix binding (Flannery et al., 1999). The N- and C-terminal 
domains of PRG4, which lie either side o f the central mucin domain, contain a number o f protein 
motifs relevant to functionality. To assess these potential functions the N- and C-terminal 
domains o f bovine and human PRG4 were cloned for expression in a Drosophila Schneider-2 
insect cell expression system, and this chapter describes the production o f these PRG4 domains 
as recombinant proteins. The domains that were targeted for PCR cloning are detailed in figure 
3.1. The N-terminal sequence is 525 base pairs in length, encoding for a protein with a calculated 
mass o f 20 kDa, whilst the C-terminal sequence is 792 base pairs long representing a protein with 
a calculated molecular weight o f 30 kDa (Stothard, 2000). A cleavable FLAG epitope (reviewed 
in Einhauer & Jungbauer, 2001) was inserted N-terminal to the PRG4 domains for the detection 
and purification o f the secreted proteins. The expression and purification of these polypeptides 
facilitated studies involving the characterisation o f the biological activity o f these PRG4 
domains, based on their ability to interact with other matrix molecules, using binding assays such 
as ELISA and BIACore, and also by utilising the recombinant PRG4 domains in cell biology 
systems.
f \k iN-terminal 1 t C-terminal \
- Vn Hep mucin-like Vn Hep Hpx -COOH Recombinant
protein
1 Exons 2-5 ' Exon 6 Exons 7-12 * expression
Figure 3.1 -  Schem atic d iagram  of PRG4 illustra ting  the dom ains ta rgetted  fo r PC R  
cloning and recom binant protein expression. Vn -  vitronectin-like; Hep -  heparin-binding site; 
Hpx -  hemopexin-like.
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3.2 Materials and Methods
3.2.1 Materials
All chemicals were o f an analytical grade and were purchased from Sigma-Aldrich unless 
indicated otherwise. A detailed list o f the materials used in this research project and their 
suppliers is listed in Appendix A. Tissue culture plastics were purchased from Coming.
3.2.1.1 Stock solutions
Stock solutions and their components are listed in table 3.1. Solutions for use in tissue culture 
were autoclaved or filtered before use (0.22pm filters, Millipore).
Table 3.1 -  Stock solutions and their components.
Solution Components
2X HEPES buffered saline (HBS) 50mM HEPES, pH 7.1, 1.5mM NaH P04, 280mM NaCl
0.5X Tris-borate-EDTA (TBE) From a 5X solution (0.445M Tris-borate, pH 8.3, lOmM 
EDTA) made with Milli-Q H20  and a powdered stock (Sigma 
T3913)
Phosphate buffered saline (PBS) Dulbecco A: 0.16M NaCl, 3mM KC1, 8mM Na2H P 04, ImM 
KH2P 0 4, pH 7.3
Tns-buffered saline (TBS) 50mM Tris-HCl, pH 7.4, 0.15M NaCl
100 mM C u S 04 lOOmM in H20 ,  passed through 0.22jiM filter
3.2.1.2 Culture media
Schneider’s Drosophila medium, Drosophila-SFM (serum free medium), heat-inactivated FCS, 
and L-glutamine were all purchased from Invitrogen. Culture medium was formulated as listed 
later in table 3.10, and was passed through 0.22pm filters (Millipore, UK) before use.
LB plates (100mm) for the growth o f transformed E. Coli were prepared with LB agar (Sigma) 
containing 50pg/ml ampicillin. For blue-white selection, 40pl o f 40mg/ml X-gal solution was 
spread onto plates 1 hour before the addition o f E. coli. For the expansion o f E. Coli, LB broth 
(Sigma) was supplemented with lOOpg/ml ampicillin.
3.2.1.3 Antibiotics
Penicillin-Streptom ycin-Glutam ine solution (100X) was purchased from Invitrogen and 
comprised of 10,000 units/ml penicillin G, lOmg/ml streptomycin sulphate and 29.2 mg/ml L- 
Glutamine in a 8.85% saline and lOmM citrate buffer to maintain penicillin potency. L-
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Glutamine (100X) and Hygromycin B solution (50mg/ml in PBS) were purchased from 
Invitrogen.
3.2.1.4 Host strains/cell lines/plasmid vectors
The competent cells used for transformation were from the TOP 10 E. Coli strain from Invitrogen. 
Drosophila  S2 cells were purchased from Invitrogen. Information concerning the pMT-BiP, 
pCoHYGRO (Invitrogen) and pTAg (R & D Systems) plasmid vectors used can be found in 
appendix B. The CHO-MegN141 cell line was a gift from Wyeth Research.
3.2.1.5 Molecular biology reagents
RT-PCR was carried out using an RNA PCR core kit from Applied Biosystems. The kit consists 
of GeneAmp 10X PCR buffer II (lOOmM Tris-HCl, pH 8.3, 500mM KC1), MgCh (25mM), 
dNTPs (dATP, dCTP, dGTP, dTTP); all at lOmM, RNase inhibitor, MuLV (murine leukaemia 
virus) reverse transcriptase and oligo dT. Taq DNA polymerase from Thermus aquaticus strain 
Y T1 was purchased from Promega.
3.2.2 General molecular biology methods
3.2.2.1 Preparation o f  glassware & plastics
All glassware and media used for culture o f E. Coli was autoclaved before use. Pre-sterilised 
filter pipette tips were used for PCR and also for tissue culture after opening within a sterile 
environment. Non-sterile pipette tips without filters were autoclaved before use in tissue culture. 
Glassware and Eppendorf™ tubes were autoclaved prior to use in DNA manipulation and tissue 
culture.
3.2.2.2 Transformation o f  competent E. coli
A 20pl aliquot o f TOP 10 E. coli cells was used for each transformation. Plasmid ligation mixture 
(lp l) was added and mixed with a pipette tip, and the mixture was incubated on ice for 30 
minutes. The mixture was then transferred to a 42°C water bath for 30 seconds before the 
addition of 225pi SOC medium, followed by incubation at 37°C for 1 hour with shaking. This 
culture was then spread on LB agar plates (50-100pl/plate) and incubated overnight at 37°C.
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3.2.2.3 Agarose gel electrophoresis o f  DNA
Agarose gels were prepared using SeaKem agarose (Cambrex) and 0.5X TBE buffer (table 3.1). 
For DNA fragments over lOOObp, 1% [w/v] gels were used, for DNA fragments under lOOObp, 
2% [w/v] gels were used. Ethidium bromide was included in the gels at a concentration o f 
lpg/ml: 3pl o f a lOmg/ml stock solution was added for a 30ml gel. 6 X running buffer (Cambio) 
was added to DNA samples before loading on to agarose gels. Low (50bp-lOOObp) and high 
m olecular w eight (500bp-10kb) DNA size standards were supplied by Cam bio, UK. 
Electrophoresis was carried out in horizontal gel apparatus (BioRad, UK) at a constant voltage of 
100 volts for approximately 1 hour in 0.5X TBE (table 3.1). Gels were visualised under 
ultraviolet light, and image capture was performed using a gel documentation system (BioRad) 
linked to an Apple G3 computer.
3.2.2.4 Extraction o f  DNA from  agarose gel
DNA bands o f interest within ethidium bromide-containing gels were viewed with a UV 
transilluminator and excised with the aid o f scalpel blades. DNA was purified from the excised 
agarose bands using the QIAquick gel extraction kit (Qiagen) according to the manufacturers 
instructions. The resultant DNA was analysed to assess purity and concentration by measuring 
absorbancies at 260nm and 280nm using a spectrophotometer (UltroSpec 2000, Pharmacia).
3.2.2.5 Small-scale preparation o f  plasmid DNA
Transformed E. coli colonies were picked from inoculated LB agar/ampicillin plates with a clean 
10p.l pipette tip and grown overnight in 3ml o f ampicillin-containing LB broth (section 3.2.1.2) at 
37°C with shaking. Plasmid DNA was purified using the Wizard®F7ws SV Miniprep DNA 
Purification System from Promega according to the manufacturers instructions. DNA 
concentration was calculated by reading absorbance values at 260/280nm.
3.2.2.6 Large-scale preparation o f  plasmid DNA fo r  transfection
For transfections, plasmid DNA was purified from a 100ml LB/ampicillin broth culture grown 
overnight at 37°C in 500ml conical flasks with vigorous shaking (300rpm). Plasmid DNA was 
purified using an EndoFree plasmid midiprep kit (Qiagen) according to the manufacturers 
instructions in order to remove endotoxin, or lipopolysaccharide (LPS). A single E. Coli cell
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contains about 2 million LPS molecules (Rietschel & Brade, 1992; Raetz, 1990), and during lysis 
of bacterial cells for plasmid DNA purifications, endotoxin molecules are released from the outer 
membrane into the lysate. Endotoxin or LPS can reduce transfection efficiency in eukaryotic cell 
lines (Weber et al., 1995). Levels o f endotoxin in plasmid preparations depend on the type of 
purification method employed (Cotten et al., 1994), and the EndoFree purification kit removes 
most endotoxin, and yields around 400pg o f plasmid from a 100ml E. Coli culture. DNA 
concentration was calculated by reading absorbance values at 260/280nm.
3.2.2.7 Preparation o f  frozen plasmid stocks
Ampicillin-containing LB broth cultures (3ml) o f transformed colonies picked from agar plates 
were grown overnight at 37°C with continuous shaking (225rpm). For the preparation of glycerol 
stocks for long-term storage o f plasmids, 0.5ml o f broth culture was mixed with 0.5ml o f sterile 
50% [v/v] glycerol in a Nalgene cryovial. Stocks were stored at -80°C.
3.2.2.8 Restriction enzyme digestion
Restriction endonuclease digestions were performed according to the manufacturers instructions, 
in the buffers recommended by the suppliers (Promega) for 2 hours at 37°C, in the absence of 
acetylated BSA. For a reaction volume o f 20p,l, lp g  of DNA was used. Following digestion, 6 X 
running buffer (Cambio) was added and products were separated on 1% (vector DNA) or 2% 
(PCR product DNA) agarose gels containing 0.5pg/ml ethidium bromide (section 3.2.2.3). Bands 
of interest were excised and purified using the QIAquick gel purification system (section 3.2.2.4).
3.2.3 RNA isolation
3.2.3.1 Cell sources
(a) Bovine chondrocytes
For the amplification o f bovine cDNA, total RNA was isolated from bovine superficial zone 
chondrocyte monolayer cultures. Chondrocytes were isolated as described in section 2.2.2. Cells 
were then cultured in monolayer at an initial seeding density o f 0.8 x 106 cells/ml in DMEM 
supplemented with 5% [v/v] FCS and 50p,g/ml gentamicin. Upon confluency, cells were washed 
with PBS prior to the addition of 3ml Tri-Reagent (Sigma) per 60mm dish. The Tri-Reagent was
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allowed to sit for 15 minutes before removal into 1.5ml microcentrifuge tubes containing 
chloroform (0.2ml/lml Tri-Reagent).
(b) Human chondrocytes
For the PCR amplification of human cDNAs, total RNA originating from explant cultures o f 
human osteoarthritic cartilage was used (gift from Dr. C. R. Flannery).
(c) Drosophila S2 cells
To investigate the expression o f PRG4 domains by stable S2 cell lines, 12 x 106 cells from 
confluent cultures were washed twice with PBS before the extraction of total RNA with lml Tri- 
Reagent.
3.2.3.2 Procedure fo r  RNA isolation
The Tri-Reagent/chloroform samples were vortexed and left to stand at room temperature for 15 
minutes, then centrifuged at 16,000 x g for 15 minutes. The upper aqueous phase was carefully 
removed and mixed with an equal volume o f 70% [v/v] ethanol. Total RNA was isolated using 
RNeasy mini-columns and reagents (Qiagen) according to the manufacturers protocol. This 
procedure is based on the binding properties o f a silica gel-based membrane with microspin 
technology. RNA contained in the sample binds to the membrane allowing contaminants to be 
washed away. To remove contaminating DNA, DNAse I solution (80pl, Qiagen) was incubated 
with the membrane in between two wash steps. RNA was eluted from the membrane with sterile 
water, and amount and purity was assessed by measuring absorbance values at 260 and 280nm 
using a spectrophotometer (UltroSpec 2000, Pharmacia).
3.2.4 Reverse transcription o f RNA and PCR amplification o f cDNA
Reverse transcription-polymerase chain reaction (RT-PCR) is a two-step process comprised o f 
the reverse transcription o f RNA into cDNA, followed by the amplification o f cDNA by PCR 
with oligonucleotide primers specific to the required target sequence. For the first step, cDNA 
was synthesised by reverse transcription by using 50-100ng of RNA in a reaction with a final 
volume of 20pl, as detailed in table 3.2. This reaction was mixed by vortexing and then incubated 
at room temperature for 10 minutes. The mixture was then subjected to the following cycle: 42°C 
for 30 minutes, 99°C for 5 minutes with a final soak of 4°C.
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Table 3.2 -  Reverse transcription reaction mixture
Component Volume
10X PCR buffer II 2.0pl
25mM MgCF 1.6pl
2.5mM dNTPs 1.6pl
RNase inhibitor l.Opl
MuLV reverse transcriptase l.Opl
Oligo dT l.Opl
Total RNA sample (50-100ng) Xpl
Water To 20pl
3.2.5 PCR reactions
3.2.5.1 Oligonucleotide primers
For the construction of oligonucleotides to amplify PRG4 cDNA sequence(s), a number o f primer 
design criteria were considered. These included the following:
(i) ‘standard’ PCR primers were 20-25 nucleotides long;
(ii) melting temperatures were within the range of 50-65°C;
(iii) the GC content was generally kept to 40-60%; and
(iv) self-complementarity was avoided to minimise primer secondary structure and
primer-dimer formation.
In addition, ‘expression primers’ were designed to generate PCR products that could be inserted 
into an expression vector. These primers were designed to contain the following features:
(i) primers, and therefore PCR products, contained a 5' Ncol cleavage site and a 3' Xhol
cleavage site so that digested PCR products can be inserted into the polylinker region 
of a cleaved pMT-BiP vector (appendix B);
(ii) 5 ' and 3' restriction sites to include an appropriate overhang in order to ensure 
efficient restriction enzyme digestion o f the amplified cDNA ends (technical 
information obtained from Promega 2002 catalogue);
(iii) forward primers contained a FLAG® protein purification/detection epitope, encoding 
for the amino acid sequence DYKDDDDK;
(iv) forward primers were designed so that the PRG4 protein-encoding sequence o f the 
PCR product would be in frame with the FLAG epitope, and that after restriction 
digestion the PCR product could be ligated into the cleaved expression vector pMT-
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BiP, with PRG4 sequence in frame with the BiP secretion signal present in the vector 
(for details see appendix B);
(v) reverse primers were to contain a stop codon (AMB) in frame with the PRG4- 
encoding PCR product.
For the amplification o f specific portions o f human and bovine PRG4, primers were designed 
using sequences that are available in Genbank, and their Accession numbers are listed in table 
3.3. Primer sequences and relevant features are listed in table 3.4. Primers were designed using 
the Oligo 4.0s program for Macintosh (MBI Inc.) or the MacDNAsis system (Hitachi Software, 
Japan).
3.2.5.2 Protocol fo r  PCR reactions
PCR reaction mixtures were prepared as detailed in table 3.5. Reactions were performed in a 
Technegene thermal cycler (Techne, UK). Cycling parameters were as follows: following an 
initial denaturation step of 60 seconds at 95°C, amplification consisted of 35 cycles o f 30 seconds 
at 95 °C, 45 seconds at the annealing temperature o f the primer set (52°C for the primers listed in 
table 3.4), 45 seconds at 72°C followed by a final extension step of 5 minutes at 72°C. Reaction 
mixtures were then separated by agarose gel electrophoresis as detailed in section 3.2.2.3.
Table 3.3 -  Sequences used in the design of PRG4-specific primers
Target G enbank  
Accession No.
Sequence Reference
Human PRG4, 
exons 2-5
U70136 Homo sapiens megakaryocyte stimulating 
factor
(Turner e ta l.,  1991)
Bovine PRG4, 
exons 2-5
U70136 Homo sapiens megakaryocyte stimulating 
factor
(Turner et al., 1991)
Human PRG4, 
exons 7-12
U70136 Homo sapiens megakaryocyte stimulating 
factor
(Turner et al., 1991)
Bovine PRG4, 
exons 7-12
AF056218 Bos taurus superficial zone protein (Flannery et al., 1999)
Table 3.4 -  Oligonucleotide primers used in the RT-PCR amplification o f human and bovine isl­
and C-terminal domains o f PRG4.
Primer
pair
Specificity Sequence Expected  
size o f  
product
HC1
HC2
Human PRG4 
Exons 7-12 
(C-terminal)
5 '-G ATG AG ACC A AT AT ATGC A AT 
5'-CT A AGG AC AGTTGT ACC AG AC
792bp
BC1
BC2
Bovine PRG4 
Exons 7-12 
(C-terminal)
5'-GATGAAACTAATCTATGCAACG  
5 ’-CTAAGG AC AGTTGTACCAGGTA
792bp
N 1
N2
Human & Bovine 
PRG4
Exons 2-5 (N-terminal)
5”-CAAGATTTATCAAGCTGTGCA
5„ c t a t t t g a g t t t c t t c t g t a a
525bp
H Cla
HC2a
Human PRG4 
Exons 7-12 
(C-terminal) 
w / restriction sites & 
FLAG
5'- AC AT GCC AT GGG ACT AC A AGG ACG ACG A 
T G AC AAGG ATG AG ACC AAT AT ATGC A AT 
5'-CCGCTCGGAGCTAAGGACAGTTGTACCAGAC
815bp
B C la
BC2a
Bovine PRG4 
Exons 7-12 
(C-terminal) 
w/ restriction sites & 
FLAG
5'- ACATGCCATGGGACTACAAGGACGACGA 
T G AC AAGG ATG A AACT AAT CT ATGC AAC
815bp
N la
N2a
Human & Bovine 
PRG4
Exons 2-5 (N-terminal) 
w/ restriction sites & 
FLAG
5'- ACATGCCATGGGACTACAAGGACGACGA  
TGACAAGCAAGATTTATCAAGCTGGGCA 
5'- CCGCTCGAGCTATTTGAGTTTCTTCTGTAA
548bp
Table 3.5 -  PCR reaction mixture
C om ponent Volum e
10X PCR buffer II 2pl
25mM MgCh 1.2 pi
2.5mM dNTPs 1.6pl
Primers (stock = lOpM) 0.4pl o f  each
Taq polymerase 0.12pl
RT sample lp l
Water To 20 pi
3.2.5.3 Cloning o f  PRG4 cDNA fragments into pTAg TA cloning vector
PRG4 domain cDNAs were amplified by PCR with the primers detailed in table 3.4. If a strong 
single band was apparent, the PCR reaction mixture was included in a ligation mixture as detailed 
in table 3.6. This mixture was incubated overnight at 14°C and transformed into E coli as 
described in section 32.2.2. Transformants were grown on LB agar with X-Gal (5 -b rom o-4-
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chloro-3-indoly l-B -D -galactoside) for blue-white selection of transformed colonies (section 
3.2.1.2).
Table 3.6 -  Ligation reaction mixture for plasmid vector pTAg
Com ponent V olum e
10X ligation buffer (Promega) 0 .5p l
T4 DNA Ligase 0 .5p l
20-50ng cleaved pMT vector X pl
Cleaved PCR product X pl
H20 To 5 pi
3.2.5.4 Cloning o f  PRG4 cDNA fragm ents into pM T expression vector
DNA fragments were generated by PCR using primers containing sequences designed to 
incorporate a 5' Ncol site and a 3 ' Xhol site into the product (table 3.4). The forward primer was 
designed so that a FLAG detection/purification epitope was incorporated into the product. The 
PCR products and the pM T-BiP vector (see appendix B) were both cleaved with the 
aforementioned restriction endonucleases (section 3.2.2.8 ) and subjected to agarose gel 
electrophoresis (section 3.2.2.3). The desired products were excised from the ethidium bromide- 
stained gel with the aid o f a UV transilluminator and gel-purified (section 3.2.2.4). The purified 
PCR products were then cloned into the cleaved pMT-BiP vector. This was performed by 
preparing a 5pl ligation reaction containing the components listed in table 3.7.
Table 3.7 -  Ligation reaction mixture for plasmid vector pMT-BiP
Component Volume
10X ligation buffer (Promega) 0.5pl
T4 DNA Ligase 0.5pl
20-50ng cleaved pMT vector Xpl
Cleaved PCR product Xpl
H20 To 5pl
This mixture was then incubated overnight at 14°C and transformed into the TOP 10 E. Coli strain 
(Invitrogen) as in section 3.2.2.2. Transformants were grown on LB agar (section 3.2.1.2).
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3.2.5.5 Screening o f  colonies
Analysis o f transformants was carried out by preparing plasmid miniprep DNA o f colonies 
apparent on LB agar plates (see section 3.2.2.5). To confirm the insertion o f PCR products, 
plasmid preparations were analysed by restriction digestion with Ncol/Xhol, PCR followed by 
gel electrophoresis, and automated DNA sequencing (section 3.2.5.6 ).
3.2.5.6 Automated DNA sequencing
Plasmid preparations were sequenced using the primers relevant to the plasmid vectors used, as 
listed in below in table 3.8.
Table 3.8 -  Sequencing primers for plasmid vectors
Vector Primer Sequence
pMT-BiP MT forward 5 '-C ATCTC AGTGC AACTA AA
pMT-BiP BGH reverse 5-TAGAAGGCACAGTCGAGG
pTAg M13 (+) 5 -GTAAAACGACGGCCAGT
pTAg M13 (-) 5'-AACAGCTATGACCAT
Sequencing reactions were prepared using the ABI Prism™ BigDye™ Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, USA) as detailed in table 3.9. 
BigDye™ contains dNTPs and the four ddNTPs with their associated differing fluorescence 
labels. The reaction mixture was then subjected to a thermal cycling program using a Technegene 
cycling machine (Techne). The parameters used were as follows: an initial denaturation step of 
95°C for 30 seconds was followed by 26 cycles of 96°C for 20 seconds, 50°C for 10 seconds and 
60°C for 4 minutes, with a final hold at 4°C.
Table 3 .9 - Sequencing reaction mixture
Com ponent Volume
BigDye solution lp l
ABI Better Buffer 5pl
Sequencing primer (2pM ) 1.5pl
DNA 200-400ng
H20 To 15pl
The products of sequencing reactions were purified after cycling. 3M Sodium acetate, pH 3.1 
(2|jl1), H2O (3fil) and ethanol (40|xl) were added to the reaction mixture, which was vortexed and
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allowed to stand at room temperature for 20 minutes. The mixture was centrifuged for 20 minutes 
at 16,000 rpm on a benchtop centrifuge and the supernatant was removed, and the DNA pellet 
was washed with 250p,l o f 70% [v/v] ethanol and centrifuged for 10 minutes. The supernatant 
was removed and the pellet was allowed to dry at 90°C and stored at -20°C before sequencing on 
an ABI Prism 310 automated sequencer, or transfer to the Molecular Biology Support Unit, 
Cardiff University, to be sequenced on an ABI Prism 3100 automated sequencer.
3.2.6 Cloning o f  PR G4 domains
3.2.6.1 Overview
The overall aim o f this technique was to obtain the cDNAs for human and bovine C-terminal and 
N-terminal domains o f PRG4 in order to produce them in a protein expression system. The 
position o f the N- and C-terminal domains targeted for PCR cloning are indicated in figure 2.1. 
The system used in this instance utilises the pMT-BiP-V5 plasmid vector from Invitrogen. This 
vector gives inducible, secreted expression of protein encoded by insert DNA in Drosophila S2 
cells.
3.2.6.2 Primers fo r  PCR amplification ofPRG 4 domains
PRG4-specific primers without ‘expression primer’ features (HC1/HC2, BC1/BC2, N1/N2; see 
table 3.4) were used to amplify the desired PRG4 sequence using cDNA from human and bovine 
chondrocytes. The products from these reactions were then cloned into a TA cloning vector 
(pTAg, section 3.2.5.3). Plasmid preparations of transformed colonies were then used as 
templates for PCR using the FLAG/restriction site ‘expression’ primers, alongside RT samples 
from human or bovine chondrocytes. The ‘expression’ primer sets HCla/HC2a, BCla/BC2a and 
N la/N2a (see table 3.4) were all designed with the appropriate restriction sites at the 5’ end to 
enable cloning of the resultant PRG4 cDNA products into a digested pMT-BiP vector, in frame 
with the vector BiP secretion signal sequence. Sets HCla/HC2a and B Cla/B C 2a are specific to 
human and bovine PRG4 C-terminal regions, respectively. The prim er pair N la /N 2a was 
designed using the human PRG4 N-terminal sequence but was also functional with bovine 
samples. Forw ard prim ers were designed w ith an en terok inase-c leavab le  FLAG 
identification/purification epitope (amino acid sequence DYKDDDDK) 5 ' to the start o f the 
PRG4 sequence. Reverse primers included a stop codon (AMB). The restriction sites used were
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Ncol for the forward primers and Xhol for the reverse primers, and the sites were designed so 
that the start codon, FLAG epitope and PRG4 sequence would be in frame with the BiP secretion 
signal of the expression vector.
3.2.6.3 Expression constructs
Before ligation into the expression vector, PRG4 domain PCR products were double-digested 
with Ncol and Xhol (section 3.2.2.8 ) and gel purified (section 3.2.2.4). Digested PCR products 
were ligated into the pMT-BiP expression vector (section 3.2.5.4) following digestion o f the 
expression vector (pMT-BiP-V5) with Ncol and Xhol, and gel purification o f the linearised 
vector. Plasmid preparations (section 3.2.2.5) o f all constructs were sequenced (section 3.2.5.6 ) 
to check for in-frame insertion o f PRG4 cDNA and lack of PCR-introduced mutants. Verified 
expression constructs and the selection vector pCoHYGRO (see appendix B) were prepared to a
high degree of purity with an endotoxin-removal kit (see section 3.2.2.6) prior to transfection into
Drosophila S2 cells (section 3.2.8.1).
3.2.7 Drosophila S2 cell culture
3.2.7.1 Drosophila S2 cell line
The pMT-BiP expression vector (appendix B) is designed for use with Schneider-2 (S2) cells, a 
cell line derived from a primary culture o f late stage (20-24 hours old) Drosophila melanogaster 
embryos (Schneider, 1972).
3.2.7.2 Culture media
The culture media used in conjunction with the Drosophila S2 cell line is listed in table 3.10.
Table 3.10 -  Culture media used with Drosophila S2 cells
Media Components
DES complete medium Schneider’s Drosophila Medium with 10% heat-inactivated FCS, 50pg/ml 
penicillin G, 50pg/ml streptomycin & 2mM L-glutamine
DES selection medium Schneider’s Drosophila Medium with 10% heat-inactivated FCS, 50pg/ml 
penicillin G, 50pg/ml streptomycin, 2mM L-glutamine and 300pg/m l 
hygromycin B
DES expression medium Drosophila-SFM with 50pg/ml penicillin G, 50pg/ml streptomycin, 2mM L- 
glutamine and 300pg/ml hygromycin B
DES freezing medium 45% [v/v] fresh DES complete medium, 45% [v/v] conditioned DES 
complete medium, 10% [v/v] DMSO
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3.2.7.3 Culture and maintenance o f  S2 cells
DES complete medium (see table 3.10) was used for the in itiation  and expansion o f the 
Drosophila S2 cell line. S2 cells grow at room temperature as a loose, semi-adherent monolayer 
and have a doubling time of approximately 24 hours. Cells were cultured in 25cm2 (3-5ml culture 
volume) or 75cm2 (10-15ml culture volume) tissue culture flasks w ith vented lids (Coming), and 
were incubated at 26°C without CO2 . Cells were passaged when cell density reached between 8 
and 20 x 106 cells/ml and were split using dilution factors of 1:2 to 1:5. S2 cells do not require 
trypsinisation; they can be detached by washing the surface of the flask with conditioned medium 
with a pipette during passage. Conditioned media w as always carried over; for example a 1:3 
dilution of a confluent 15ml culture would involve transferring 5ml o f the culture to 10ml of 
fresh medium in a new flask. For expansion purposes cells were subcultured in serum-containing 
medium to a final density of 2 - 4 x 106 cells/ml. S2 cells were never seeded below a density of 
0.5 x 106 cells/ml, as these cells do not grow well at low  density.
3.2.7.4 Initiation o f S2 cell culture from  frozen stocks/preparation o f  frozen S2 cell stocks
For the initiation of cell culture from frozen stocks, frozen aliquots were thawed quickly at 37°C 
and added to 25cm2 flasks containing 5ml o f com plete m edium . Following a 45-minute 
incubation, cells were centrifuged at 1000 x g for 4 m inutes and the DMSO-containing freezing 
medium was aspirated. Cells were re-suspended in 5ml of com plete medium and grown to 
confluency (8-20 x 106 cells/ml) before dilution. For storage, 11 x 106 cells from confluent (10- 
20 x 106 cells/ml) cultures in serum-containing m edia were frozen  to -80°C in lm l freezing 
medium (see table 3.10) in Nalgene cryovials. Styrofoam containers were used to ensure a slow 
freezing process, and vials were transferred to liquid nitrogen for long-term  storage.
3.2.8 Generation o f  PRG4 domain-expressing Drosophila S2 cell lines
3.2.8.1 Transfection o f  cultured S2 cells
The aim o f this technique was to generate stable D rosophila  S2 cell lines that secrete target 
proteins (PRG4 domains) into the culture media upon induction w ith  CUSO4. S2 cells were co­
transfected with pMT-BiP PRG4 domain-containing expression constructs (section 3.2.6 .3) and a 
hygromycin selection vector (pCoHYGRO, appendix B) using a calcium  phosphate transfection 
kit (Invitrogen). A 19:1 [w/w] ratio o f expression vecto r to selec tion  vector was used, and
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expression or selection vectors were omitted where appropriate as negative controls for selection 
and expression experiments. Briefly, the solution described in table 3 .1 1 was added dropwise to 
300pl o f HBS (see table 3.1) with continuous mixing.
Table 3.11 - Calcium phosphate transfection solutions for Drosophila S2 cells
Component Volume
2M CaCl2 36pl
19pg pMT expression construct Xpl
1 pg pCoHYGRO selection vector Xpl
H;0 to 300pl
The resulting solution was incubated for 45 minutes at room temperature, mixed and added 
dropwise to S2 cells. For transfections, 3 x 106 cells were grown in 25cm2 flasks for 16 hours in 
3ml of complete medium before the addition of transfection mixture. Cells were incubated for 24 
hours before centrifugation and removal o f the transfection mixture from the cell pellet by 
aspiration. Cells were resuspended in 3ml o f complete medium and allowed to recover for 48 
hours
3.2.8.2 Selection o f  stable S2 cell lines
Following the recovery o f cells after transfection in complete medium (48 hours), cells were 
pelleted by centrifugation and re-plated in 3ml o f selection medium (complete medium with 
300p.g/ml hygromycin B, table 3.10) into the same vessel. Selection medium was replaced every 
4 days and hygromycin-resistant cells started to expand 2 to 3 weeks post-transfection. This was 
assessed by applying selection medium to untransfected S2 cells. Hygromycin B is an 
aminocyclitol antibiotic that strongly inhibits protein synthesis through an action on mRNA 
translation (Cabanas et al., 1978). The hygromycin-resistance vector (pCoHYGRO) used in these 
experiments contains a gene encoding for hygromycin B phosphotransferase (Hph). This enzyme 
catalyses the phosphorylation of the 4-hydroxyl group on the cyclitol ring o f hygromycin, 
producing 7’-0-phosphoryl-hygromycin B which lacks biological activity (Pardo et al., 1985). 
Hygromycin-resistant S2 cells were split 1:2 upon reaching confluency (6-20 x 106 cells/ml), and 
frozen stocks were prepared after multiple passes and expansion o f the stable cell line in 
hygromycin-containing complete medium. Cell viability was assessed visually or by trypan blue 
assay: 0.1ml o f cell suspension (1 x 106 cells/ml, no serum) was mixed with 0.1ml 0.4% [w/v]
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trypan blue solution. Trypan blue is excluded from viable cells, and cells were counted and 
assessed with a haemocytometer.
3.2.8.3 Expression and detection o f recombinant protein from stable cell lines 
For the expression and purification of recombinant proteins, Stable S2 cell lines were transferred 
to DES serum free expression medium (see table 3.10) and incubated at 26°C. Expression of 
recombinant proteins was induced by the supplementation of CuSCL to a final concentration of 
500pM, inducing expression from the metallothionein (MT) promoter of the transfected pMT- 
BiP expression vector (Bunch et al., 1988). S2 cells transfected with the pCoHYGRO vector only 
were used as a negative control. For the harvest of conditioned medium, stable cell lines were 
plated at a density o f 4-10 x 10 cells/ml in 15ml serum free medium in 75cm flasks with vented 
lids. Media was harvested every 3-5 days by centrifugation (1000 x g for 4 minutes), or when 
plates reached confluency. S2 cells are viable in serum free medium up to a density o f 30 x 106 
cells/ml. After harvest o f conditioned medium cells were re-plated at a density o f 4-10 x 106 
cells/ml in fresh DES expression medium. 30pl aliquots of conditioned medium were analysed 
by SDS-PAGE using 15% [w/v] Tris-Glycine slab gels (acrylamide and bis-acrylamide from 
National Diagnostics). The SDS-PAGE methods used are detailed in chapter 2, section 2.2.9. 
Recombinant proteins were detected using silver staining for total protein (chapter 2, section 
2.2.12) and Western blottting (as described in section 2.2.9) with a monoclonal antibody specific 
to the FLAG detection/purification epitope at the N-terminus of recombinant proteins, anti 
FLAG-M2 AP-conjugate (Sigma). This was used at a concentration of 1:1000 in 1% [w/v] BSA 
diluted in TSA. A FLAG fusion protein, rAggl (recombinant aggrecan-1), was used as a positive 
control for blotting and was supplied by Dr. Clare Hughes (Hughes et al., 1997).
3.2.9 Purification o f recombinant PRG4 domains from the conditioned medium o f stable S2 
cell lines
Conditioned media was passed through 0.22pm filters and dialysed against TBS (table 3.1) with 
repeated changes before immunoaffinity chromatography using an anti-FLAG M2 affinity gel 
(Sigma). For each purification, FLAG affinity gel (lm l) was equilibrated with 10ml TBS (see 
table 3.1) prior to pre-elution with 5ml glycine-HCl (pH 3.5) and re-equilibration in TBS. The 
FLAG affinity gel was then mixed with TBS and added to 40ml of conditioned medium and
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incubated at 4°C for 1 hour on an orbital mixer. The immunoaffinity resin was collected by 
passing the mixture over an empty 10ml chromatography column (BioRad) that had previously 
been washed in TBS. Vessels containing the mixture of conditioned medium and affinity gel 
were washed with TBS to remove the remaining affinity gel, and this TBS was passed over the 
column. The resin bed was washed with 20ml TBS to remove unbound proteins, and the 
efficiency of washing was determined by reading absorbance values at 280nm. Bound protein 
was eluted with 5 x lm l aliquots of glycine-HCl (pH 3.5), into vials containing 25p,l o f 1.5M 
Tris-HCl (pH 8 .8 ). The concentration of eluents was calculated by reading absorbance values at 
280nm, and protein species were separated by SDS-PAGE and analysed by Western blot and 
silver stain. FLAG M2 agarose was washed with 20ml TBS before washing in 10 column 
volumes of storage buffer (50% [v/v] glycerol with TBS containing 0.02% sodium azide). 5ml of 
storage buffer was added to the column, which was stored at 4°C without draining.
3.2.10 CHO-MegN141 cell line
The CHO-MegN141 cell line, supplied by Wyeth, was generated to express human PRG4 from 
the initial Gin1 residue to Asn141 as a secreted protein from a stably transfected Chinese hamster 
ovary (CHO) cell line. Cells were cultured and conditioned serum free media was collected as 
described in chapter 2, section 2.2.4. Conditioned medium was concentrated using a Centriplus 
centrifugal filter device (Millipore) with a YM10 cut-off membrane to retain macromolecules of 
over 10 kDa. 30 mis of media was passed over the filter by adding 10 ml at a time and spinning 
for 1.5 hours at 3000 x g at 4°C. This process was repeated until all the media was passed over 
the column. The proteins in concentrated media were separated by SDS-PAGE as described in 
chapter 2, section 2.2.9 and subjected to a Western blot probed with a polyclonal antibody to 
exon 3 o f human PRG4.
3.3 Results
3.3.1 Amplification o f cDNAs for human and bovine N- and C-terminal PRG4
Previous studies have deduced the complete cDNA sequence (GenBank Accession No. U70136) 
encoding for human MSF precursor (Merberg et al., 1993), which is homologous to PRG4. The 
partial cDNA sequence (GenBank Accession No. AF056218) encoding the C-terminal 401 amino
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acids o f  bovine articular cartilage PRG4 (Flannery e t  al., 1999). In this study the human MSF 
precursor sequence was used to design primers N1 and N2, specific for exons 2 to 5 o f MSF 
precursor/PRG4 (amino acids Gln25-Lys199). Exon 1 was not included, as this is the secretion 
signal for PRG4, and the expression system used in this study has an expression vector with a 
built-in BiP secretion signal (reviewed in Gething, 1999). PCRs performed using cDNA from 
bovine chondrocyte monolayer and human cartilage explant cultures generated products o f the 
expected size of 525bp (figure 3.2, lanes 1 and 3, respectively).
The human MSF precursor sequence was also used to  design primers HC1 and HC2, specific to 
exons 7-12 (amino acids Asp144'-P ro 1404) o f human M S F  precursor/PRG4, and PCR with human 
cartilage cDNA generated a product of the expected s iz e  of 792bp (figure 3.2, lane 4). Previously 
identified cDNA sequence encoding the C-terminal portion o f bovine articular cartilage PRG4 
was used to design primers BC1 and BC2, specific for exons 7-12 of bovine PRG4. RT-PCR 
amplification using bovine articular cartilage chondrocyte cDNA as a template produced a 
fragment with the expected size of 792bp (figure 3.2, lane 2).
3.3.2 Sequencing o f cDNAs for PRG4 N-terminal a n d  C-terminal structural domains 
The cDNAs encoding human and bovine N -term inal (exons 2-5) and C-terminal (exons 7-12) 
PRG4 were ligated into the TA-cloning vector pTAg and sequenced using the M13 forward and 
reverse primers listed in table 3.8. The sequences obtained were subjected to BLAST searches 
(Altschul et al., 1997) and their homology with existing MSF precursor/PRG4 cDNA sequences 
was confirmed. Sequence data was deposited in G enBank as detailed in table 3.12. Novel bovine 
cartilage PRG4 N-terminal cDNA sequence (29Ser-191Glu) was deposited to Genbank under the 
Accession No. AY397646, and the position o f this sequence is shown in figure 3.3. The bovine 
amino acid sequence displays a homology o f 8 6 % w ith  the human sequence. Other sequences 
were almost completely homologous to already published PRG4 sequence data.
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Figure 3.2 -  RT-PCR analyses of bovine and hum an chondrocyte cDNA using prim ers 
specific for N -term inal (exons 2-5) and C -term inal (exons 7-12) PRG4. The primer pair 
N1/N2, designed using human N-terminal PRG4 sequence, was used in lanes 1 and 3 to amplify 
human and bovine PRG4 DNA, respectively. Primer pairs BC1/BC2 and HC1/HC2, designed 
using bovine and human C-terminal PRG4 sequence, were used in lanes 2 and 4, respectively. 
The migration positions of PRG4 N-terminal and C-terminal cDNAs are indicated by arrows on 
the right. Migration of size standards is shown on the left.
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Hum MAWKTLPIYLLLLLSVFVIQQVSSQDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDF 60 
Bov SCAGRCGEGYSRDAICNCDYNCQHYMECCPDF
Hum KRVCTAELSCKGRCFBSFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKKAP 120  
Bov KKECTVELSCEGRCFETFARGRECDCDSDCKKYGKCCS DYGAFCEAVHNPTTPPPPKTAP
Somatomedin 
B homology
Hum PPSGASQTIKSTTKRSPKPPNKEETKEVIBSEBITEEHSVSBNQESSSSSSSSSSSSTIW  
Bov PPPGASQTIKSTTKRSPKSPNXKKTXKVIESEEITEEHSVSEHQE— S S S S 6 S S S S S T I R
_______N-t*rm< -T j4 6 ._________________________________
Hum KIKSSKNSAANRELQKKLK 
Bov KIKSSKNSGANRELQKKLK
180 heparin
binding
Figure 3.3 -  A lignm ent of hum an a n d  bovine PR G 4 N -term inal dom ain am ino acid 
sequences. Bovine PRG4 sequence iden tified  by this study (Genbank Acc. No. AY397646) is 
highlighted in bold. Heparin-binding reg io n s  are shown in red. Sources of the other human and 
bovine PRG4 sequence are listed in table 3 .3 .
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Table 3.12 -  PRG4 sequence data obtained during this study, along with their GenBank 
Accession numbers.
Species and PRG4 domain PRG4 region GenBank Acc. No.
Bovine N-terminal (exons 2-5) 29Ser-,91Glu AY397646
Human N-terminal (exons 2-5) 2VSer-193Glu AY653037
Bovine C-terminal (exons 7-12) 114(,G ly-li95Ser A Y 536119
Human C-terminal (exons 7-12) n48G ly-,397Ser AY653038
3.3.3 Generation o f expression constructs for human and bovine PRG4 domains
The expression system chosen for the purpose of producing recombinant PRG4 domains was the 
Drosophila Expression System from Invitrogen, which utilises a cell line derived from 
Drosophila melanogaster Schneider 2 (S2) cells and a simple plasmid vector. There are a number 
of vectors available for use with this system, for this application the pMT-BiP-V5/His plasmid 
was used. This vector allows inducible expression from the metallothionein (MT) promoter, and 
inserts can be cloned in-frame with an N-terminal Drosophila secretion signal sequence (BiP) 
which causes recombinant proteins to be secreted into the culture medium of transfected S2 cells. 
The expression vector also encodes a C-terminal peptide containing the V5 epitope for antibody 
detection and a polyhistidine (6 xHis) tag for purification, but in this study these features were not 
used, and a stop codon was included in the reverse expression primers. Instead, an 8  amino acid 
FLAG® epitope (AspTyrLysAspAspAspAspLys) was included in forward expression primers to 
facilitate the production of PRG4 domains as N-terminal FLAG fusion proteins, which can be 
detected and purified using anti-FLAG antibodies. The FLAG epitope was specifically designed 
for immunoaffinity chromatography and contains an enterokinase cleavage site (reviewed in 
Einhauer & Jungbauer, 2001). ‘Expression’ primer sets were designed in order to manipulate 
PRG4 domains into this system. These comprised o f the regular primers as used in figure 3.2, 
with added features including a FLAG epitope sequence in the forward primer and a stop codon 
in frame with PRG4-coding sequence in the reverse primer. The expression primers also included 
Ncol (forward) and Xhol (reverse) restriction sites to enable the insertion o f restriction enzyme- 
digested PCR products into the pMT-BiP vector. PRG4 cDNA sequence was checked for Ncol 
and Xhol sites using MacDNAsis software (Hitachi). Figure 3.4 shows the results o f PCR using 
human and bovine chondrocyte cDNA and pTAg cloning vectors with PRG4 inserts as template 
material. PRG4 primer pairs containing only PRG4 sequence (1), and modified ‘expression’ 
primer pairs (2 ).
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Figure 3.4 -  PCR analyses of bovine chondrocyte and hum an cartilage e x p l a n t  cDNA (RT 
samples) and TA-cloned pTAg-PRG4 domain constructs for the bovine a n d  hum an N- and 
C-terminal domains of PRG4. In each case conventional (A) and ‘expression’ (B) primer sets 
were used. Expression primers incorporated the modifications necessary to ligate the PCR 
products into the pMT-BiP expression vector in order to express FLAG-tagged recombinant 
PRG4. The migration of molecular size standards is shown on the left.
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As shown in figure 3.4, in most cases PCR products o f the correct size were generated with 
expression primers when using bovine or human cDNA samples as a template, but in the case of 
bovine C-terminal PRG4 a fragment was only generated when using the pTAg vector with 
inserted bovine PRG4 sequence as a template (figure 3.4, lower left panel). The cDNA products 
resulting from PCRs with the ‘expression’ primer sets were subsequently gel purified, digested 
with Ncol and Xhol, gel purified for a second time and ligated into the expression vector pMT- 
BiP. To enable this ligation, the expression vector was digested with Ncol and Xhol and gel 
purified. Plasmid preparations o f transformed colonies were sequenced with the supplied 
sequencing primers MT-F (forward) and BGH-R (reverse) to verify that the inserted PRG4- 
expressing domains contained no mutations and were in frame with the BiP secretion signal 
included in the vector. Expression constructs are shown in figure 3.5 after digestion with either 
one or both o f the restriction endonucleases used to cut the polylinker region o f the expression 
vector prior to insertion o f the PRG4 cDNA, with unmanipulated pMT-BiP vector as a control 
(lanes 9 & 10). In the first lane in each case the vector is digested with Xhol alone yielding a 
linearised product o f around 3.6kb, whereas in the second lane the construct has been digested 
with Ncol and Xhol, and the PRG4 cDNAs of 562 (N-terminal, lanes 2 & 4) and 829bp (C- 
terminal, lanes 6  & 8 ) are apparent.
After the expansion of expression construct LB broth cultures, plasmids were purified using a kit 
designed for the removal o f endotoxin (EndoFree, QIAgen). Removal of endotoxin from plasmid 
preparations can dramatically increase transfection efficiency in many cell lines. This effect was 
apparent in these experiments: S2 cells transfected with plasmid preparations without endotoxin 
removal steps were not viable under selection conditions, indicating poor transfection efficiency 
(data not shown). The expression constructs generated by this study and their associated PRG4 
domains are listed in table 3.13.
Table 3.13 -  List o f PRG4 expression constructs
Construct name PRG4 domain
pMT-BN Bovine N-terminal (exons 2-5)
pMT-HN Human N-terminal (exons 2-5)
pMT-BC Bovine C-terminal (exons 7-12)
pMT-HC Human C-terminal (exons 7-12)
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Figure 3.5 -  Restriction digestion analysis of bovine and human N- and C-term inal dom ain 
PRG4 expression constructs. One or both of the endonucleases Ncol and Xhol was used, which 
were the endonucleases used to insert the PRG4 PCR product into the pMT expression vector 
(3.6 kb). Linearised vector can be seen after digestion with Xhol. Excised PRG4 domains (562bp 
for N-terminal domain, 815bp for C-terminal domain) can be seen after digestion with Xhol and 
Ncol. Migration of size standards is shown to the left.
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3.3.4 Generation o f stable, PRG4 domain-expressing S2 cell lines
To facilitate the large-scale production o f recombinant proteins from stable S2 cell lines. 
Drosophila S2 cells were transfected with PRG4 domain expression constructs as listed in table 
3.12 along with the selection vector pCoHYGRO (see appendix A). Following the seeding of 
transfected cells into selection medium containing hygromycin B, resistant cells started to grow 
out after 2-3 weeks. Selection was monitored by culturing untransfected S2 cells in selection 
medium and monitoring cell death visually and by trypan blue assay. Stocks o f stable cell lines 
were prepared for long-term storage before expansion into serum free medium for analysis o f 
recombinant protein expression. Hygromycin-resistant cell lines were seeded into serum free 
medium at a density o f 8  x 106 cells/ml and induced with 500pM  CuSC>4 , and conditioned 
medium was harvested after 5 days.
Figure 3.6 shows a silver stain and a Western blot o f conditioned medium (30pl) probed with 
anti-FLAG M2 mAb after separation under native (3.6A) and reduced (3.6B) conditions. 
Production o f FLAG-tagged recombinant PRG4 domains was seen in 3 cell lines: S2-HN (human 
N-terminal PRG4, exons 2-5), S2-BN (bovine N-terminal PRG4, exons 2-5) and S2-BC (bovine 
C-terminal PRG4, exons 7-12). A stable S2-HC line was generated (human C-terminal PRG4, 
exons 7-12), but under the conditions used did not appear to express any detectable recombinant 
human C-terminal PRG4 protein. An S2 cell line transfected with only the selection vector 
pCoHYGRO was generated as a negative control and did not secrete any FLAG-tagged protein 
(data not shown). Table 3.14 details the nomenclature of all S2 cell lines generated by this study 
and their expressed proteins.
Table 3.14 -  Nomenclature of PRG4 domain-expression stable Drosophila S2 cell lines
Cell line Expression construct PRG4 domain Expressed protein
S2-BN pMT-BN Bovine N-terminal (exons 2-5) BovN-PRG4
S2-HN pMT-HN Human N-terminal (exons 2-5) HumN-PRG4
S2-BC pMT-BC Bovine C-terminal (exons 7-12) BovC-PRG4
S2-HC pMT-HC Human C-terminal (exons 7-12) -
S2-Hyg - - -
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Figure 3.6 -  W estern blot and silver stain analysis of serum free conditioned media 
(30ixl) from the S2-HN, S2-BN and S2-BC cell lines. Cell lines were seeded into serum 
free conditioned medium at a density o f  6  x 106 cells/ml and induced for 72 hours in the 
presence of 500pM CuSC>4. Proteins were separated under native (A) and reducing (B) 
conditions. The Western blot was probed with anti FLAG M2 mAb. Migration o f size 
standards is shown to the left. The arrows to the right indicate the migration positions of 
recombinant PRG4 proteins.
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3.3.5 Production o f recombinant N-terminal PRG4 by the S2-HN and S2-BN cell lines 
The S2-HN and S2-BN cell lines were established in order to express recombinant N-terminal 
(exons 2-5) region of human and bovine PRG4, respectively. As seen in figure 3.6A, under native 
conditions the FLAG proteins appeared as high MW aggregates, and FLAG staining is 
considerably weaker than under reducing conditions (3.6B), making their molecular weights 
more difficult to determine. As seen in figure 3.6B, SDS-PAGE under reducing conditions and 
Western blotting enabled the visualisation o f two FLAG-positive proteins with molecular weights 
of 27 and 16 kDa in the conditioned medium of the S2-HN and S2-BN cell lines after induction 
with 500pM CuSC>4. Both the S2-BN and the S2-HN cell lines appeared to express more o f the 
27 kDa species, based on the strength o f FLAG-immunopositive staining. The predicted 
molecular weights of HumN and BovN were calculated using a web-based protein sequence 
analysis program (Stothard, 2000), and were found to be 20.92 kDa and 20.5 kDa, respectively. 
These are based on sequences o f 187 (HumN) and 185 (BovN) amino acids including the 8  
residue FLAG tag and the 4 residues (RSPW) of the expression vector polylinker region that is 
between the vector BiP signal sequence and the inserted PCR product. However, the cell lines 
S2-BN and S2-HN each appeared to secrete two FLAG-immunopositive proteins that migrated 
with apparent molecular weights o f 27 and 16 kDa under reducing conditions (figure 3.6B). This 
discrepancy in predicted and apparent molecular weight(s) of recombinant proteins may be due to 
post-translational modifications, degradation within the culture system or anomalous migration in 
SDS-PAGE. The observation that both human and bovine recombinant proteins run at similar 
molecular weights would indicate that post-translational modifications for recombinant human 
and bovine N-terminal (exons 2-5) PRG4 are similar in this expression system. Discrepancies 
between the predicted and apparent molecular weights of recombinant PRG4 N-terminal proteins 
and the presence o f two protein species is observed elsewhere. The CHO-MegN141 cell line 
(Wyeth) was generated to express human PRG4 from the initial *Gln residue to 141 Asn, a 117- 
residue protein with a predicted molecular weight of 12.96 kDa (Stothard, 2000). In figure 3.7, a 
Western blot o f concentrated conditioned medium from this cell line (under reducing conditions) 
was probed with a polyclonal antibody raised to a peptide from exon 3 of human PRG4, and the 
antibody detected two protein species of ~21 and 18 kDa.
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Figure 3.7 -  W estern blot analysis of concentrated conditioned medium from  the C H O - 
MegN141 cell line (W yeth). This cell line secretes human PRG4 N-terminal domain G in 1 to 
Asn141). 30ml o f conditioned medium was concentrated to 6 6 pl, a concentration factor o f 454. 
20^il o f the concentrated medium was run on a 15% (w/v) SDS-PAGE gel under reducing 
conditions, and a Western blot was probed with a polyclonal antibody to exon 3 o f human PRG4. 
This Western blot illustrates the atypical migration of N-terminal recombinant PRG4 molecule. 
Migration of molecular size standards is shown to the right.
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3.3.6 Production o f recombinant C-terminal PRG4 by the S2-BC cell line
Figure 3.6 also shows a 30pl aliquot o f conditioned medium from the cell line S2-BC after 
separation by SDS-PAGE and detection by silver stain and Western blotting with anti-FLAG M2 
antibody. The S2-BC cell line was expected to secrete recombinant bovine C-terminal PRG4 
from the start o f exon 7 to the end of exon 12 (BovC). The predicted molecular weight o f the 
entire BovC protein is 31.77 kDa (277 amino acid residues, including FLAG and 4 residues of 
vector polylinker) (Stothard, 2000). Under non-reducing conditions (figure 3.6A), a FLAG- 
immunopositive protein species o f ~30kDa is apparent. However, under reducing conditions 
(figure 3.6B) it was apparent that two recom binant proteins are produced, the FLAG- 
immunopositive BovCl (20 kDa) and the FLAG-immunonegative species BovC2 (12 kDa). If 
both proteins represent the C-terminal of PRG4 it suggests that a splice mechanism or proteolysis 
is causing BovC to be visible as two separate molecules under reducing conditions. BovC 1 and 
BovC2 appeared to be associating under native conditions resulting in the appearance of a 
FLAG-immunopositive protein species o f -3 0  kDa, the approximate sum o f the apparent 
molecular weights of BovC 1 (20 kDa) and BovC2 (12 kDa).
3.3.7 Effect o f  CUSO4 concentration on the secretion o f recombinant proteins
To assess the levels o f protein secretion over time, and the effect o f differing concentrations of 
the inducing agent CuSC>4 on the levels of protein secretion, cell lines were seeded into serum 
free medium at a density o f 6  x 1 0 6 cells/ml and induced with CuSCU concentrations in the range 
of O-lOOOpM. Aliquots o f conditioned media (30pl) were removed at 24, 48 and 72 hour 
intervals. Proteins were visualised by means o f SDS-PAGE under reducing conditions using 15% 
gels (30pl media/lane) and Western blotting with anti-FLAG M2 monoclonal antibody, and in 
the case of the S2-BC cell line, silver staining. The effect of increasing CuSCL concentrations on 
the production of FLAG-tagged protein by the three S2 cell lines is seen in figures 3.8 (S2-HN 
line), 3.9 (S2-BN line), and 3.10 (S2-BC line). These results show that optimal secretion of 
recombinant proteins occurred with a CUSO4 concentration o f between 500-1000p,M, based on 
intensity of staining. Levels of protein increased significantly over a 72 hour culture period. Both 
species of BovC protein were apparent (figure 3.10), and increased with equal intensity o f 
staining in the 72 hour culture period. However, only the 27 kDa species was detected in the 
culture medium of the S2-HN and S2-BN cell lines (figures 3.8 and 3.9).
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Figure 3.8 -  W estern blot analysis of recom binant human N -term inal (exons 2-5) PRG4 
domain expressed by the stable Drosophila S2 cell line S2-HN. Stably transfected cells were 
seeded at a density o f 6  x 1 0 6 cells/ml and treated with different concentrations of inducing agent 
(CUSO4). Recombinant protein levels in 30pl of conditioned media was analysed over a 72 hour 
period by SDS-PAGE (reducing conditions) and Western blot probed with an anti-FLAG M2 
antibody. Migration of standards is shown to the right.
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Figure 3.9 -  W estern blot analysis of recom binant bovine N -term inal (exons 2-5) PRG4 
domain expressed by the stable Drosophila S2 cell line S2-BN. Stably transfected cells were 
seeded at a density of 6  x 1 0 6 cells/ml and treated with different concentrations of inducing agent 
(CUSO4). Recombinant protein levels in 30pl of conditioned media was analysed over a 72 hour 
period by SDS-PAGE (reducing conditions) and Western blot probed with an anti-FLAG M2 
antibody. Migration of standards is shown to the right.
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Figure 3.10 -  Analysis of recom binant bovine C -term inal (exons 7-12) PRG4 dom ain 
expressed by the stable Drosophila S2 cell line S2-BC. Stably transfectd cells were seeded at a 
density o f 6 x 106 cells/ml and treated with different concentrations o f inducing agent (CUSO4). 
Recombinant protein levels in 30pl o f conditioned media was analysed over a 72 hour period by 
SDS-PAGE (reducing conditions) and silver staining (30pl medium/lane). Migration o f standards 
is shown to the right.
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This may be due to the initial cell density being lower than for the blot shown in figure 3.6B, in 
which both the 27 and 16 kDa species were detected. Conditioned medium was also harvested 
sooner (72 hours) than for the conditioned media used in figure 3.6 (5 days), which could further 
account for the non-appearance of the 16 kDa species. It is suggested that the 16 kDa protein is a 
minor degradation production of the FLAG-tagged protein secreted by the S2-HN and S2-BN 
cell lines.
3.3.8 RT-PCR analyses o f PRG4 domain-expressing S2 cell lines
The observed molecular weights o f the recombinant PRG4 domains differed greatly from their 
predicted molecular weights. To investigate whether or not the PRG4-expressing stable S2 cell 
lines were expressing mRNA of the predicted size, RT-PCR analyses were performed. Total 
RNA was extracted from S2-HN and S2-BC cell lines, and RT-PCR experiments were conducted 
(figure 3.11) with the primers N1/N2 (figure 3.11, lanes 1 and 3) for the S2-HN cell line and 
BC1/BC2. (lanes 2 and 4) for the S2-BC cell line. PCR experiments using the expression 
constructs pMT-HN and pMT-BC as templates were used as positive controls (lanes 3 & 4). It is 
evident that RT-PCR with the S2-HN cell line and N1/N2 primers generates a product o f the 
expected size of 525bp (figure 3.11, lane 1), as seen with the positive control (lane 3). This 
product was subsequently sequenced and subjected to a BLAST search, and was found to encode 
the N-terminal (exons 2-5) o f human PRG4. RT-PCR experiments with the S2-BC cell line and 
BC1/BC2 primers generates a product o f ~825bp (figure 3.11, lane 2), similar to the positive 
control. This product was sequenced and subjected to a BLAST search, whereupon it was found 
to encode bovine C-terminal PRG4, exons 7-12. It is worth noting that as these were not 
quantitative experiments, as GAPDH controls were not included. Also, these experiments do not 
provide any data that would detect the expression o f splice variants in the stable cell lines, which 
could also explain the secretion o f two proteins by each cell line where only one is expected. 
Splicing of the transfected PRG4 domain-expressing segment could be investigated by designing 
a series of primer pairs spanning each region.
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Figure 3.11 -  RT-PCR analyses of RNA from  stable Drosophila S2 cell lines expressing 
recombinant hum an N -term inal PRG4 (lane 1) and bovine C -term inal PRG4 (lane 2). For
positive controls, PCRs were performed using pMT expression constructs as templates (lanes 3 
and 4). The primer pairs used were N1/N2 (lanes 1 and 3) and BC1/BC2 (lanes 2 and 4). 
Migration o f size standards is shown on the left.
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3.3.9 Purification o f  recombinant bovine and human N-terminal and bovine C-terminal 
PRG4 by FLAG M2 immunoaffinity chromatography
The recombinant PRG4 proteins (HumN, BovN and BovC) produced in the S2 expression system 
all have an N-terminal FLAG epitope (DYKDDDDK). As demonstrated in the expression 
experiments, the FLAG epitope o f these recombinant proteins can be detected on a Western blot 
by a commercial anti-FLAG M2 monoclonal antibody (Sigma), and this interaction was utilised 
to purify recombinant proteins from the conditioned media o f induced cell lines using anti-FLAG 
M2 mAb covalently linked to an agarose support (Sigma), a technique first described by Brizzard 
et al. (1994). Yields o f recombinant proteins were in the region o f 2-5 mg/L for each o f the S2 
cell lines.
3.3.9.1 Purification o f  N-terminal PRG4 by FLAG immunoaffinity chromatography
Figure 3.12 shows the results o f passing 40ml o f conditioned serum free media from induced S2- 
BN cells over a FLAG-M2 agarose column and eluting bound protein under acidic conditions. 
Two BovN protein species o f 27 and 16 kDa (BovNl and BovN2) were purified to homogeneity 
as seen by silver staining (figure 3.12, eluent fractions 3-6). Both species were detected on a 
Western blot probed with anti-FLAG M2 mAb (figure 3.12, Western blot). Table 3.14 describes 
the protein concentrations of each eluent fraction and the amount loaded on to the gel. A similar 
result to the purification of bovine N-terminal PRG4 was obtained for the purification o f human 
N-terminal PRG4 from the conditioned medium of the S2-HN cell line (data not shown).
3.3.9.2 Purification o f  C-terminal PRG4 by FLAG immunoaffinity chromatography
FLAG M2 immunoaffinity chromatography was also used to purify recombinant bovine C- 
terminal PRG4 (BovC) from the conditioned medium of the S2-BC cell line (figure 3.13). Two 
BovC protein species were purified with apparent molecular weights o f ~20 and 12 kDa, 
visualised using silver staining after separation by SDS-PAGE under reducing conditions (figure 
3.13, eluents 3-6). Table 3.15 describes the protein concentrations o f each eluent fraction and the 
amount loaded on to the gel. Immunoblotting with FLAG M2 shows that only the 20 kDa species 
contains a FLAG epitope, and both the 20 kDa species and the FLAG-immunonegative 12 kDa 
species are purified by this process, which suggests that association between the two species may 
be occurring under non-reducing conditions.
1 2 2
50kDa 
37kDa —
25kDa — 
20kDa —
15kDa —
elution fractions
2 3 4 5 6
Western blot
(F A G M2)
1 3 4 5 10
Figure 3.12 -  FLAG M2 im m unoaffin ity  ch ro m ato g rap h y  purification  of recom binan t 
bovine N -term inal PRG4 dom ain (exons 2-5) from  the conditioned m edium  of S2-BN cells.
Conditioned medium from the Drosophila S2-BN cell line (40ml) was passed over a 1ml bed 
volume o f anti-FLAG M2 agarose, and bound protein was eluted with 6 x 1ml aliquots o f 
glycine-HCl, pH 3.5. Fractions were separated by SDS-PAGE under reducing conditions 
(30pl/lane) and visualised by silver staining (lanes 1-9). A Western blot o f elution fraction 4 
using anti-FLAG M2 mAb is shown to the right (lane 10), and migration o f molecular size 
standards is shown to the left.
Table 3.15 -  Calculation of the concentration o f BovN FLAG column eluent fractions and 
protein loaded in figure 3.12, as assessed by absorbancy measured
Eluent C oncentration (m g/m l, A280) Am ount loaded (pg)
1 0.002 0.06
2 0.011 0.33
3 0.075 2.25
4 0.372 11.16
5 0.148 4.44
6 0.034 1.02
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Figure 3.13 -  FLAG M2 im m unoaffin ity  chrom atography  purification  of recom binan t 
bovine C -term inal PRG4 dom ain (exons 7-12) from  the conditioned m edium  of S2-BC cells.
Conditioned medium from the Drosophila S2-BC cell line (40ml) was passed over a 1ml bed 
volume o f  anti-FLAG M2 agarose, and bound protein was eluted with 6 x 1ml aliquots o f  
glycine-HCl, pH 3.5. Fractions were separated by SDS-PAGE under reducing conditions 
(30pl/lane) and visualised by silver staining (lanes 1-9). A Western blot o f  elution fraction 4 
using anti-FLAG M2 mAb is shown to the right (lane 10), and migration o f  molecular size 
standards is shown to the left.
Table 3.16 -  Calculation o f the concentration o f  BovC FLAG column eluent fractions and 
protein loaded in figure 3.12, as assessed by absorbancy
Eluent Concentration (m g/m l, A280) Amount loaded (i*g)
1 0 0
2 0.004 0.12
3 0.017 0.51
4 0.015 0.45
5 0.019 0.57
6 0.016 0.48
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This is supported by the observation that when separated by SDS-PAGE, the BovC protein runs 
as a single band under non-reducing conditions (figure 3.6A) and 2 proteins under reducing 
conditions (figure 3.6B).
3.4 Discussion
In its alternate guises as cartilage superficial zone proteoglycan, lubricin, megakaryocyte 
stimulating factor and CACP protein, PRG4 has been studied using a num ber o f different 
experimental approaches. These include the study of its homologies to other proteins (Merberg et 
a l 1993; Ikegawa et al., 2000; Flannery et al. , 1999), its ability to lubricate (Swann et al., 1985; 
Jay et al., 2001a), its expression in a number o f healthy and diseased tissues including cartilage 
and tendon (Ikegawa et al., 2000; Tudor, 2002; Rees et al., 2002) and its alteration during 
inherited CACP syndrome (Marcelino et al., 1999). However, to date there have been no 
investigations into the predicted functions o f the N- and C-terminal domains o f  the molecule. 
PRG4 is made up of 12 exons, where exons 2-5 and 7-12 flank a central mucin domain, exon 6. 
The aim of this work was to produce recombinant PRG4 non-mucin domains and use them to 
investigate the functions o f individual domains o f PRG4 by using binding assays directed 
towards ECM molecules, and by conducting cell biology experiments. A recent example o f the 
strategy o f utilising a recombinant segment o f an extracellular matrix protein in functional 
analyses is the N-terminal heparin-binding domain o f thrombospondin-1, which was found to 
constitute an adhesive support for human umbilical vein endothelial cells (HUVECs), possibly 
mediated by syndecan-4 (Outeiro-Bemstein et al., 2002). This chapter describes the successful 
production o f stable Drosophila S2 cell lines that secrete human and bovine N-terminal (HumN 
& BovN) and bovine C-terminal (BovC) PRG4 domains as N-terminal FLAG fusion proteins (S2 
cells also were transfected with an expression construct to produce the human recombinant C- 
terminal domain o f PRG4, although no protein was detected in the conditioned medium of 
induced cells. The reason for the absence o f recombinant protein secretion is unclear. Production 
and secretion was induced with CuSC>4, which stimulates expression o f recombinant proteins 
from the metallothionein promoter region in the expression construct. The presence o f an 8 
amino acid FLAG tag (DYKDDDDK) at the N-terminus of these recombinant PRG4 proteins 
greatly facilitated their purification from crude insect cell culture medium. A wide variety o f 
affinity tags are available to facilitate the detection and purification o f recombinant proteins,
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reviewed in (Terpe, 2003), but the FLAG-tag was used in this instance. The FLAG epitope o f the 
tagged proteins was used for immunoaffinity purification using a commercially available anti- 
FLAG monoclonal antibody (M2) covalently attached to an agarose chromatography matrix. In 
addition, an anti-FLAG antibody conjugated to alkaline phosphatase has been used to 
immunolocate recombinant proteins in Western blotting experiments.
With each stable cell line, two recombinant proteins were identified by SDS-PAGE under 
reducing conditions and were subsequently purified by FLAG immunoaffinity chromatography, 
not the expected single protein. The presence o f two proteins may be due to splice variants or 
partial degradation within the expression system. Degradation during purification may be a 
factor, but two species are usually apparent in freshly isolated conditioned media (figure 3.6). For 
the PRG4 N-terminal domain-expressing lines S2-HN and S2-BN, ‘N T  and *N2* FLAG- 
immunopositive proteins were purified, running on SDS-PAGE gels under reducing conditions at 
27 and 16 kDa respectively. For the bovine PRG4 C-terminal domain-expressing cell line, S2- 
BC, two proteins BovCl and BovC2 were purified by FLAG affinity chromatography that ran on 
reduced SDS-PAGE gels at 20 and 12 kDa, respectively. Only BovCl is FLAG-immunopositive, 
which would indicate that there is association between the 2 species under non-reducing 
conditions in order for them to be co-purified by FLAG chromatography. This is supported by the 
observation that under non-reducing conditions, BovC is apparent as a single, FLAG-positive 
band o f around 32 kDa.
Recombinant protein expression in a Drosophila S2 cell system has a number o f advantages, and 
a variety o f proteins have been expressed using Drosophila S2 cells including recom binant 
secreted, membrane and cytosolic proteins (Benting et al., 2000), erythropoietin (Lee et al., 
2000), hepatitis B virus surface antigen (Demi et al., 1999) and human glucagon receptor (Tota et 
al., 1995). Cells are easily maintained at room temperature, do not require CO2 , have a doubling 
time of around 24 hours and do not require trypsinisation during passaging as they are loosely 
adherent and may grow in suspension. When grown in suspension to a high density, cell numbers 
can reach 30 x 107 cells/ml, which is 10-fold higher than other insect cell lines such as S/9 (Perret 
et al., 2003), and there is growing interest in using insect cell culture for the industrial production 
of recombinant proteins (Ikonomou et al., 2003). Cells can be maintained in the presence o f the
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inducing agent C uS 04 for up to 4 months (Johansen et al., 1989). Insect cells perform 
comparable post-and co-translational modifications compared to mammalian cells except for N- 
glycosylation: Drosophila N-linked glycosylation is less complex in that it is not trimmed and 
sialylated (Jarvis & Finn, 1995). Post-translational modifications o f recombinant proteins, 
including glycosylation, may affect functionality. In some cases, the utilisation o f commonly- 
used mammalian cell lines for recombinant protein expression, such as the CHO (Chinese 
hamster ovary, Cricetulus griseus) or COS (African green monkey kidney, C ercopithecus  
aethiops) lines, may be more appropriate for functional assays o f mammalian recombinant 
proteins. The characterisation of the purified recombinant proteins described in this chapter is 
further described in chapter 4, and their utilisation in proteinase digestion experiments and 
functional analyses is described in chapters 5 and 6, respectively.
3.5 Chapter Summary
• The N-terminal (exons 2-5) and C-terminal (exons 7-12) cDNAs o f human and bovine 
PRG4 were successfully amplified by PCR and ligated into a TA cloning vector. cDNAs 
were sequenced and a number of sequences were deposited in Genbank.
• Expression constructs were manufactured in order to produce human and bovine N- and 
C-terminal PRG4 domains in Drosophila  S2 cells as fusion proteins containing an N- 
terminal FLAG purification/detection epitope.
• Stable cell lines were generated for the expression of human and bovine N-terminal PRG4 
(termed HumN and BovN) and bovine C-terminal PRG4 (BovC)
• Recom binant proteins were purified to homogeneity by FLAG im m unoaffinity 
chromatography. Their predicted molecular weights, apparent molecular weights and 
FLAG immunoreactivity are listed in table 3.17.
Table 3.17 -  Recombinant PRG4 domains produced by this study
Cell line Species Exons Predicted
molecular
weight
Apparent molecular 
weights (reduced, 15% 
SDS-PAGE)
N-terminal FLAG 
epitope (assessed by 
Western blot)
S2-HN Human 2-5 20.9 kDa 27 kDa +
16 kDa +
S2-BN Bovine 2-5 20.5 kDa 27 kDa +
16 kDa +
S2-BC Bovine 7-12 31.7 kDa 20 kDa +
12 kDa -
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4. CHARACTERISATION OF RECOMBINANT PRG4 DOMAINS
4.1 Introduction
Chapter 3 describes the cloning, production and purification o f recombinant PRG4 domains. 
However, these proteins did not correspond to their predicted molecular weights, and two 
recombinant protein species were secreted by each stable Drosophila S2 cell line, rather than a 
single species. Before embarking on further studies with these proteins, such as their ability to 
interact with other matrix molecules in binding assays and their activity in cell biology systems 
(chapter 6), it was important to further characterise these recombinant proteins. This was 
achieved using several approaches: (i) by studying the interactions o f recom binant PRG4 
domains with a panel o f antibodies raised against PRG4; (ii) N-terminal amino acid sequencing; 
(iii) study o f the heparin-binding capability o f the molecules; and (iv) by studying post- 
translational modifications by means o f lectin affinity blotting and enzymatic deglycosylation.
4.2 Materials and Methods
4.2.1 Materials
All chemicals were o f an analytical grade and were purchased from Sigma-Aldrich unless 
otherwise indicated. A detailed list o f the materials used in this research project and their 
suppliers is listed in Appendix A. Sequencing-grade PVDF transfer membrane was purchased 
from Millipore. The enzymatic deglycosylation (EDEGLY) kit was purchased from Sigma. 
Recombinant enterokinase was from Calbiochem. Other materials are listed earlier in this thesis, 
and section references are provided in the relevant methods sections within this chapter.
4.2.2 Purification o f  recombinant PRG4 domains by heparin-agarose a ffin ity  
chromatography
The recombinant PRG4 domains purified by FLAG immunoaffinity chromatography (chapter 3, 
section 3.3.8) were subjected to heparin-agarose affinity chromatography as described in chapter 
2, section 2.2.5. In addition, heparin-binding proteins were also concentrated from the 
conditioned media of the stable cell lines S2-HN, S2-BN and S2-BC by heparin-agarose affinity 
chromatography. Fractions were separated by SDS-PAGE under reducing conditions (chapter 2,
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section 2.2.9) using 15% slab gels and proteins were visualised by silver staining for total protein 
(chapter 2, section 2.2.12) and Western blot probed with an anti-FLAG M2 AP-conjugate mAb 
(chapter 3, section 3.2.8.3) to detect recombinant FLAG-tagged PRG4 domains.
4.2.3 Protein sequencing
Proteins were concentrated from the conditioned media o f stable Drosophila S2 cell lines S2-HN, 
S2-BN and S2-BC (described in chapter 3) by heparin affinity chromatography as described in 
chapter 2, section 2.2.5. Fractions were separated by SDS-PAGE under reducing conditions using 
15% slab gels, and proteins were then transferred to sequencing-grade polyvinylidene fluoride 
(PVDF) transfer membrane (Immobilon-PSQ, Millipore) as described in chapter 2, section 2.2.9. 
Before use, the PVDF membrane was soaked in methanol for 1-3 seconds, immersed in water for 
2 minutes and equilibrated in transfer buffer (chapter 2, table 2.1) for 3 minutes. Membranes 
were stained for total protein with Coomassie Blue R250 (lg /L  in 50% [v/v] methanol, 40% [v/v] 
water and 10% [v/v] acetic acid). Membranes were washed 3 times in water before the addition 
of Coomassie solution for 1 minute with gentle agitation. Membranes were de-stained with a 
50% [v/v] methanol solution followed by 10% [v/v] methanol solution followed by water. The 
membranes were dried, scanned and sent to an off-campus protein sequencing facility (Dr. W.J. 
Manby, Department o f Biochemistry, Bristol University), with instructions on a duplicate 
printout of the scanned membrane highlighting the bands to be sequenced.
4.2.4 Western blot analysis o f  recombinant PRG4 domains
Purified PRG4 domains were subjected to SDS-PAGE using 15% [w/v] slab gels (5pg/lane), 
under reduced and non-reduced conditions (section 2.2.9). Protein concentrations were calculated 
by taking absorbance readings at 280nm in an Ultrospec 2000 spectrophotometer (Pharmacia). 
Proteins were transferred to nitrocellulose as described in chapter 2, section 2.2.9 before Western 
blotting with a panel o f PRG4-specific antibodies (chapter 2, table 2.4) as well as an anti-FLAG 
M2 monoclonal antibody (chapter 3, section 3.2.8.3).
4.2.5 Identification o f the carbohydrate side chains o f recombinant PRG4 domains 
Characterisation o f the carbohydrate moieties o f recombinant PRG4 domains was performed 
using lectin affinity blotting. PRG4 dom ains purified by FLAG M2 im m unoaffinity
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chromatography and heparin-agarose affinity chromatography were run on 15% SDS-PAGE gels 
at 5pg/lane under reducing conditions followed by transfer to nitrocellulose. Lectin affinity 
blotting was performed using the DIG Glycan Detection system (Roche), previously used to 
characterise the carbohydrate moieties o f full-length PRG4 from a number o f sources in chapter 2 
of this study. Kit components and methods are listed in chapter 2, section 2.2.10.
4.2.6 Deglycosylation o f  recombinant PRG4 domains
Deglycosylation o f  recom binant proteins was perform ed using the EDEGLY protein 
deglycosylation kit from Sigma-Aldrich. The enzymes contained in this kit and their specificities, 
sources and molecular weights are listed in table 4.1.
Table 4.1 -  Specificity o f enzymes contained within the EDEGLY kit
Enzyme Source M W Specificity
PNGase F from Chryseobacterium  
meningosepticum
36 kDa Asparagine-linked complex, hybrid or 
high mannose oligosaccarides unless 
a ( l-3 )  core fucosylated
a-2(3,6,8,9) Neuraminidase recombinant from 
Arthrobacter ureafaciens
60 kDa and 
69 kDa
All non-reducing terminal branched 
and unbranched sialic acids.
O-Glycosidase recombinant from 
Streptococcus pneum onia
180 kDa Serine or threonine-linked 
unsubstituted Gal-P( 1 -3)-G alN A c-a-
P( 1 -4)-Galactosidase recombinant from 
Streptococcus pneum onia
350 kDa Releases only P(l-4)-linked, non­
reducing terminal galactose
{1-N-Acetylglucosaminidase recombinant from 
Streptococcus pneum onia
140 kDa All non-reducing terminal p-linked N- 
acetylglucosamine residues
Three reactions were performed for each of the recombinant proteins comprising of (a) PNGase F 
alone, (b) a combination of O-glycosidase, a-2(3,6,8,9) Neuraminidase, |3(l-4)-Galactosidase and 
|3-N-Acetylglucosaminidase and (c) a negative control. For each reaction 20pg o f FLAG-purified 
recombinant PRG4 domain was lyophilised and resuspended in 30pl H2O before the addition of 
the supplied 5X reaction buffer (10pl) and denaturation solution (2.5pl). The mixture was heated 
at 100°C for 5 minutes and allowed to cool to room temperature before addition o f Triton X-100 
(2.5pl) and lp.1 each o f the relevant enzymes. Reactions were made up to 50pl with MilliQ H2O 
and incubated at 37°C for 3 hours before the addition of 40pl 2X SDS-PAGE sample buffer and 
lOpl p-mercaptoethanol. Reactions were separated on two SDS-PAGE gels (lOpg protein per 
gel) and visualised by silver stain (section 2.2.12) and Western blot with FLAG M2 monoclonal 
antibody (section 3.2.8.3).
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4.3 Results
4.3.1 Characterisation o f  the heparin-binding properties o f  recombinant PRG 4  domains by 
heparin-agarose affinity chromatography
Heparin-binding site sequences are found in a number o f  matrix proteins, and are characterised 
by an overall positive charge. The consensus sequences BBAB, XBBXBX  and XBBBXXBX  
(where B designates a basic amino acid and X  designates any other residues) have been  
identified, and are known as ‘Cardin-Weintraub’ sequences (Cardin & Weintraub, 1989). In 
exons 4 and 10 o f  human PRG4 there are two sequences that match the eight-residue consensus 
sequence as illustrated in figure 4.1. It has already been demonstrated in Chapter 2 o f  this study 
that full-length human recombinant PRG4, bovine tendon PRG4 and bovine articular cartilage 
PRG4 bind to heparin as assessed by heparin-agarose affinity chromatography, so the potential 
heparin-binding activity o f  recombinani N-terminal and C-terminal PRG4 domains was 
investigated on the basis that both the N-terminal (exons 2-5) and C-terminal (exons 7-12) 
domains o f  PRG4 contain a heparin-binding consensus sequence (figure 4.1).
Cardin-Weintraub heparin-binding XBBBXXBX
consensus sequences: XBBXBX
Human ,34KRSPKPPNKKKTKKV 
PRG4 exon 4; Bovine ,34KRSPKSPNKKKTKKV
Human 1298QVRRRRFERAIG 
PRG4 exon 10: Bovine 1298QVRRRRFERAIG
Figure 4.1 -  Predicted heparin-binding consensus sequences in PRG4. For the consensus 
sequence, B represents a basic amino acid and X denotes any amino acid (Cardin & Weintraub, 
1989). Basic amino acid residues relevant to the heparin-binding consensus sequence are 
highlighted in red.
4.3.1.1 Characterisation o f  the heparin-binding properties o f  human recombinant PRG4 N- 
terminal domain (HumN) by heparin-agarose affinity chromatography
Heparin-agarose affinity chromatography was performed using human N-terminal PRG4 
(HumN) purified by FLAG M2 immunoaffinity chromatography as starting material (5ml o f  
~0.2mg/ml in heparin-agarose equilibration buffer). As previously described in chapter 3, FLAG
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M2 immunoaffinity chromatography yields two FLAG M2-immunopositive molecular species of 
27 and 16 kDa, HumNl and HumN2. These two bands can be seen in lane 1 o f figure 4.2, which 
shows the separation of HumN after heparin-agarose affinity chromatography by SDS-PAGE, 
visualised by Western blot probed with anti-FLAG M2 mAb (figure 4.2A) and silver stain for 
total protein (figure 4.2B). This data clearly shows the binding o f the 27 kDa form o f HumN 
PRG4 to heparin, with the 16 kDa isoform remaining in the flowthrough fraction o f the column 
(figure 4.2, lane 2). The 27 kDa HumN isoform was eluted from the heparin-agarose column at a 
salt concentration o f 0.4-0.6M (figure 4.2, lanes 6 & 7). This data suggests that HumNl contains 
an active heparin-binding site, likely to be the putative heparin-binding site within exon 4 
illustrated in figure 4.1, and that HumN2 is likely to represent a C-terminally truncated form of 
HumN that does not contain the heparin-binding consensus sequence in exon 4.This prediction of 
C-terminal truncation in HumN2 is supported by the observation that it is immunopositive for the 
anti-FLAG M2 antibody: it contains the N-terminal FLAG purification/detection epitope. These 
results therefore demonstrate that heparin-agarose affinity chromatography can separate the two 
recombinant HumN PRG4 species.
Similar data was obtained when FLAG-purified recombinant bovine N-terminal PRG4 (BovN) 
was applied to a heparin-agarose affinity chromatography column. BovNl (27 kDa) was seen to 
bind to heparin-agarose and was eluted with a salt concentration o f 0.4-0.6M NaCl, whilst 
BovN2 did not bind to heparin-agarose and was apparent in the flowthrough fraction (data not 
shown).
4.3.1.2 Characterisation o f the heparin-binding properties o f bovine recombinant PRG4 N- 
terminal domain (BovN) species by heparin-agarose affinity chromatography 
The heparin-binding activity of bovine recombinant N-terminal PRG4 domain (BovN) was 
investigated by applying the conditioned media o f induced S2-BN cells (chapter 3, section 3.3.4) 
to a heparin-agarose affinity chromatography column. Conditioned media from the S2-Hyg cell 
line (transfected with only the pCoHYGRO selection vector) was also passed over a heparin- 
agarose affinity column as a negative control, and fractions from these purifications can be seen 
in figure 4.3 as analysed by Western blot probed with anti-FLAG M2 mAb.
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Figure 4.2 -  H eparin-agarose affinity chrom atography  of purified recom binant hum an N- 
terminal PRG4 (exons 2-5). FLAG-purified recombinant protein was applied to a 1ml heparin- 
agarose column and bound protein was eluted with a stepwise gradient o f NaCl in 1ml fractions. 
Fractions were separated by SDS-PAGE (30pl/lane, reducing conditions) and visualised by (A) 
Western blot probed with anti-FLAG M2 mAb and (B) silver stain showing total protein. 
Migration of molecular weight standards (kDa) is shown to the left.
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Figure 4.3 -  H eparin-agarose affinity chrom atography purification of recom binant bovine 
N-terminal PRG4 (exons 2-5). Conditioned medium (15ml) from the S2-BN (A) and S2-Hyg 
(B) lines was applied to a 1ml heparin-agarose column and bound protein was eluted sequentially 
with increasing concentrations o f NaCl in 1ml fractions. Fractions were separated by SDS-PAGE  
(30pl/lane, reducing conditions) and visualised by Western blot probed with anti-FLAG M2 
mAb. The S2-Hyg cell line was transfected with the selection vector pCoHYGRO only. 
Migration o f molecular weight standards (kDa) is shown to the left.
134
The 27 kDa BovN species (B ovN l) bound to heparin-agarose and was eluted with 0.4-0.6M 
NaCl (figure 4.3A, lanes 5 & 6). Therefore this data shows that BovN and HumN (figure 4.2) 
bind heparin with a similar affinity. As stated previously, the 16 kDa BovN species does not bind 
to heparin (data not shown), similar to the 16 kDa HumN species (figure 4.2), but it should be 
pointed out that in this instance the 16 kDa BovN species is not visible in conditioned media or 
the flowthrough fraction (figure 4.3, lanes 1 & 2). The likely reason for this is that the S2-BN and 
S2-HN cell lines tended to secrete more detectable 27 kDa FLAG fusion protein compared to 16 
kDa FLAG protein, as discussed in chapter 3. As expected, the conditioned medium o f the S2- 
Hyg cell line does not contain any FLAG-tagged protein (figure 4.3B, lane 1), and no FLAG- 
tagged proteins are purified by heparin-agarose affinity chromatography (figure 4.3B, lanes 3-8).
4.S.1.3 Characterisation o f  the heparin-binding properties o f  bovine recombinant PRG4 C- 
terminal domain (BovC) by heparin-agarose affinity chromatography
Heparin-agarose affinity chromatography was also perform ed using recom binant bovine C- 
terminal (exons 7-12) PRG4 (BovC) initially purified from the conditioned medium o f the S2-BC 
cell line by FLAG immunoaffinity chromatography. Under reducing conditions 2 protein species 
o f-20 kDa (B ovC l) and 12 kDa (BovC2) were apparent using SDS-PAGE (chapter 3, figure 
3.11). Figure 4.4 shows a silver stain (A) and W estern blot (B) o f BovC eluted from a heparin- 
agarose affinity chrom atography column. Both species appeared to bind to heparin as 
demonstrated by the analysis o f the start and flowthrough fractions (figure 4.4, lanes 1 & 2). 
BovC protein was eluted from the column with a NaCl concentration o f 0.4- 0.8M (figure 4.4, 
lanes 6-8). However, that is not to say that both species are capable o f binding to heparin: BovCl 
is FLAG-immunopositive and BovC2 is not, yet both are purified by FLAG affinity 
chromatography, no doubt due to an interaction between the two species under non-reducing 
conditions. It is likely that this interaction may cause a non-heparin-binding BovC species to be 
co-purified with a heparin-binding BovC species.
4.3.2 N-terminal amino acid sequencing o f recombinant PRG4 domains
The aim o f this work was to determine the N-terminal amino acid sequence for the bovine C- 
terminal PRG4 protein species BovC2 (12 kDa). The other recombinant PRG4 proteins produced 
by this work - Hum Nl, HumN2, B ovN l, BovN2 and BovCl -  are stained with an anti-FLAG
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Figure 4.4 -  H eparin-agarose affinity ch rom atography  of purified recom binant bovine C- 
terminal PRG4 (exons 7-12). FLAG-purified recombinant protein was applied to a 1ml heparin- 
agarose column and bound protein was eluted sequentially with a stepwise gradient o f NaCl in 
lml fractions. Fractions were separated by SDS-PAGE (30pl/lane, reducing conditions) and 
visualised by (A) silver stain showing total protein and (B) Western blot probed with anti-FLAG 
M2 mAb. Migration of molecular weight standards (kDa) is shown to the left.
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M2 monoclonal antibody, which indicates that the FLAG tag is present at the amino terminus of 
the protein. In contrast, BovC2 is FLAG immunonegative, strongly suggesting that its N-terminal 
amino acid sequence does not contain the FLAG epitope. H eparin-agarose affin ity  
chromatography was used to partially purify HumN and BovC from the conditioned media of 
stably transfected S2-HN and S2-BC cell lines, respectively. Proteins were separated by SDS- 
PAGE, transferred to PVDF and stained with Coomassie Blue to visualise total protein. Bands of 
interest were excised for sequencing as shown in figure 4.5. This sequencing was performed by 
an off-cam pus facility  (B risto l U niversity). The sequences obtained  for the FLAG 
immunopositive protein species HumNl and BovCl (figure 4.5A & B) contained 4 amino acids 
originating from the expression vector and the FLAG epitope, as expected. The sequence 
obtained for BovC2 (figure 4.5C) relates to a sequence that resides in exon 10 o f PRG4: 
1507AIGPSQVHT. The predicted molecular weight o f BovC from 1307AIGPSQVHT to the end of 
exon 12 is 11.16 kDa, and the predicted molecular weight of BovC from the start o f exon 7 to 
1J0'AIGPSQVHT is 20.56 kDa. These molecular weights approximate to the observed molecular 
weights o f the BovCl and BovC2 proteins as seen on reduced SDS-PAGE gels. Collectively, 
these results indicate that BovC is a polypeptide o f approximately 30 kDa that has been cleaved 
attheRRRFER1306 - l307AIG PSQ  site.
4.3.3 Characterisation o f  recombinant PRG4 domains by Western blotting with a panel o f  
PRG4-specific antibodies
The recom binant PRG4 dom ains produced in this study were used in W estern b lotting 
experiments with a panel o f antibodies designed to recognise PRG4 (chapter 2, table 2.4) These 
included polyclonal antibodies raised against synthetic peptides from human PRG4 (anti-exon 3, 
anti-exon 12) (Lori Fitz, W yeth, Cam bridge MA), and monoclonal antibodies raised against 
purified bovine superficial zone chondrocyte PRG4 (6-A -l, 3-A-4) (Schumacher et al.. 1999). 
This was carried out in order to confirm the presence o f PRG4 epitopes within the recombinant 
PRG4 domains and to characterise the recombinant protein species produced by the stable S2 cell 
lines. Work o f this nature would also help to partially map the PRG4 recognition epitopes for the 
antibodies 3-A-4 and 6 -A -l, and would help determ ine the extent o f cross-species reactivity 
displayed by each o f these antibodies.
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Figure 4.5 -  Amino te rm in a l  sequence analysis of recom binant hum an N-term inal PRG4 
(lane 1) and recom binan t b o v in e  C -term inal PRG4 (lane 2) proteins expressed by stable 
Drosophila S2 cell lines. Conditioned media (30ml) was concentrated by heparin-agarose affinity 
chromatography (1ml bed volum e), separated by SDS-PAGE, transferred to a PVDF membrane 
and stained with Coomassie b lue . Bands of interest were selected based on prior Western blotting 
experiments, excised, and sequenced  by a core facility at Bristol University. The sequences 
obtained are shown on the r ig h t  (one-letter amino acid code). Migration o f  molecular size 
standards is shown to the left.
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4.3.3.1 Immunodetection o f  recombinant PRG4 domains using polyclonal antibodies to human 
PRG4
Recombinant PRG4 domains BovNl, HumNl and BovC were purified by FLAG immunoaffinity 
chromatography and heparin-agarose affinity chromatography and subjected to SDS-PAGE 
(5pg/lane) under reducing and non-reducing conditions. Western blots probed with anti-exon 3 
and anti-exon 12 polyclonal antibodies raised against human PRG4 synthetic peptides (Wyeth, 
see table 2.4 for details) are shown in figure 4.6. A silver stain and Western blot probed with anti- 
FLAG M2 mAb are shown as a reference (lanes 1-6). It is apparent from the silver stains and 
FLAG M2 immunoblots of the recombinant proteins that they run very differently under native 
(figure 4.6A) and reducing conditions (figure 4.6B). BovNl and HumNl both run at -2 7  kDa 
under reducing conditions, whereas under non-reducing conditions BovN appears as a single 
band o f -5 0  kDa and HumNl runs as 2 bands o f -3 7  and 55 kDa (figure 4.6, lanes 1 & 2). Under 
reducing conditions, two species of BovC are apparent at -2 0  (B ovC l) and 12 (BovC2) kDa, 
whereas under non-reducing conditions 1 band of -3 2  kDa is visible, which indicates that the two 
molecular species are disulphide-bonded with one another (figure 4.6, lane 3). This proposed 
interaction is supported by the observation that both species of BovC are purified by FLAG 
immunoaffinity chromatography even though only the 20 kDa BovCl species is FLAG 
immunopositive (chapter 3, figure 3.12). The polyclonal antibody to exon 3 of human PRG4 
recognised HumNl in reduced and non-reduced forms (figure 4.6, lane 8), although staining was 
enhanced in reducing conditions. There was a weak interaction of the anti-exon 3 antibody with 
reduced BovNl (figure 4.6, lane 7). This antibody was raised against a synthetic peptide from 
exon 3 o f  human PRG4, 72GRCFESFERGRECD. The corresponding bovine PRG4 amino acid 
sequence is 72GRCFETFARGRECD, and the difference o f  2 amino acids between the 2 species 
(highlighted in bold) appears to be sufficient to significantly reduce the binding of the antibody to 
this epitope. The difference between 79E in human PRG4 and 79A in bovine PRG4 could be 
particularly relevant: glutamic acid possesses an acidic side chain whereas the side chain of 
alanine is nonpolar. The anti-exon 3 antibody also fails to react with full-length bovine articular 
cartilage or tendon PRG4, as shown in chapter 2, figure 2.9. Hum Nl shows greater 
immunoreactivity with the anti-exon 3 antibody than HumN2, demonstrated by the Western blot 
shown in figure 4.7. This suggests that HumN2 contains a truncated anti-exon 3 epitope, and that 
the site of C-terminal truncation of the HumN molecule occurs near the anti-exon 3 epitope site.
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Figure 4.6 -  Im m unoblo tting  experim ents  using bovine and hum an N -term inal 
(exons 2-5) PR G 4 (BovN & H um N ) purif ied  by FLA G  and heparin  affinity 
chrom atography , and bovine C -te rm ina l (exons 7-12) PRG4 (BovC) purified by 
FLAG affinity ch rom atog raphy . All samples were run in (A) native and (B) reduced 
states, at 5pg total protein/lane. Silver stain and Western blot probed with anti-FLAG 
M2-AP conjugate mAb are shown alongside blots probed with polyclonal antibodies to 
human PRG4, and an anti-rabbit secondary antibody control is shown in the far right 
panel. Migration o f  molecular size standards is shown to the left.
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Figure 4.7 -  W estern blot analysis of hu m N l and humN2 PRG4 protein species. Proteins 
were purified by FLAG immunoaffinity chromatography and separated by SDS-PAGE under 
reducing conditions (5pg total protein/lane). A Western blot was probed with a polyclonal 
antibody to an epitope within exon 3 o f  human PRG4 and FLAG M2 monoclonal antibody. 
Migration o f  standards is shown on the left.
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As expected, the anti-exon 12 antibody, raised against a peptide sequence in the C-terminal 
domain o f  human PRG4, did not react with BovN or HumN (figure 4.6, lanes 10 & 11). The 
antibody did recognise a single non-reduced BovC band o f  32 kDa and also reacted with the 
BovC2 species under reducing conditions (figure 4.6, lane 12), but not the FLAG 
immunopositive BovCl 20 kDa protein species. This supports the conclusion made earlier after 
the amino-terminal sequencing of BovC2, that BovCl (20 kDa) represents bovine PRG4 from the 
start of exon 7 to F 1306, and that BovC2 (12 kDa) represents bovine PRG4 starting at A 1307 in exon 
10 to the end of exon 12. The anti-exon 12 antibody was raised against a synthetic peptide from 
human PRG4, 1373QYYNIDVPSR,  and there is no difference in amino acid sequence between 
human and bovine PRG4 within this peptide. This would explain why an antibody raised against 
a human PRG4 peptide would recognise the recombinant bovine protein.
4.3.3.2 Immunodetection o f  recombinant PRG4 domains using monoclonal antibodies raised 
against purified bovine articular cartilage PRG4
In a similar fashion to figure 4.6, figure 4.8 shows the results o f  immunoblotting experiments 
using bovine and human N-terminal (exons 2-5) PRG4 (BovNl & H um N l) purified by FLAG 
immunoaffinity chromatography and heparin-agarose affinity chromatography, which purifies the 
higher molecular weight species only (see figure 4.2). Bovine C-terminal (exons 7-12) PRG4 
(BovC) purified by FLAG immunoaffinity chromatography was also used in these analyses. 
After separation under native (figure 4.8A) and reducing (figure 4.8B) conditions, proteins were 
immunoblotted using two monoclonal antibodies raised against purified bovine PRG4, 3-A-4 and 
6-A-l (Schumacher et a l., 1999). A silver stain and Western blot probed with anti-FLAG M2 
mAb are shown as a reference (figure 4.8, lanes 1-6). Non-reduced forms of BovNl and HumNl 
show weak immunopositive staining with 6-A-l and 3-A-4 (figure 4.8A). Figure 4.8B shows that 
under non-reducing conditions, HumNl and BovNl are weakly stained by the antibodies 6-A-l 
and 3-A-4. There was no staining o f BovC protein with any of the mAbs used. This result was 
unexpected as 6-A-l was thought to recognise a C-terminal bovine PRG4 epitope based on the 
isolation o f  a Xgt 11 clone with 6-A-l (Schumacher et al., 1999). As seen in figure 4.8A, lane 10, 
3-A-4 recognises non-reduced BovNl, but not Hum Nl. This is in keeping with results shown 
earlier in this study (chapter 2, figure 2.9) and results shown by others (Tudor, 2002), which 
show that 3-A-4 recognises a non-reduced epitope on non-reduced full-length bovine PRG4
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Figure 4.8 -  Immunoblotting exper im en ts  using bovine and human N-terminal 
(exons 2-5) PRG4 (BovN & H u m N ) purified by FLAG and heparin affinity 
chromatography, and bovine C - te rm in a l  (exons 7-12) PRG4 (BovC) purified by 
FLAG affinity chromatography. A ll samples were run in (A) native and (B) reduced 
states, at 5pg total protein/lane. A silver stain and Western blot probed with anti-FLAG 
M2-AP conjugate mAb are shown alongside blots probed with monoclonal antibodies 
raised against purified bovine PRG4, and  an anti-mouse secondary antibody control is 
shown in the far right panel. Migration o f  molecular size standards is shown to the left.
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isolated from cartilage and tendon, but not full-length human PRG4. This work, therefore, maps 
the 3-A-4 epitope to between exons 2 and 5 o f  bovine PRG4. This also indicates that the 
recombinant N-terminal domain that was produced as part o f  this study has similar structural 
features to the N-terminal domain contained within native bovine full-length PRG4. These 
recombinant PRG4 domains, once fully characterised, could be used to further epitope-m ap the 
monoclonal antibodies raised against bovine PRG4 (6 -A -l, 3-A-4, 5-D -l and 5-B-6).
4.3.4 Predicted structure o f  recombinant PRG4 structural domains
4.3.4.1 Predicted structure o f  recombinant PRG4 N-terminal (exons 2-5) domain species 
The results from Western blotting, protein sequencing and affinity chromatography experiments 
presented in this chapter enable the prediction o f  structural features for the different recombinant 
PRG4 proteins produced in chapter 3. A schematic representation o f  the human N-terminal PRG4 
species HumNl and HumN2 is shown in figure 4.9. As HumNl is immunopositive for anti- 
FLAG M2 and anti-exon 3 antibodies (figure 4.6), and also binds to heparin (figure 4.2), it is 
predicted that the protein represents PRG4 exons 2-5. As HumN2 does not bind to heparin- 
agarose (figure 4.2) and is immunopositive for anti-FLAG and weakly immunopositive for anti­
exon 3 (figures 4.2 and 4.7), it is predicted that N2 comprises exon 2 and exon 3 up to the amino 
acid sequence used in the manufacture o f  the anti-exon 3 antibody. Similar structures could be 
proposed for the B ovN l and BovN2 species, based on similarities with the HumNl and HumN2 
species in terms o f  molecular weight, heparin-binding characteristics and FLAG M2 mAb 
immunopositivity.
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Figure 4.9 -  Schematic representation of H um N l and HumN2 recombinant PRG4 protein 
species based  on W es te rn  b lo t t in g  e x p e r im en ts  and h e p a r in -a g a ro s e  a f f in i ty  
chromatography. HBD = heparin-binding domain.
144
4.3.4.2 Predicted structure o f  recombinant PRG4 C-terminal (exons 7-12) domain species 
The predicted structure o f  the human C-terminal PRG4 species, BovC l and BovC2, is shown in 
figure 4.10. B ovC l is immunonegative for a polyclonal antibody raised against a peptide from 
exon 12 whereas BovC2 is immuopositive (figure 4.6). Therefore it can be concluded that BovC2 
contains PRG4 exon 12 and BovCl does not. At the N-terminus o f  the 2 species, BovC l has the 
FLAG epitope and BovC2 has an internal sequence from exon 10 o f  PRG4 (figure 4.5). From 
these observations it can be predicted that the sum o f  BovC l and BovC2 equate to exons 7-12 o f  
bovine PRG4. It can also be predicted that BovC2 contains a free cysteine residue and B ovC l 
contains four cysteine residues. Therefore, it is likely that disulphide bonding between the two 
species must take place in order for them to be co-purified by FLAG im m unoaffinity  
chromatography. The separation o f  the two BovC species could be a useful tool in further 
characterisation experiments. However, preliminary reduction/alkylation experiments based on a 
method used by Calabro et al. (1992) proved to be unsuccessful, as under native conditions, 
BovCl and BovC2 did not run as two bands on SDS-PAGE gels after this process.
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Figure 4.10 -  Schematic representation of BovCl and BovC2 recombinant PRG4 proteins 
based on  W este rn  blotting experim ents and N-terminal amino acid sequencing. Arrows 
indicate potential disulphide bonding. HBD = heparin-binding domain. C = cysteine residue.
4.3.5 Identification of carbohydrate  side chains on recombinant PRG4 domains
Glycosylation o f  recombinant proteins can cause altered migration in SDS-PAGE that is not in 
concordance with the predicted molecular weight o f  the protein core. The glycosylation o f  
purified recombinant PRG4 domains was investigated by separation using SDS-PAGE under
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reducing conditions followed by lectin affinity blotting experiments performed using methods 
described in Chapter 2 o f  this study (section 2.2.10). The specificities o f  the lectins used are 
described in table 2.5.
Figure 4.1 1 shows the results o f  lectin affinity blotting experiments with Hum N l, BovNl and 
BovC recombinant proteins. Hum Nl and BovNl show positive staining for the lectin PNA, 
which recognises the core disaccharide galactose (3(1-3) N-acetylgalactosamine (figure 4.1 1, 
lanes 1 & 2). Bovine and human full-length PRG4 are also positive for PNA staining as shown in 
chapter 2, figure 2.10, and also for MAA which specifically binds to sialic acid linked a(2-6) to 
galactose. As shown in figure 4.11 (lanes 4 & 5), HumN and BovN display a weak affinity with 
MAA, along with DSA (lanes 7 & 8), which recognises galactose linked (3(1-4) to N-acetyl 
glucosamine, and SNA (lanes 10 & 11), which recognises sialic acid linked a(2-6) to galctose. 
Full-length human or bovine PRG4 does not appear to be recognised by DSA, SNA or GNA 
(chapter 2, figure 2.10). BovCl (though not BovC2) is recognised by GNA (figure 4.11, lane 15), 
which is specific to terminal mannose a ( l -3 ) ,  a ( l - 6 )  or a ( l -2 )  linked to mannose, identifying 
high mannose N-glycan chains.
4.3.6 Deglycosylation o f  recombinant proteins
Carbohydrates in the form o f  asparagine-linked (N-linked) or serine/threonine-linked (O-linked) 
oligosaccharides are post-translational modifications that are present in many eukaryotic proteins, 
and often introduce heterogeneity in the mass and charge of glycoproteins. The recombinant 
PRG4 proteins investigated b y  this study are predicted to have a number o f  O- and N-linked 
glycosylation sites, as illustrated in tables 4.2 and 4.3, respectively. Potential glycosylation sites 
were predicted by inputting the  PRG4 core protein amino acid sequence into the NetOGlyc and 
NetNglyc online glycosylation prediction engines.
HumN and BovN are predicted to have 28 and 24 O-glycosylation sites, respectively, whilst 
BovC is predicted to have 2 N-linked and 2 O-linked glycosylation sites. Human and bovine N- 
terminal PRG4 has 1 consensus sequence for N-linked glycosylation (NXS/T), but as the middle 
residue is proline the acceptor capability of the site is markedly reduced (Ronin et al., 1981).
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Table 4.2 -  Predicted mucin-type O-linked glycosylation sites in recombinant PRG4 domains, as 
predicted by the NetOGlyc 3.0 server, URL http://www.cbs.dtu.dk/services/NetOGlvc/ (Hansen
e/a/., 1998). Predicted O-glycosylation sites are shown in red.
Protein No. o f
predicted
sites
Am ino acid sequ en ce
Human recombinant 
PRG4 N-terminal 
domain (exons 2-5)
28 J5q d l s s c a g r c g e g y s r d a t c n c d y n c q h y m e c c p d f k r v c t a e l s
CKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPS
SKKAPPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITEEHSVS
ENQESSSSSSSSSSSSTIWKIKSSKNSAANRELQKKLK
Bovine recombinant 
PRG4 N-terminal 
domain (exons 2-5)
24 “ QDLSSCAGRCGEGYSRDAICNCDYNCQHYMECCPDFKKECTVELS
CKGRCFETFARGRECDCDSDCKKYGKCCSDYGAFCEAVHNPTTPPP
PKTAPPPPGASQTIKSTTKRSPKSPNKKKTKKVIESEEITEEHSVS
ENQESSSSSSSSSSTIRKIKSSKNSGANRELQKKLK
Bovine recombinant 
PRG4 C-terminal 
domain (exons 7-12)
2 1141DETNLCNGRPVDGLTTLRNGTLVAFRGH YFWMLTPFTPPPPPRR 
ITEVWGIPSPIDTVFTRCNCEGKTFFFKGSQYWRFTNDIKDAGYPK 
LISKGFGGLNGKIVAALSIAQYKSRPESVYFFKRGGSVQQYTYKQE 
PTQKCTGRRPAINYSVYGETAQVRRRRFERAIGPSQVHTIRIHYTP 
VRVP Y QDKGFLHNE VKVSTLWRGLPNWTS AISLPNIRKPDGYDY Y 
ALSKDQYYNIDVPSRTARAITTRSGQTLSNTWYNCP
Table 4.3 -  Predicted N-linked glycosylation sites in recombinant PRG4 domains (Asn-Xaa- 
Ser/Thr). Sites were found using the NetNGlyc 1.0 server, URL
(http://www.cbs.dtu.dk/services/NetNGlvc/). Predicted N-glycosylation sites are shown in red,
consensus sequence residues are shown in blue.
Protein No. o f
predicted
sites
Sequence(s)
Human recombinant 
PRG4 N-terminal 
domain (exons 2-5)
1* “ QDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDFKRVCTAELS
CKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKK
APPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITEEHSVSENQESS
SSSSSSSSSSTIWKIKSSKNSAANRELQKKLK
Bovine recombinant 
PRG4 N-terminal 
domain (exons 2-5)
1* 23q d l s s c a g r c g e g y s r d a ic n c d y n c q h y m e c c p d f k k e c t v e l s
CKGRCFETFARGRECDCDSDCKKYGKCCSDYGAFCEAVHNPTTPPPPKT
APPPPGASQTIKSTTKRSPKSPNKKKTKKVIESEEITEEHSVSENQESS
SSSSSSSSTIRKIKSSKNSGANRELQKKLK
Bovine recombinant 
PRG4 C-terminal 
domain (exons 7-12)
2 1141 DETNLCNGRPVDGLTTLRNGTLVAFRGH YFWMLTPFTPPPPPRRITE 
VWGIPSPIDTVFTRCNCEGKTFFFKGSQYWRFTNDIKDAGYPKLISKGF 
GGLNGKIVAALSIAQYKSRPESVYFFKRGGSVQQYTYKQEPTQKCTGRR 
PAINYSVYGETAQVRRRRFERAIGPSQVHTIRIHYTPVRVPYQDKGFLH 
NEVKVSTLWRGLPNWTSAISLPNIRKPDGYDYYALSKDQYYNIDVPSR 
TARAITTRSGQTLSNTWYNC P
•Denotes Asn-Pro-Ser/Thr sequence, which is less likely to be glycosylated
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These potential glycosylation sites within recombinant proteins were investigated by enzymatic 
deglycosylation, the extent o f  which was determined by analysing mobility shift on SDS-PAGE 
gels. Proteins were detected after deglycosylation by silver stain and Western blot using anti- 
FLAG M2 mAb, and the results can be seen in figure 4.12. A mixture o f  O-glycosidases (see 
table 4.1) appeared to reduce the apparent MW of HumN 1 and BovN 1 proteins by ~2 to 3 kDa 
(figure 4.12, lanes 3 & 9), and had no effect on the migration o f  BovC protein (lanes 15 & 18). 
N-deglycosylation with PNGaseF had no effect on N-terminal PRG4 species, corresponding to 
the observ ation that there are no consensus sequences for N-glycosylation within the N-terminal 
domain (table 4.3). PNGaseF digestion reduced the molecular weight o f  the 20 kDa BovCl 
species by around 2 kDa (figure 4.12. lanes 14 & 17), confirming the activity of the two predicted 
N-glycosylation sites (table 4.3) as acceptors. The 12 kDa BovC2 protein was unaffected by 
digestion with PNGase F (lanes 14 & 17), in keeping with the prediction that no N-glycosylation 
consensus sequences are present after the N-terminal BovC2 sequence 1307AIGPSQVHT (table 
4.4), determined by N-terminal amino acid sequencing (figure 4.5). The presence o f  N-glycans in 
BovC is supported by the positive staining with the lectin GNA, which identifies N-linked 
glycans (figure 4.11).
4.4 Discussion
Before embarking on further studies with the recombinant PRG4 domains described in Chapter 3 
of this study, it was desirable to characterise the recombinant proteins. The experiments 
described in this chapter have partially characterised the recombinant PRG4 domains by Western 
blotting, affinity chromatography and N-terminal amino acid sequence analysis.
HumNl and BovNl proteins (27 kDa) bind to heparin-agarose, whereas HumN2 and BovN2 (16 
kDa) do not. This would indicate that HumNl and BovNl proteins contain a functional heparin- 
binding site, probably conferred by the consensus sequence within exon 4 o f  PRG4, whereas 
HumN2 and BovN2 proteins do not. This in turn led to the prediction that N1 represents PRG4 
N-terminal exons 2-5 and N2 represents PRG4 exons 2-4, truncated before the heparin-binding 
sequence.
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Figure 4.12 -  E nzym atic  deglycosylation o f recom binan t PRG4 dom ains followed by 
analyses of mobility shift on SDS-PAGE gels. (A) human and bovine N-terminal species 
detected by Western blot with anti FLAG M2 mAb. (B) bovine C-terminal species detected by 
Western blot with anti FLAG M2 mAb and silver stain. Migration of molecular size standards is 
shown to the left.
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This work would benefit from a more detailed characterisation o f  the recombinant proteins, such 
as by the calculation o f  the mass of tryptic peptides by Matrix Assisted Laser Desorption 
Ionisation-Time o f  Flight (MALDI-TOF) mass spectrometry. BovN2 and HumN2 represent 
recombinant PRG4 N-terminal domains that are C-terminally truncated and other such techniques 
could reveal the nature o f  these truncations. The monoclonal antibody to bovine PRG4, 3-A-4, 
recognises a conformation-dependant non-reduced epitope on BovNl (but not Hum Nl). This is 
similar to results obtained in immunoblotting experiments with native full-length PRG4, where 3- 
A-4 recognises a non-reduced conformation-dependent epitope on PRG4 isolated from bovine 
articular cartilage and synovial fluid (Tudor. 2002), but not full-length human recombinant PRG4 
(chapter 2). This work therefore maps the specificity of 3-A-4 to exons 2-5 of bovine PRG4. The 
presence of this domain in bovine synovial fluid adds to results presented in two papers by Jay 
and others, which document the presence of PRG4 containing only exons 6-9 in human synovial 
fluid (Jay et a l., 2000), and the variable expression o f exons 2, 4 and 5 by synovial fibroblasts 
and articular chondrocytes at an mRNA level (Jay et al., 2001b). Previously, Tudor (2002) found 
that chondrocytes from the deep zone o f  bovine articular cartilage were positive in 
immunohistochemical experiments with 6 -A -l, but not 3-A-4, and that C-terminal but not N- 
terminal PRG4 mRNA was expressed by deep zone chondrocytes. This led to the hypothesis that 
6-A-l recognises a C-terminal PRG4 epitope and 3-A-4 recognises an N-terminal epitope, the 
second part o f  which has been supported by work presented in this study. The physiological 
function of different PRG4 isoforms in synovial fluid, articular cartilage matrix and chondrocytes 
from different territorial regions has yet to be resolved, and 3-A-4 could be used to determine the 
nature of different PRG4 populations once its epitope has been fully mapped.
For the bovine PRG4 C-terminal domain-expressing cell line, S2-BC, two proteins BovCl and 
BovC2 were purified by FLAG affinity chromatography, running on reduced SDS-PAGE gels at 
20 and 12 kDa, respectively. Results presented in this chapter show that the N-terminal amino 
acid sequence o f  BovC2 is 1307AIGPSQVHT, which is located within exon 10 of PRG4. BovC2 is 
immunopositive for an antibody raised against a peptide from exon 12 of PRG4 whereas BovCl 
is immunonegative, which has led to the predicted structure of BovCl and BovC2 as illustrated in 
figure 4.10. From these data it is predicted that BovCl and BovC2 represent products from the 
cleavage of BovC (exons 7-12) PRG4 at the site RRRFERA1306 -  1307AIGPSQ.
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The recombinant PRG4 domain proteins Hum Nl, BovNl and BovC all appear to be able to bind 
heparin. Taken together, these results suggest that the heparin-binding consensus sequences in 
exons 4 and 10 of PRG4 are functionally active in these proteins. This was also the case with the 
full-length molecule: in chapter 2 of this study it has been shown that human recombinant, bovine 
articular cartilage and bovine tendon PRG4 bind to heparin-agarose in affinity chromatography 
experiments. This would indicate that PRG4 has two functionally active heparin-binding sites. It 
has been suggested that the ability of PRG4 to bind glycosaminoglycan chains on both sides o f  
the central lubricating domain would serve to stabilise lubricating activity on cartilage covered 
with the lamina splendens (Jay et al., 2001a).
The results presented in this chapter demonstrate a degree of similarity in glycosylation patterns 
between the recombinant PRG4 domains and full-length PRG4, based on results obtained in 
lectin affinity blotting experiments with the recombinant domains. Full-length PRG4 is 
recognised by the lectins PNA and MAA, which also recognise human and recombinant N- 
terminal PRG4 domains (Tudor, 2002). The bovine C-terminal recombinant PRG4 domain is 
positive for binding with GNA, and the N-terminal domains are also weakly stained with DSA 
and SNA, but this data differs with results seen with the full-length native molecule. This could 
be due in part to the slightly different glycosylation patterns in Drosophila  cells as compared 
with mammalian cells. The sialylation o f  glycoproteins produced by insect cells has been a 
subject of debate, and it has been concluded that sialylation in insect cells is probably a highly 
specialised function that occurs rarely (reviewed in Marchal et al., 2001). The recognition of 
BovN and HumN proteins by MAA and SNA in this study would indicate the presence o f sialic 
acid on these recombinant proteins. However, more extensive controls, such as the use of 
competing monosaccharides and or endoglycosidase and neuraminidase treatment, are necessary 
to verify the carbohydrate-binding specificity of the lectin affinity blot results.
Enzymatic deglycosylation o f  the recombinant proteins has confirmed the presence o f  N- 
glycosylation sites within the C-terminal domain o f  PRG4 (exons 7-12) and O-glycosylation sites 
within the N-terminal domain of PRG4 (exons 2-5). Other researchers have utilised fluorophore- 
assisted carbohydrate electrophoresis (FACE) to discover a small amount o f  asialo-, 
digalactosylated bi-antennary, bisecting GlcNAc, tri-mannosyl core fucosylated N-link on human
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PRG4 isolated from synovial fluid (Jay & Cha, 2002). This bi-antennary structure on other 
glycoproteins has been associated with protein folding (reviewed by Yamaguchi, 2002), and the 
data presented in this chapter details N-glycosylation as being present in the C-terminal domain 
of PRG4. Interestingly, the study that characterised the N-linked glycans o f  human PRG4 by 
FACE did not find N-linked oligosaccharides on bovine PRG4 (Jay & Cha, 2002), which is 
contrary to the results documented in this study. The glycosylation o f  recombinant PR G 4 
domains c o u ld  be fu r th e r  c h a ra c te r i s e d  by d e g ly c o s y la t io n  w ith  T F M S  
(trifluoromethanesulphonic acid, reviewed by Edge, 2003). The glycans present could be further 
characterised by deglycosylation with specific glycosidases (as performed in this study) followed 
by FACE.
4.5 Chapter Summary
• Affinity chromatography experiments with recombinant PRG4 domains have shown that 
there are heparin-binding sites in the N- (exons 2-5) and C- (exons 7-12) terminal 
domains o f  PRG4.
• N-terminal amino acid sequencing and Western blot analyses o f  the two BovC protein 
species has revealed that the BovC2 species starts with internal PRG4 sequence from 
exon 10. BovC2 is also immunopositive for an antibody to PRG4 exon 12 w hereas 
BovCl is immunonegative, suggesting that the BovCl species represents bovine PR G 4 
exons 7-9 and part o f exon 10, and that BovC2 represents the remainder o f  exon 10 to the 
end o f exon 12.
• Western blot analysis of the recombinant N-terminal PRG4 domains have shown that 
monoclonal antibody 3-A-4 recognises a non-reduced conformation-dependent epitope on 
bovine (but not human) PRG4, exons 2-5. This is a similar antibody recognition pattern as 
seen with native bovine articular cartilage PRG4, and maps the specificity of antibody 3- 
A-4 to the N-terminal region of PRG4.
• Lectin affinity blotting and enzymatic deglycosylation o f recombinant PRG4 dom ains 
have partially characterised the glycosylation patterns of the recombinant proteins.
• The experiments described in this chapter have facilitated the characterisation o f  the 
recombinant PRG4 protein species.
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5. PROTEINASE DIGESTION OF PRG4
5.1 Introduction
This chapter presents results from in vitro digestions of full-length PRG4 described in Chapter 2 
and the purified recombinant PRG4 structural domains described in Chapters 3 and 4. The 
rationale for these digestions can be described under the following three sub-headings.
(a) Generation o f  distinct structural PRG4 domains.
The initial aim of the work presented in this chapter was to digest purified full-length human and 
bovine PRG4 with a view to obtaining distinct structural domains of PRG4 that could be used for 
biochemical analyses and cell biology experiments. This would enable investigations into the link 
between the structural features of PRG4 and its proposed independent physiological functions. 
The generation o f  the central mucin-like region encoded for by exon 6 was o f  particular interest, 
as the recombinant protein expression work described earlier in this thesis was limited to the non­
mucin N- and C-terminal domains. The derivation of other PRG4 domains from the full-length 
molecule by enzymatic digestion was a secondary aim of this work.
(b) Identification o f  proteinoses capable o f  degrading full-length PRG4.
Previous work has identified lower molecular weight forms of PRG4 in cartilage and synovial 
fluid (Schumacher et al., 1999; Tudor, 2002), and the occurrence of a number o f  different forms 
of PRG4 within the synovial joint has been documented (Jay et a l., 2001b). Along with 
alternative splicing, proteinase digestion may contribute to the different forms o f PRG4 found 
within the synovial joint. Different forms o f PRG4 may possess different structural features, and 
this may affect the functionality o f  the molecule. In addition to this, it is interesting to consider 
that degradation o f  PRG4 by proteinases present within an inflamed synovial joint could affect 
the functional integrity o f  the molecule. The susceptibility of full-length PRG4 to digestion 
within the synovial joint was investigated by performing in vitro proteinase digests o f  purified 
preparations o f  full-length PRG4 (chapter 2) with a panel of physiologically relevant proteinases.
(c) Identification of proteinases capable o f degrading recombinant PRG4 domains.
The specificity of the digestions of full-length PRG4 observed in part (b) was investigated by 
performing in vitro proteinase digests with preparations of recombinant PRG4 N- and C-terminal 
domains (chapter 3) and PRG4-degrading proteinases.
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§.2 Materials and Methods
All chemicals were o f  an analytical grade and were purchased from Sigma-Aldrich unless 
indicated otherwise. A detailed list o f  the materials used in this research project and their 
suppliers is listed in Appendix A.
5.2.1 Materials
5.2.1.1 Source o f  PRG4 (full-length and domains)
The purification of human recombinant full-length PRG4 from the culture medium of a PRG4- 
expressing CHO cell line is described in chapter 2, section 2.3.1. The partial purification of 
bovine cartilage PRG4 from the culture medium o f  superficial zone chondrocytes cultured in 
agarose is described in chapter 2, section 2.3.2. The cloning, expression and purification of 
bovine and human N-terminal (exons 2-5) and bovine C-terminal (exons 7-12) PRG4 domains is 
described in chapter 3. Protein concentrations were calculated by reading absorbency values at 
280nm.
5.2.1.2 Enzymes and reaction buffers
The enzymes used are listed in table 5.1 (over page), along with their sources, EC number and 
digestion buffers used in each case. Digestion buffers were formulated with the advice o f enzyme 
suppliers, with the exception of the cathepsin digestion buffer, which is a formulation, previously 
used by Fosang et al. (1992).
5.2.2 Enzyme concentrations
The enzyme concentrations used for preliminary experiments using an excess o f  enzyme are 
listed in table 5.2 (over page). In experiments with different amounts o f  enzymes, enzyme 
concentrations are described within the relevant figures.
5.2.3 Preliminary digestions o f  full-length PRG4
Human recombinant full-length PRG4 was purified from the conditioned medium of a stable, 
PRG4-expressing polyclonal CHO cell line as described in chapter 2. Initial digestions were 
carried out with an excess of each enzyme. For each separate digestion, 40p.g of PRG4 was added 
to a 1.5ml screw-cap tube. Appropriate amounts o f  MilliQ water, 10X digestion buffer (table 5.1)
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and enzyme (table 5.2) was added to total a reaction o f  100^1. For control digestions the 
constituents o f  the reaction were the same, and included 10X MMP reaction buffer, but did not 
contain enzyme.
Table 5.1 -  Enzymes and digestion buffers used during in vitro digestions of PRG4
Enzvme Source EC number Digestion buffer
Cathepsin B. from bovine spleen Sigma 3.4.22.1 0.25M Na-Acetatc, pH 5.5. 0.2M  
NaCl, ImM EDTA, lOmM DTT
Cathepsin D, from bovine spleen Sigma 3.4.23.5 0.25M Na-Acctate, pH 5.5, 0.2M  
NaCl, ImM EDTA, lOmM DTT
MMP-1, human recombinant Gift from Paul C annon 
(Roche)
3.4.24.7 0 .1M Tris-HCl, pH 7.5, 50mM  
NaCl, ImM CaCl2, ImM APMA
MMP-3, human recombinant Gift from Paul Gannon 
(Roche)
3.4.24.17 0.1M Tris-HCl, pH 7.5, 50mM  
NaCl, ImM CaCl2, ImM APMA
MMP-7, human recombinant Gift from Paul Cannon 
(Roche)
3.4.24.23 0.1M Tris-HCl, pH 7.5, 50mM  
NaCl, ImM CaCl2, ImM APM A
Trypsin, from bovine pancreas, 
TPCK-treated
Sigma 3.4.21.4 0.1M Na-Acetate, pH 7.3, 0.1M  
Tris
Chymotrypsin, from bovine pancreas, 
TLCK-treated
Sigma 3.4.21.1 lOmM Tris-HCl, pH 7.8, lOmM 
CaCl2
Plasmin, from human plasma Sigma 3.4.21.7 20mM Tris-HCl, pH 7.4, 0 .15M 
NaCl
ADAM TS-4, human recombinant
i
Gift from Dr. C. R. 
Flannery (Wyeth. MA)
3.4.24.82 0.1M Tris-HCl, pH 7.4, 50mM  
NaCl, lOmM CaCl2, lOmM M gCl2
| ADAM TS-5, human recombinant Gift from Dr. C. R. 
Flannery (Wyeth, MA)
3.4.24.- 0.1M Tris-HCl, pH 7.4, 50mM  
NaCl, lOmM CaCl2, lOmM M gCl2
j Calpain 11. from porcine kidney Calbiochem 3.4.22.17 0 .1 1M imidazole, pH 7.5, ImM 
EGTA, 5mM h-mercaptoethanol
j Elastase. from human leukocytes
i
Sigma 3.4.21.37
i
0.1M Tris-HCl. pH 8.8. 0.1M  
CaCE
A 50mM stock solution of APMA (p-aminophenyl mercuric acetate) was made up in 50mM Tris- 
HC1, pH 7.5, ImM CaCl2, 0.05% Triton X-100.
Table 5.2 -  Enzyme concentrations used in preliminary digestions o f  full-length PRG4. These 
concentrations equate to a large excess of enzyme based on information from the suppliers.
Enzyme Concentration
Elastase 0.2U/ml
Calpain lpg/m l
Cathepsin B 0.5U/ml
Cathepsin D 0.5U/ml
Plasmin 0.2U/ml
ADAMTS-4 9.3pg/m l
MMP-1 5 p g m l
MMP-2 5pg/m l
MMP-3 lOpg/ml
MMP-7 lOpg/ml
156
Reactions were incubated at 37°C for 16 hours followed by dialysis against w ater and 
lyophilisation. Reaction mixtures were reconstituted in 90pl IX SDS-PAGE sample buffer 
(chapter 2, table 2.1) and lOpl p-mercaptoethanol and separated on two 4-12% SDS-PAGE 
gradient gels (50pl/lane).
5.2.4 Titrated digests o f  full-length PRG4 and domains o f PRG4
Human recombinant, bovine cartilage, recombinant human N-terminal (exons 2-5) and bovine C- 
terminal (exons 7-12) PRG4 were purified and characterised as described in chapters 2 and 3, 
respectively. For digests with different amounts of enzyme, the type and amount o f  PRG4, along 
with the enzyme used and its concentration, are listed within the relevant figures. For all 
reactions, a total volume of 50pl was adjusted with the appropriate 10X reaction buffer specific 
to the enzyme used (table 5.1). Control digestions were performed without enzyme. Reactions 
were incubated for 2 hours at 37°C before the addition of 40pl 2X SDS-PAGE sample buffer 
(chapter 2, table 2.1) and lOpl p-mercaptoethanol. Proteins were then separated by SDS-PAGE 
(50pl/lane) prior to detection.
5.2.5 Analysis o f digestion products
Digestion products were separated by SDS-PAGE under reducing conditions as described in 
chapter 2, section 2.2.9. Digestions o f  full-length PRG4 (-340 kDa) were separated on 4-12% 
gradient gels and digestions o f  recombinant PRG4 domains (-10-30 kDa) were separated on 15% 
slab gels. Detecting PRG4 with a number o f  methods assessed the extent o f  proteolytic 
degradation. Total protein was detected by silver stain as described in chapter 2, section 2.2.12. 
For the immunolocation o f  PRG4, gels were electro-eluted on to nitrocellulose and Western 
blotting was performed using a variety o f  antibodies, the specificities o f  which are detailed in 
chapter 2, table 2.4. The central mucin domain o f  PRG4 was detected using lectin affinity 
blotting with the lectin MAA (chapter 2, table 2.5). The Western blotting procedures used are 
described in chapter 2, section 2.2.9 and the lectin affinity blotting procedures used are described 
in chapter 2, section 2.2.10.
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5.3 Results
The in vitro proteinase digests o f  PRG4 documented in this chapter were either preliminary 
digests with a fixed amount of enzyme, or digests with the inclusion of different amounts of 
enzymes. The am ount of substrate was constant within each set of digests.
5.3.1 Generation o f  PRG4 mucin-like domain by proteolytic digestion o f  full-length PRG4 
As stated in the introduction to this chapter, the cloning and expression of PRG4 domains in this 
study was lim ited to the non-mucin, vitronectin-like N-terminal (exons 2-5) and C-terminal 
(exons 7-12) dom ains, therefore it was of interest to obtain the mucin-like central domain of 
PRG4 (exon 6). This would enable studies of its physiological function. The strategy to facilitate 
this was to derive the central mucin-like domain from purified full-length human recombinant 
and bovine native PRG4 by means of proteolytic digestion. To facilitate the removal o f  the non­
mucin domains from purified human recombinant PRG4 (hrPRG4) for future functional studies, 
digestion studies were performed using trypsin and chymotrypsin. Figure 5.1 shows the residues 
within the human PRG4 sequence that would be affected by trypsin or chymotrypsin digestion, 
highlighted in red and blue, respectively. In the case of trypsin, it was predicted that lysine and 
leucine residues within the central mucin domain of hrPRG4 would be protected from limited 
trypsin digestion by  virtue o f  the steric hindrance provided by its extensive oligosaccharide 
substitutions, a phenomenon observed in other glycoproteins such as ribonuclease (Bernard et al., 
1983). As regards chymotrypsin digestion of PRG4, the central mucin domain does not contain 
aromatic amino acids, so theoretically the region would be left intact (Jay et al., 2001b).
5.3.1.1 Digestion o f  human recombinant full-length PRG4 with trypsin
For these in vitro  digestion experiments, the substrate was hrPRG4 purified by heparin agarose 
and PNA lectin affinity chromatography (see chapter 2). The hrPRG4 substrate was incubated 
with TPCK -treated trypsin, and the first of these experiments is shown in figure 5.2, where 
different amounts o f  trypsin were used to digest 1 Opig of hrPRG4 in a 50(li1 reaction with a 2 hour 
incubation. A no enzyme control is shown in lane 1, and all reactions were visualised by SDS- 
PAGE followed by silver stain (figure 5.2A) or MAA lectin affinity blotting (figure 5.2B). 
HrPRG4 was com pletely digested with trypsin concentrations o f  20 and 8 (ig/ml (figure 5.2, 
lanes 2 & 3), as there were no protein species apparent with a silver stain or a lectin affinity blot.
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Figure 5.1 -  Predicted trypsin  and chym otrypsin  cleavage sites within hum an PRG4.
Trypsin theoretically cleaves C-terminal to lysine and arginine residues (shown in red); 
chymotrypsin theoretically cleaves after phenylalanine, tryptophan or tyrosine residues (shown in 
blue. Exon boundaries are shown above the amino acid sequence. Most o f  the exon 6 mucin-like 
repeat sequence has been omitted for clarity. Adapted from Flannery et a l., 1999.
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Figure 5.2 -  Digestion of hum an recom binan t PRG4 w ith  decreasing concentrations of 
trypsin. Reaction mixtures of 50pl containing 10pg PRG4 were separated by SDS-PAGE under 
reducing conditions (25pl/lane, 5pg PRG4/lane) and were visualised by (A) silver stain and (B) 
lectin affinity blot with the lectin MAA. A control reaction showing PRG4 with no enzyme (NE) 
is shown in lane 1. Migration positions of molecular mass standards are shown to the left o f the 
panel.
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Decreasing trypsin concentrations resulted  in a decrease in the extent o f  hrPRG4 digestion 
(figure 5.2, lanes 4-9), as the observed silver stain and lectin affinity b lo t  intensity increases. 
However, the hypothesis that exon 6 o f  PRG4 is protected from tryptic d ig e s t io n  by its extensive 
oligosaccharide side chains was not p roved  in this instance, as there w as  a  lack o f  any reduced 
molecular weight hrPRG4 catabolites th a t  were stained by MAA. The p re s e n c e  o f  any reduced 
molecular weight hrPRG4 catabolites w ith  oligosaccharide substitutions w o u ld  signify that the 
domains either side of the mucin dom ain had been digested, and these c a ta b o l i te s  could then be 
assessed further by Western blot to exam ine look for the presence or a b se n c e  o f  these non-mucin 
domains. The overall loss in the strength of silver and MAA staining o f  th e  trypsin digestion 
products in figure 5.2, lanes 4 & 5, suggests that digestion of the mucin d o m a in  has also taken 
place, and that this domain was not protected from proteolytic d ig e s t io n .  These data show, 
therefore, that under the conditions used, trypsin digestion would be an in e ff ic ien t  way to derive 
the central mucin domain of hrPRG4 from  the full-length molecule.
5.3.1.2 Digestion o f  human recombinant full-length PRG4 with chym otrypsin.
As stated in the introduction to this section, the central mucin domain o f  P R G 4  does not contain 
any aromatic amino acid residues a n d  should therefore be in su scep tib le  to chymotrypsin 
digestion. Figure 5.3 shows the separation by SDS-PAGE of reaction  m ixtures containing 
hrPRG4 and different concentrations o f  chymotrypsin. Again, reactions w e r e  incubated at 37°C 
for 2 hours, and a no enzyme (NE) control is shown in figure 5.3, lane 1. P ro teins  in the reaction 
mixture were detected by silver stain (figure 5.3A) and an immunoblot w i th  antibodies to exon 3 
and exon 12 of human PRG4 (figure 5.3B). At chymotrypsin concen tra tions  o f  20pg/ml and 
lOfig/ml (figure 5.3, lanes 2 & 3), a reduced molecular weight protein s p e c ie s  was generated that 
was visible by silver stain (figure 5.3A) but was not positive for anti- exon  3 or exon 12 antibody 
staining (figure 5.3B, lanes 2 & 3). This indicates that either the anti-exon 3 an d  12 epitopes were 
removed by digestion as predicted, or that the protein concentration w a s  to o  low for antibody 
staining. However, a reduction in the silver staining intensity of the r e d u c e d  molecular weight 
PRG4 species indicates that digestion o f  the molecule as a whole also t o o k  place, and that the 
mucin domain was not protected from digestion. A chymotrypsin c o n c e n tra t io n  o f  10pg/ml 
equates to an enzyme.substrate ratio o f  1:10 in this case.
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Figure 5.3 -  Digestion of hum an recom binan t PRG 4 with decreasing concentra tions of 
chymotrypsin. Reaction mixtures of 50pl containing 5pg PRG4 were separated by SDS-PAGE 
under reducing conditions (25pl/lane, 2.55pg PRG4/lane) and were visualised by (A) silver stain 
and (B) Western blot with the anti-exon 3 and anti-exon 12 polyclonal antibodies. A control 
reaction with no enzyme (NE) is shown in lane 1. Migration positions of molecular mass 
standards are shown to the left of the panel.
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Digestion of PRG4 as a whole also occurred at a chymotrypsin concentration o f  2(ig/ml as seen 
in figure 5.3, lane 2. In this case there was no shift in molecular weight compared with the no 
enzyme control (lane 1), but there was a reduction in silver staining intensity, which is likely to 
signify non-specific digestion of the entire PRG4 molecule rather than specific digestion o f  the 
non-mucin domains. Therefore it can be concluded that chymotrypsin digestion removes the non­
mucin domains from PRG4, as assessed by a Western blot with anti- exon 3 & 12 antibodies, but 
that it would be an inefficient way o f  generating the mucin domain o f  PRG4 for further 
experiments due to the losses that occurred under the conditions used.
5.3.1.3 Digestion of native bovine full-length PRG4 with chvmotrypsin
Chymotrypsin digestions were also performed using as a substrate bovine articular cartilage 
PRG4 purified from the conditioned media of superficial zone chondrocyte agarose cultures by 
heparin agarose affinity chromatography (see chapter 2). Figure 5.4 shows the analysis o f  
reaction mixtures containing bovine articular cartilage PRG4 and different concentrations of 
chymotrypsin where reactions were incubated at 37°C for 2 hours, and a no enzyme (NE) control 
is shown in figure 5.4, lane 1. Proteins in the reaction mixture were separated by SDS-PAGE and 
detected by silver stain (figure 5.4A) and a Western blot with the monoclonal antibody 6-A-l 
(figure 5.4B). At chymotrypsin concentrations of 2()ug/ml and 10pg/ml, a reduced molecular 
weight catabolite was apparent by silver stain (figure 5.4A, lanes 2 & 3), although intensity of 
staining was greatly reduced compared to the no enzyme control, signifying that as in the 
chymotrypsin experiments with hrPRG4, digestion of the molecule as a whole took place.
These catabolites were negative for staining with the antibody 6-A -l, which has been purported 
to have a recognition epitope in the non-mucin C-terminal domain o f  bovine PRG4 (Schumacher 
et al., 1999). However, this may be due to low overall protein concentration. Another catabolite 
was observed after digestion with a chymotrypsin concentration o f  2.0p,g/ml (figure 5.4A, lane 4) 
that was of a higher molecular weight and silver stain intensity than the catabolites seen in lanes 
2 & 3. This catabolite was also negative for 6 -A -l . and this is less likely to be due to low protein 
concentration than for the catabolites seen in lanes 2 Si 3, which suggests that the C-terminal 
domain o f  bovine PRG4 has been digested.
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Figure 5.4 -  Digestion of bovine articu lar cartilage PRG4 with decreasing co n cen tra t io n s  of 
chymotrypsin. Reaction mixtures of 50pl containing 2.5pg PRG4 were separated by SDS-PAGE 
under reducing conditions (25pl/lane, 1.25pg PRG4/lane) and were visualised by (A) silver stain 
and (B) Western blot with the monoclonal antibody 6-A-l. A control reaction with no enzym e 
(NE) is shown in lane 1. Migration positions of molecular mass standards are shown to the left of 
the panel.
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Therefore, similarly to the chymotrypsin digestion experiments with human recombinant full- 
length PRG4, it can be concluded that digestion of the non-mucin domains o f  bovine PRG4 is 
effected by chymotrypsin, but that digestion of the molecule as a whole also takes place, making 
chymotrypsin digestion an inefficient method for the production of the central mucin domain of 
bovine articular cartilage PRG4.
$.3.2 Identification o f  physiologically relevant proteinases capable o f  degrading full-length  
PRG4
The susceptibility o f  full-length human recombinant and bovine articular cartilage PRG4 to 
digestion within the synovial joint was investigated by performing in vitro digests o f  purified 
preparations o f  full-length PRG4 (chapter 2) with a panel o f  physiologically relevant proteinases. 
These digests were conducted overnight, and the enzyme concentrations used was predicted to be 
concentrations that would facilitate complete digestion of a substrate based on information from 
the individual enzyme suppliers.
5.3.2.1 Identification o f  proteinases capable of degrading human recombinant full-length PRG4  
A number o f  preliminary digestions o f  full-length human recombinant PRG4 (hrPRG4) were 
conducted, using a panel o f  proteinases o f  potential physiological relevance. These results are 
summarised in table 5.3.
Table 5.3 -  Results o f  preliminary hrPRG4 digestion experiments, where 40pg hrPRG4 was 
included in a lOOpl reaction with enzymes at the concentrations shown. The table indicates if
hrPRG4 was digested (+) or undigested (-).
Enzyme C oncentration H rPRG 4 digestion
Cathepsin B 0 51' ml t
Cathepsin D 0 5U ml
Elastase 0.2U ml »
MMP-7 10ug/ ml *
Plasmin 0.2 U/ml ♦
ADAMTS-4 9.3pg/m l -
ADAMTS-5 1 Sug/ml -
Calpain lug/m l -
MMP-1 5pg/m l -
MMP-2 5ng/ml -
MMP-3 10ng/ml -
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For these experiments, 40pg of purified hrPRG4 was incubated in a lOOpl reaction with a fixed 
concentration o f  each enzyme at 37°C for 16 hours. Reaction mixtures were separated by 
electrophoresis on SDS-PAGE gradient gels under reducing conditions, and catabolites were 
identified by silver stain. Western blot with the antibody 06A10, or affinity blot with the lectin 
MAA, which recognises the oligosaccharide side chains substituted on full-length PRG4 (chapter 
2, figure 2.10).
As listed in table 5.3, digestion of the hrPRG4 substrate was observed with cathepsin B, 
cathepsin D, elastase, MMP-7 and plasmin, and SDS-PAGE analyses o f  these reactions are 
shown in figures 5.5 and 5.6. No digestion o f  hrPRG4 was observed with ADAM TS-4, 
ADAMTS-5, calpain, MMP-1, MMP-2 or MMP-3, and these data are not shown. With these 
enzymes, the electrophoretic mobility and the antibody staining intensity o f  PRG4 was not 
discemibly altered.
Figure 5.5 shows SDS-PAGE analyses o f  hrPRG4 after digestion by cathepsin B (figure 5.5B) 
and cathepsin D (figure 5.5C). A no enzyme control reaction is shown in figure 5.5A, and PRG4 
was identified in each case by silver stain and Western blot with the antibody 06A10, a 
polyclonal antibody raised against purified human PRG4. Silver stain analysis of an enzyme only 
reaction is shown in each panel in order to evaluate the contribution o f the enzyme preparations 
to the overall protein staining pattern. Complete digestion o f  the hrPRG4 substrate was observed 
with cathepsin B (figure 5.5B), as no protein was apparent with either silver stain or Western 
blot. Digestion o f  hrPRG4 by cathepsin D was less comprehensive (figure 5.5C). No shift in 
electrophoretic mobility was observed by silver staining, although intensity was reduced. 
Antibody binding was considerably reduced, suggesting an alteration in the 06A10 antibody 
recognition epitope.
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Figure 5.5 -  Analysis of human recom binant PRG4 proteinase digestion reactions 
including (A) no enzyme, (B) cathepsin B or (C ) cathepsin D. Reactions (40pg/100pl 
reaction) were subjected to SDS-PAGE under reducing conditions (20pg/lane) and were 
visualised by silver stain and Western blot with the polyclonal antibody 06A10. The 
enzyme concentrations used are listed in table 5.2, and no substrate (enzym e only) 
control reactions are shown for each enzyme after silver staining. The migration positions 
of molecular mass standards are shown to the left o f  each panel.
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Figure 5.6 shows SDS-PAGE analyses o f  digestion reactions including hrPRG4 substrate and 
elastase (Figure 5.6B) MMP-7 (Figure 5.6C) or plasinin (figure 5.6D). Again, a no enzyme control 
reaction is shown in Figure 5.6A, and PRG4 was identiFied in each case by silver stain and either 
Western blot with the antibody 06A10 or a lectin affinity blot using MAA. Silver stain analyses 
of reactions performed in the absence o f hrPRG4 substrate are shown to the right o f  each panel. 
Complete digestion o f hrPRG4 was observed with elastase (Figure 5.6B). Digestion o f  hrPRG4 
with MMP-7 (Figure 5.6C) generated a catabolite o f -2 8 0  kDa that was visible by silver staining. 
No intact hrPRG4 remained in this reaction, a loss in 06A 10 antibody binding was observed. 
Plasmin digestion (Figure 5.6D) generated a hrPRG4 catabolite with a slightly reduced molecular 
weight, although much o f  the PRG4 was digested based on the reduction in silver stain intensity 
and the large reduction in 06A10 antibody staining intensity.
In the preliminary experiments shown in Figures 5.5 and 5.6, cathepsin B and plasmin appeared to 
digest hrPRG4. Further digestions with these enzym es were conducted where hrPRG4 was 
incubated with decreasing concentrations o f  proteinase, and a shorter incubation period o f  2 
hours was used. Reactions o f  50pl were separated by SDS-PAGE under reducing conditions and 
were analysed by silver stain and Western blot with antibodies specific to the non-mucin domains 
of PRG4, the polyclonal antibodies anti-exon 3 and anti-exon 12 (Wyeth). The results can be 
seen in Figure 5.7, where 5.7A is a silver stain and 5TB is a Western blot. A control reaction that 
contained no enzyme is shown in lane 1.
Digestion with a cathepsin B concentration o f 0.2U/ml (Figure 5.7, lane 2) resulted in a PRG4 
catabolite o f  reduced m olecular w eight ( -3 0 0  kDa) that was apparent by silver stain. 
Interestingly, this catabolite was not visible with antibodies directed towards sequences in exon 3 
and exon 12 (Figure 5.7B, lane 2), and two lower molecular weight catabolites ( -2 5  kDa) are 
immunopositive for these antibodies. This suggests that limited cathepsin B digestion removes 
non-mucin domains from hrPRG4. Digestion with higher concentrations o f  plasmin (Figure 5.7, 
lanes 5-9) resulted in a reduction in silver staining intensity with a slight reduction in 
electrophoretic mobility, although the relatively huge mass ot hrPRG4 makes it difficult to assess 
small changes in electrophoretic mobility on a gradient polyacrylamide gel.
168
250 kDa
150 kDa
No enzyme
©
< 3  S <
« <  I § | ACL J  Z  M
N S I
MMP-7
250 kDa -
150 kDa _
B.
250 kDa _  
150 kDa _
D.
Elastase
= <  I
C/5 to Z  to
S3 , > 5
250 kDa -  
150 kDa _|
Plasmin
%
°  I
> 5 <
a S  8 1  i t
12 13 14
Figure 5.6 -  Analysis of human recom binant PRG4 proteinase digestion reactions 
including (A) no enzyme, (B) elastase, (C ) MMP-7 or (D) plasmin. R eaction s  
(40pg/reaction) were subjected to SDS-PAGE under reducing conditions (20|Lig/lane) and 
were visualised by silver stain. PRG4 was identified either by MAA lectin affinity blot or 
a Western blot with the polyclonal antibody 06A 10. The enzyme concentrations used are 
listed in table 5.2, and no substrate (enzyme only) control reactions are shown for each 
enzyme after silver staining. The control reaction is duplicated from figure 5.5. The 
migration positions o f  molecular mass standards are shown to the left o f  each panel.
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Figure 5.7 -  A nalysis of hum an recom binant PRG4 proteinase digestion reactions 
with decreasing  concen tra tions of cathepsin B or plasmin. Reactions (5pg/50p l 
reaction) w ere incubated for 2 hours and subjected to SDS-PAGE under reducing 
conditions (2 .5p g /lan e). Total protein was visualised by silver stain (A). PRG4 was 
identified by W estern blotting with polyclonal antibodies to sequences within exon 3 and 
exon 12 o f  human PRG4. A no enzyme (NE) control reaction is shown on the left. The 
migration positions o f  molecular mass standards are shown to the left.
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Interestingly, a loss o f staining in the W estern blot with antibodies to exon 3 and exon 12 
signifies that the remaining PRG4 species does not contain these domains. Catabolites containing 
these epitopes can be seen towards the bottom o f  the gel, running at around 20 kDa. Taken 
together, these results suggest that limited digestion o f  hrPRG4 by cathepsin B or plasmin may be 
a useful method for deriving different structural domains from a full-length PRG4 molecule.
53.2.2 Digestion o f  native full-length PRO 4 from  bovine articular cartilage with cathepsin B and  
plasmin
Bovine PRG4 was partially purified from the conditioned m edium  o f  superficial zone 
chondrocyte agarose cultures as described in chapter 2. This material was then subjected to 
digestion experiments with decreasing amounts o f cathepsin B and plasmin, with an incubation 
time of 2 hours at 37°C The reaction mixtures were separated as before and can be seen in figure 
5 8, visualised by silver stain (5.8A) and W estern blot with the monoclonal antibody 6-A -l 
(5.8B). A negative control is shown to the left (lane 1). At a cathepsin B concentration o f 
0 2U/ml (figure 5.8, lane 2), there was a shift in the electrophoretic mobility o f PRG4 to around 
300 kDa and a concom itant loss o f 6-A -l im m unoreactivity. However, two 6-A -l positive 
catabolites o f around 100 kDa and 60 kDa w ere generated. Amino acid sequencing o f  these 
catabolites could be useful in the epitope-mapping o f 6-A -l. At lower cathepsin B concentrations 
(figure 5.8, lanes 3-5) digestion o f bovPRG4 was less comprehensive, and the 60 kDa catabolite 
predominates over the 100 kDa species (figure 5.8B, lanes 3-5).
Digestion o f bovPRG4 with a plasmin concentration o f 0.2U/ml (figure 5.8, lane 2) resulted in a 
reduced molecular weight catabolite o f -3 0 0  kDa that displays a reduction in silver staining 
intensity. This catabolite is not positive for 6-A -l (figure 5.8B). This could be due to the amount 
of protein being too small, or the lack o f 6-A -l epitope within the catabolite. Interestingly, a 
catabolite o f -6 0  kDa is generated that was detected by 6-A -l (lanes 3 & 4), though this too is 
degraded by plasmin a 0 2U/ml (lane 4). In general, digestion o f bovPRG4 with decreasing 
concentrations o f cathepsin B and plasmin (figure 5.8) resulted in a similar pattern to that seen 
when hrPRG4 was digested by cathepsin B and plasmin (figure 5.7).
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Figure 5.8 -  Analysis of bovine a rticu la r cartilage PRG4 proteinase digestion reactions with 
decreasing concentrations of cathepsin B o r plasm in. Reactions (2.5pg total protein/50pl 
reaction) were incubated for 2 hours and subjected to SDS-PAGE under reducing conditions 
(1.25pg/lane). Total protein was visualised by silver stain (A). PRG4 was identified by Western 
blotting with the monoclonal antibody 6-A-l. A no enzyme (NE) control reaction is shown on the 
left. The migration positions o f molecular mass standards are shown to the left.
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5.3.3 In vitro proteinase digestion o f  recombinant PRG4 structural domains
So far this chapter has d o cu m en ted  th e  in vitro  digestion o f full-length PRG4 by a num ber o f  
proteinases, and the o ccu rrence  o f  lo w er m olecular weight PRG4 catabolites as a result o f  these 
digestions. The action o f  th ese  p ro te in ases  on PRG4 was investigated further by utilising 
recombinant PRG4 structura l d o m ain s  in sim ilar in vitro digestion experiments. The cloning, 
expression and purification o f  recom binan t human N-terminal PRG4 (exons 2-5) and bovine C- 
terminal PRG4 (exons 7 -12) dom ains is detailed in chapter 3 o f this study. Purified recombinant 
human N-terminal (H um N ) and b o v in e  C-terminal (BovC) domains were utilised in proteinase 
digestion experiments w ith  d ifferent am ounts o f  enzyme and constant amounts o f PRG4 domain 
substrate D igests w ere perfo rm ed  in  a sim ilar m anner to the experim ents with hrPRG4 and 
bovPRG4 described e a r lie r  in th is  chapter, w ith an incubation time o f 2 hours at 37°C . 
Recombinant human N -te rm in a l do m ain  (H um N ) was purified by FLAG im m noaffinity 
chromatography and h ep arin -agarose  affinity chromatography to yield one protein species that 
runs at -27  kDa on an S D S -PA G E  gel under reducing conditions. It should be borne in mind that 
the FLA G-purified re c o m b in an t C -te rm ina l dom ain o f  bovine PRG4 (BovC) preparation 
described in chapters 3 and  4 co n ta in s  two protein species. There is a species o f around 20 kDa, 
BovCl, which is negative for stain ing  with an antibody to exon 12 o f human PRG4, and a 12 kDa 
species, BovC2, which is im m unopositive  for anti-exon 12. It was concluded (see chapter 3) that 
BovCl contains exons 7, 8, 9 and p a rt o f  exon 10, whereas BovC2 contains the rem ainder o f  
exon 10 plus exons 11 and  12.
5.3.3.1 Digestion o f  recom binan t P R (j 4 domains with leukocyte elastase
Aliquots o f human reco m b in an t N -term inal PRG4 domain (HumN) and bovine recom binant C- 
terminal PRG4 dom ain (B o v C ) w e re  digested with decreasing amounts o f  elastase (2.0 -  
0.2U/ml) at 37°C for 2 hours. S im ila r to all the results described in this section, the reaction 
mixtures were separated by S D S -P A G E  and were visualised by silver stain and W estern blot with 
an anti-exon 3 antibody for H um N , o r  an anti-exon 12 polyclonal antibody for BovC (B). There 
appeared to be no ap p aren t d ig e s tio n  o f  HumN with different amounts o f elastase under the 
conditions used, as both silver stain  and  W estern blot (anti-exon 3) intensities were not reduced 
in comparison with an undigested  contro l (data not shown). It may be that the digestion o f  PRG4 
domains by elastase requires a longer incubation period than other proteinases used in this study.
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As seen in figure 5 .9, digestion o f BovC with higher amounts o f elastase reduced the intensity o f 
the 20 kDa BovCl band in comparison to undigested BovCl (figure 5.9, lanes 1-3) as viewed by 
silver staining, and resulted in a BovC2 catabolite o f  around 10 kDa (lanes 8 & 9) This 
demonstrates the sensitivity o f the C-terminal o f  PRG4 to digestion by elastase.
5.3.3.2 Digestion o f  recombinant PRC/4 domains wuh cathepsin B
Figure 5 10 shows the digestion o f human recombinant N-terminal PRG4 domain (HumN) with 
decreasing concentrations o f cathepsin B. At a cathepsin B concentration o f 0.2U/ml (figure 5.10, 
lane 2) an exon 3-containing catabolite o f around 22 kDa is generated. At lower concentrations o f 
cathepsin B, HumN appears to be undigested and appears to be similar to the undigested control 
in lane 1
The results from digestion o f bovine recom binant C-term inal PRG4 domain (BovC) with 
decreasing concentrations o f cathepsin B is shown in figure 5.11. Digestion o f BovC at higher 
concentrations o f cathepsin B appeared to digest the two protein species as seen in figure 5.11, 
lane 2 Silver stain and Western blot intensity are both reduced in comparison to the undigested 
control in lane 1.
53.3.3 Digestion o f  recombinant PRC} 4 domains with plasmin
Figure 5.12 shows the digestion o f human recombinant N-terminal PRG4 domain (HumN, figure 
5.12A) and bovine recombinant C-terminal PRG4 domain (BovC, figure 5.12B) with decreasing 
concentrations o f plasmin. At plasmin concentrations o f 0.2 and 0.1 U/ml (figure 5.12, lanes 2 
and 3), a HumN catabolite was produced o f around 17 kDa that contains the epitope recognised 
by the anti-exon 3 antibody. This is accompanied by the loss o f the 27 kDa species as viewed by 
both silver staining and W estern blot with an anti-exon 3 antibody. H igher plasm in 
concentrations also resulted in increasing digestion o f the 20 kDa BovCl species as seen in 
5.12B, lanes 7 and 8, where three species are visible by silver stain. Higher concentrations o f 
plasmin also appear to reduce the anti-exon 12 antibody staining intensity o f BovC compared to 
the undigested control (figure 5.12B).
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Figure 5.9 -  Analysis of recom binant bovine C -term inal PRG4 dom ain a fte r digestion w ith
decreasing am ounts o f elastase. Reactions containing approximately 2.5pg PRG4 dom ain/50pl 
were incubated at 37°C for 2 hours. Reaction mixtures were separated by SDS-PAGE under 
reducing conditions ( 1.25pg/lane) and were visualised by silver stain (A) and Western blot with a 
polyclonal antibody to exon 12 o f human PRG4 (B). A control reaction showing undigested 
bovine C-terminal domain is shown in lane 1(NE = no enzyme). Migration positions o f m olecular 
mass standards are shown to the left.
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Figure 5.10 — A n a ly sis  o f recom binan t hum an  N -term inal PRG4 dom ain  a f te r  d igestion  
with d e c re a s in g  a m o u n ts  of cathepsin  B. Reactions containing approxim ately 2.5pg PRG4 
domain/50pl w ere  incubated at 37°C for 2 hours. Reaction mixtures were separated by SDS- 
PAGE under reducing  conditions (1 25pg/lane) and were visualised by silver stain (A) and 
Western blot w ith  a polyclonal antibody to exon 3 o f human PRG4 (B). A control reaction 
showing undigested bovine C-terminal domain is shown in lane 1(NE = no enzyme). M igration 
positions o f  m olecular mass standards are shown to the left.
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Figure 5.11 -  Analysis of recom binant bovine C -term inal PRG4 dom ain a f te r  d igestion  with
decreasing am oun ts  o f ca thepsin  B. Reactions containing approxim ately  2 .5pg  PRG4 
domain/50pl were incubated at 37°C for 2 hours. Reaction mixtures were separated  by SDS- 
PAGE under reducing conditions (1 25pg/lane) and were visualised by silver stain (A ) and 
Western blot with a polyclonal antibody to exon 12 o f human PRG4 (B). A  control reaction 
showing undigested bovine C-terminal domain is shown in lane 1(NE = no enzym e). M igration 
positions of molecular mass standards are shown to the left.
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Figure 5.12 — Analysis of recom binan t hum an N -term inal (A) and bovine C -te rm in a l (B) 
PRG4 d o m a in s  a fte r digestion w ith decreasing  am ounts of plasm in. Reactions containing 
approximately 2.5pg PRG4 domain/50pl were incubated at 37°C for 2 hours. Reaction mixtures 
were separated by SDS-PAGE under reducing conditions (1.25pg/lane) and visualised by silver 
stain and W estern blot with a polyclonal antibodies to either exon 3 (A) or exon 12 (B) o f human 
PRG4. A control reaction showing undigested human PRG4 N-terminal domain is shown in lane 
1, undigested bovine C-terminal domain is shown in lane 6. Migration positions o f m olecular 
mass standards are shown to the left.
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It should be pointed out that the bands apparent by silver staining marked by arrows in figure 
5.12A are present in both H um N  and B ovC  digestions as viewed by silver stain, and their 
intensity increases with increased plasmin concentration. It is likely that these protein species are 
present in the plasmin preparation. The listed molecular weight o f plasmin is 92 kDa.
5.3.3.4 Digestion o f  recom binant }>R(i4  dom ains with chymotrypsin
Figure 5.13 shows the digestion o f human recom binant N-terminal PRG4 domain (HumN, figure 
5.13A) and bovine recom binant C-term inal PRG4 domain (BovC, figure 5.13B) with decreasing 
concentrations o f chymotrypsin. Although chym otrypsin is not particularly relevant as a potential 
candidate for the proteolysis o f  PRG4 in vivo , it was used to see if  any interesting catabolites 
were derived from the PRG4 domains that could be used to further characterise the recombinant 
proteins The reaction m ixtures were separated by SDS-PAGE on 15% gels and visualised by 
silver stain or W estern b lot with an anti-exon 3 or an anti-exon 12 polyclonal antibody. As 
expected, higher concentrations o f  chym otrypsin resulted in fragmentation o f  HumN and BovC 
over the concentration range used in this experim ent, as assessed by loss o f antibody epitopes. 
BovCl (20 kDa) was undigested at a chym otrypsin concentration o f 0.2 pg/ml (figure 5.13, lane 
10) but increasingly low er m olecular w eight forms were produced using chym otrypsin  
concentrations o f 2 0 and 10 pg/ml. A 10 kDa BovC2 catabolite is generated, though this too is 
further degraded by higher chym otrypsin concentrations.
5.4 Discussion
One of the aims o f  this sec tion  o f experim ental work was to enzymatically digest native or 
recombinant PRG4 to generate  different structural domains, such as the central mucin dom ain 
and the N- and C -term inal v itro nec tin -like  domains. This would enable studies on the 
contribution o f  these dom ains on the functionality  o f PRG4: the lubricating function o f  the 
central mucin domain has been  investigated (Jay et al.y 2001a), but as yet there have been no 
studies concerning the functions o f  the vitronectin-like domains either side o f the mucin domain. 
Trypsin and chymotrypsin digestions o f hum an recombinant and bovine native full-length PRG4 
were carried out, using increasing  concentrations of enzym e with a fixed concentration o f  
substrate over a 2 hour incubation period.
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Figure 5.13 -  Analysis of recom binant hum an N -term inal (A) and bovine C -term inal (B) 
PRG4 dom ains a fte r digestion with decreasing am ounts of chym otrypsin. Reactions 
containing approximately 2.5pg PRG4 domain/50pl were incubated at 37°C for 2 hours. 
Reaction mixtures were separated by SDS-PAGE under reducing conditions (1.25|jig/lane) and 
visualised by silver stain and Western blot with a polyclonal antibodies to either exon 3 (A) or 
exon 12 (B) of human PRG4. A control reaction showing undigested human PRG4 N-terminal 
domain is shown in lane 1, undigested bovine C-terminal domain is shown in lane 6. Migration 
positions of molecular mass standards are shown to the left.
t
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Limited digestions with trypsin (figure 5.3) yielded PRG4 catabolites with slightly reduced 
molecular weights, but these catabolites were present in small am ounts com pared with the 
starting material, based on silver staining intensities and lectin affinity blotting. This would 
suggest that whilst steric hindrance by oligosaccharides protected the m ucin-like dom ain o f  
PRG4 from digestion to some extent, fragm entation o f  PRG4 took place throughout the 
molecule Therefore under the conditions used, trypsin digestion was not an efficient method for 
the generation o f PRG4-domains lacking the N- and C-terminal vitronectin-like domains.
Chymotrypsin digestion would theoretically leave the central exon 6 region intact as no aromatic 
residues exist within it Digestion o f human (figure 5.4) and bovine (figure 5.6) full-length PRG4 
with increasing amounts o f chymotrypsin generated PRG4 catabolites o f approximately 275-300 
kDa, suggesting that removal o f the non-mucin dom ains had taken place. However, the overall 
protein losses during digestion as assessed by silver staining suggests that there was significant 
digestion o f the molecule as a whole Thus, as with trypsin, chym otrypsin digestion did not 
constitute an efficient method o f generating the mucin domain o f PRG4 under the conditions 
used. Future experiments could be conducted in the presence o f leupeptin and aprotinin, which 
would rule out the possibility that the commercial TLCK treatment o f chymotrypsin incompletely 
inactivated contaminating trypsin in the enzyme preparation. Chymotrypsin digestions o f  human 
recombinant N-terminal PRG4 (H um N ) and bovine recom binant C-term inal PRG4 (B ovC ) 
resulted in fragmentation o f the recombinant proteins.
The other aim o f  this section was to assess the susceptibility o f PRG4 to d igestion by 
physiologically relevant enzym es found within the synovial joint. This was carried out by 
performing in vitro digests with PRG4 from a number o f  sources: full-length human recom binant 
and bovine native PRG4 (chapter 2) and recombinant human N- and bovine C-terminal domains 
(chapter 3). Articular cartilage chondrocytes are reported to secrete MMPs, serine and cysteine 
proteinases, with enzyme activities increased in OA (for a review, see Sandell & Aigner, 2001).
As seen in figure 5.6, elastase appeared to completely digest hrPRG4 under the conditions used. 
It is possible that digestion by elastase may be directed towards exon 6, acting on the bond 
between alanine and proline within the degenerate repeating sequence o f KEPAPTT (Jay et al. ,
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2004). This hypothesis is supported by observations in this study, where full-length human 
recombinant PRG4 was completely digested by elastase. Neutrophil elastase is gaining credence 
as a candidate enzyme for the removal o f  the lubricating ability o f  synovial fluid via the removal 
of lubricin. The lubricating ability of lubricin has been shown to be labile in the presence o f  small 
amounts o f elastase (Jay, 1992), and serine proteinases such as elastase are thought to play an 
important role during tissue inflammation (for a review  see Hiemstra, 2002). A recent study has 
found an association between nucleated cell count and loss o f  lubricating ability in synovial fluid 
aspirated from patients with knee jo in t synovitis, which led the authors to suggest that the 
destruction o f  lubricin may be mediated by neutrophil elastase (Jay ct al., 2004). In experiments 
with stimulated human neutrophils, elastase was found to be the enzym e that was most relevant 
in cartilage degradation (Hilbert ct al., 2002), Levels o f  neutrophil elastase are elevated in the 
synovial fluid o f  RA cases as opposed to OA cases (M ohom ara ct a l., 1997), and high elastase 
activity has been found in the synovial fluid o f  patients with RA and non-infectious knee jo in t 
synovitis (Elsaid ct al., 2003) Another phenomenon that supports the hypothesis that the surface 
of articular cartilage is perturbed by neutrophil elastase is the reactivity o f  type II collagen 
antibodies with the articular surface following after in vitro treatm ent with elastase (Noyori et al., 
1994a). In other studies, the augm entation in type II collagen antibody reactiv ity  w ith the 
articular surface is inhibited by the non-specific serine-esterase inhibitor PM SF, but not by the 
divalent metal chelator EDTA, whilst the elastase-specific inhibitor AAPVCM K also inhibited 
most of the PM N-induced increase in antibody binding (Jasin & Taurog, 1991). It is assum ed that 
elastase, because o f  its comparatively low m olecular weight o f -3 2  kDa, penetrates into cartilage 
to smooth the way for enzymes o f higher m olecular weights such as collagenase (Starkey et al., 
1977). The infiltration o f jo in t tissues by elastase-producing  polym orphonuclear neutrophil 
leukocytes (PMN) is a prominent feature o f jo in t disease, particularly in RA (Edw ards & Hallett, 
1997). A recent study (Mitani ct al., 2001) has shown that PM N do not adhere to intact articular 
cartilage surfaces, whereas PMN adhesion occurs with cartilage explants digested with elastase 
and reconstituted with fibronectin. The study also dem onstrated that PMN adhesion to plastic- 
bound fibronectin can be inhibited by a num ber o f  cartilage m acrom olecules, which would 
suggest that macromolecules normally present on the surface o f  articular cartilage act as a barrier 
against PMN adhesion PRG4 may be part o f  this surface barrier and its degradation by elastase, 
shown in vitro in this study, could be partly responsible for an increase in PMN adhesion and the
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associated cartilage damage in inflammatory arthritis. At present, very little is known regarding 
the potential ability o f  PRG4 to act as a barrier at the cartilage surface. It has been speculated 
(Flannery et al., 1999) that the inhibition o f cartilage PRG4 biosynthesis by EL-1 would remove 
the protective functions o f the molecule, and may explain why, in rheumatoid arthritis, the 
proliferating synovial pannus can eventually invade the articular cartilage surface. Enzymatic 
degradation of PRG4 by elastase, which this study has shown is a possibility, may participate in 
this process.
PRG4 (both full-length and recombinant domains) was also found to be susceptible to plasmin, a 
serine proteinase that is upregulated in osteoarthritic cartilage (Martel-Pelletier et al., 1991). 
Serine proteinases such as plasmin are also involved in the activation of proMMPs, although the 
interplay between them is unclear (Cawston & Rowan, 2002).
MMP-7 degrades hrPRG4 producing a catabolite of around 275 kDa. MMP-7, also known as 
matrilysin, is believed to degrade components o f the extracellular matrix during tissue 
remodelling, and is reviewed in (W ilson & Matrisian, 1996). Among its substrates are 
fibronectin, type IV collagen, tenascin C, aggrecan and cartilage link protein. In osteoarthritic 
cartilage MMP-7 appears to be upregulated at the mRNA level, and immunohistochemistry has 
demonstrated its localisation to OA chondrocytes in the superficial and transitional zones (Ohta 
et a l, 1998). This would suggest that MMP-7 may play a role in the degradation o f ECM 
macromolecules in OA cartilage, and PRG4 may be a substrate at the superficial zone of articular 
cartilage. Other data concerning MMP-7 in cartilage is less conclusive. A recent study detected 
MMP-7 mRNA in tibial articular chondrocytes in the STR/ort mouse model o f OA but failed to 
detect protein expression (Flanelly et al., 2002). A study o f the MMP content of synovial fluid 
aspirated from OA and RA patients detected MMP-7 in 45% o f RA patients and 20% of OA 
patients (Yoshihara et al., 2000). The activation status o f cartilage and synovial fluid MMP-7 is 
unclear, but this study has demonstrated that PRG4 is sensitive to digestion in vitro by MMP-7.
This study found no evidence to suggest that PRG4 is sensitive to degradation by calpain. 
Calpains (calcium-dependent cysteine proteinases) have been regarded as intracellular 
proteinases, but the presence o f calpain in osteoarthritic synovial fluid has been documented,
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together with its endogenous inhibitor calpastatin (Suzuki et a l , 1990). The calpain found in OA 
synovial fluid demonstrated proteoglycan-degrading activity, and so its potential for PRG4 
proteolysis was investigated here. The extracellular appearance o f  calpain may be due to its 
secretion by synovial cells, and calpains may play a role in the cartilage damage associated with 
RA and OA (Yamamoto et a l , 1992).
Human recombinant and bovine native PRG4 appear to be sensitive to degradation by cathepsin 
B, and in the case o f  native bovine articular cartilage PRG4 a number o f 6-A -l-positive 
catabolites are generated (figure 5.8). Sequencing o f  these catabolites may be useful in 
determining the epitope recognised by 6-A -l. The N- and C-terminal domains o f  PRG4 do not 
appear to be susceptible to digestion by cathepsin B. Cathepsin B, a  cysteine proteinase (for a 
review see M ort & Buttle, 1997), may play a role during aggrecan breakdown (Fosang et a l ,  
1992) and has been proposed as an alternate enzym e for the generation o f  an aggrecan 
‘metalloproteinase’ cleavage neoepitope (Mort et a l ,  1998). Levels o f  cathepsin B are increased 
in human osteoarthritic cartilage as compared with normal tissue (Lang et a l ,  2000). Cysteine 
proteases, along with elastase, have been found in increased levels in the synovial fluid o f 
patients with inflammatory arthritis (Huet et a l ,  1992).
These results demonstrate that PRG4 is susceptible to proteolytic digestion by a number o f matrix 
proteinases, including matrix metalloproteinases (MMP-7), serine proteinases (elastase, plasmin) 
and cysteine proteinases (cathepsins B & D). However, the limitations o f this work in the context 
o f in vitro studies are that (i) not all o f the enzymes shown to be capable o f degrading PRG4 in 
preliminary experiments were used in fully titrated digestion experiments, and (ii) the full range 
o f PRG4-specific antibodies need to be used individually in order to identify and characterise 
PRG4 catabolites. A full range o f digestion experiments investigating the effects o f altering the 
variables o f  enzyme concentration, substrate concentration and incubation time would provide a 
fuller picture o f the effects o f various matrix proteinases on cartilage PRG4. Also, it would be 
reductionist to assume that these digests represent the situation in vivo within a normal or 
inflamed synovial jo in t, as these are in vitro  digests, prelim inary in nature, w ith non- 
physiological concentrations o f substrate and enzyme. Investigations into the breakdown o f 
matrix molecules can lead towards a greater understanding o f  the events leading up to and
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including cartilage degradation during inflammatory joint diseases, as seen with extensive studies 
with relatively clearly defined matrix molecules such as aggrecan (Caterson et al. , 2000). 
However, the role o f PRG4 in healthy and diseased tissue is unclear. Matrix proteinase-mediated 
catabolism o f PRG4 could affect the functionality o f the molecule, thereby compromising the 
integrity and normal function o f the surface o f articular cartilage. The results presented in this 
chapter is preliminary data that demonstrates the sensitivity of PRG4 to digestion by certain 
enzymes, and catabolites produced in some instances may be useful in other applications. For 
example, sequenced catabolites could be used in the epitope mapping o f existing PRG4 
antibodies, in the production o f novel antibodies, or in functional studies.
5.5 Chapter Summary
• Contrary to predictions, tryspsin and chymotrypsin digestion o f full-length PRG4 
substrate did not prove to be effective methods for the generation o f the PRG4 central 
mucin domain
• Full-length human recombinant PRG4 appeared to be susceptible to proteolytic digestion 
by the proteinases cathepsin B, cathepsin D, elastase and MMP-7.
• In preliminary experiments, full-length bovine articular cartilage PRG4 was also 
susceptible to digestion by plasmin and cathepsin B.
• Recombinant PRG4 N-terminal and C-terminal domains are digested by plasmin and 
cathepsin B.
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6 . FUNCTIONAL ANALYSIS OF RECOM BINANT PRG4 DOMAINS
6.1 Introduction
Sequence analyses o f cartilage PRG4 have indicated that it is a multidomain protein with the 
potential for a number o f functions including lubrication, cytoprotection, matrix-binding, cell 
proliferation and self-aggregation (Flannery et al., 1999). Chapter 3 describes the cloning, 
expression and purification o f the non-mucin N-terminal and C-terminal dom ains o f  PRG4, 
which bear similarities to vitronectin and may possess a number o f  functions. For example, the 
N-terminal portion o f MSF precursor protein (PRG4) has been shown to have cell proliferative 
effects (Merberg et al., 1993). The somatomedin B-like domains in exons 2 and 3 o f PRG4 are 
similar to the somatomedin B domain o f vitronectin, which has been implicated in the binding o f 
the serpin PAI-1 (Seiffert & Loskutoff, 1991). The C-terminal domain o f  PRG4 contains a 
haemopexin-type domain and an uneven number o f cysteine residues that could mediate PRG4 
self-aggregation and facilitate the trapping o f the molecule at the interface between cartilage and 
the synovial cavity (Flannery et al., 1999). Truncations in the C-terminal o f  PRG4 associated 
with CACP syndrome (M arcelino et al., 1999) may result in PRG4 molecules w ith reduced 
functional capability. The aim o f this work was to characterise purified recom binant PRG4 
domains and utilising them in assays to investigate some o f  the potential functions o f  the 
molecule. In this chapter, experiments were performed to assay the binding o f recombinant PRG4 
domains to structural and functional extracellular matrix proteins and also to chondrocytes.
6.2 Materials & Methods
6.2.1 Materials
All chemicals were o f an analytical grade and were purchased from Sigm a-Aldrich unless 
indicated otherwise. A detailed list o f the m aterials used in this research project and their 
suppliers is listed in Appendix A. The candidate binding proteins used are listed in table 6.1. 
Mutant PAI-1 incorporates four am ino acid m utations to ensure structural stability for an 
extended period o f time (Berkenpas et al., 1995).
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6.2.1.1 Preparation o f  recombinant proteins
Human and bovine recombinant N-terminal PRG4 domains (HumN & BovN) were produced and 
purified as described in Chapters 3 & 4 o f this study. W here H um N l/B ovN l and HumN2/BovN2 
species were used separately, heparin-agarose affinity chromatography was used to separate the 
two species following FLAG immunoafTmity chromatography. Recombinant bovine C-terminal 
PRG4 domain was purified by FLAG immunoaffinity chromatography as described in chapters 3 
&4, and included the 20 kDa and 12 kDa species.
Table 6.1 -  Candidate binding proteins
Protein Abbreviation Source
Plasminogen Activator Inhibitor-1 PAI-1 Calbiochem , San D iego, CA
Human fibronectin, 70 kDa proteolytic fragment Fn-70 Sigm a-Aldrich, UK
Human fibronectin, 45 kDa proteolytic fragment Fn-45 Sigm a-Aldrich, UK
Human fibronectin, 30 kDa proteolytic fragment Fn-30 Sigm a-Aldrich, UK
Bovine fibronectin, full-length Bov-Fn Sigm a-Aldrich, UK
Human vitronectin Hum-Vn Sigm a-Aldrich, UK
Type II collagen, from bovine articular cartilage Type II Coll Prof. V. C. Duance, Cardiff University
612 Binding o f recombinant PRG4 domains to candidate proteins (ELISA)
Microtitre plates (96-well, Elkay Products, Basingstoke, UK) were coated overnight (16 hours) at 
4°C with 0.05 - 2pg  candidate binding protein in PBS (100 p i o f  0.5-20pg/m l). Candidate 
binding protein-coated wells and negative controls w ere then w ashed 3 tim es w ith PBS 
(300fil/well) and were incubated with 5%  [w/v] BSA in PBS (200pl/w ell) for 1 hour at room 
temperature to block non-specific protein binding. After 3 washes with 300pl/well PBS, lp g  o f 
purified recombinant PRG4 domain (N-term inal FLAG fusion protein) was added to each well 
(lOfig/ml in PBS, lOOpl/well) and incubated at room tem perature for 1 hour. Unbound PRG4 
protein was removed by washing with PBS (4 times) and bound protein was detected using anti- 
FLAG M2 alkaline phosphatase-conjugated m onoclonal antibody. The mAb preparation was 
diluted by a factor o f 1:10,000 in 1% [w/v] BSA in PBS, to give a protein concentration o f  
HOgg/ml, and the resultant solution was added to the microtitre plate (lOOpl/well) for 1 hour at 
room temperature. Unbound antibody was rem oved with 5 washes o f PBS (300pl/w ell). The 
colourimetric alkaline phosphatase substrate p-nitrophenyl phosphate (PNPP, Sigm a-Aldrich 
UK) was dissolved in substrate buffer (0 .9 1M diethanolam ine, 0.126mM  M gCL, pH 9.8) 
according to the manufacturers instructions (1 tablet/5ml) and added to wells (lOOpl/well). Plates
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were incubated with the substrate for 1 -  2 hours at 37°C and absorbance values were read at 
405nm using a Labsystems Multiskan MS plate reader.
6.2.3 Co-immunoprecipitation o f  bovine recombinant PRG4 C-terminal domain with 
candidate binding proteins
Aliquots o f purified recombinant bovine C-terminal PRG4 (30pg) were incubated with candidate 
binding proteins (30pg) in 0.5ml TBS (50mM Tris-HCl, pH 7.4, 0.15M NaCl) at 37°C for 2 
hours, before addition to anti-FLAG M2 agarose (Sigma). Aliquots o f FLAG M2 agarose (40pl) 
were prepared in 1.5ml Eppendorf tubes using 80pl o f a 50% [v/v] stock solution. Prior to use 
with the sample, the resin was washed with TBS (3 x 0.5ml), pre-eluted with 3 portions o f 0.5ml 
0.1M glycine-HCl, pH 3.5 and washed again with TBS (3 x 0.5ml). For each wash and elution 
step, the resin was centrifuged at 10,000 x g for 5 seconds and allowed to settle for 1 -  2 minutes 
before the removal o f supernatant with a syringe attached to a 19G 1/2 needle (M icrolance), and 
for the acidic elution step the resin was incubated for 5 minutes at room temperature with gentle 
shaking before centrifugation. Following these pre-elution and washing procedures, the sample 
mixture was added to the resin and incubated at room tem perature for one hour w ith gentle 
agitation. The sample was removed and the resin was washed 3 times with 0.5ml TBS to remove 
unbound protein. Bound proteins were eluted with 3 x lOOpl aliquots o f glycine-HCl, pH 3.5 and 
placed into a tube containing 5pl o f 1.5M Tris-HCl, pH 8.8. Eluent fractions were separated on 
15% Tris-glycine SDS-PAGE gels which were silver stained using the method described in 
section 2.2.9.
6.2.4 Analyses o f interaction between recombinant PRG4 domains and HA by affinity 
blotting
Affinity blotting with biotinylated hyaluronan was performed as described in chapter 2, section 
2.2.11. Briefly, preparations o f purified or partially purified PRG4 domains were separated by 
SDS-PAGE (using 15% Tris-glycine gels) under reducing and non-reducing conditions and 
transferred to nitrocellulose. As a positive control for HA binding, 5pg o f  a preparation o f  link 
protein was used that runs at 45 kDa and binds HA under non-reducing conditions (bovine nasal 
cartilage A1D4 fraction, prepared by Dr. C. R. Flannery). Membranes were blocked and blotted 
as described in section 2.2.11, but with a six hour incubation in the presence o f biotinylated HA,
188
and development was with NBT/BCIP substrate (chapter 2, section 2.2.1.7) as for W estern 
blotting experiments.
6.2 .5 Immunocytochemistry with bovine chondrocytes
6 .2 .5 . P repara tion  o f  bovine superfic ia l zone chondrocyte m onolayer cultures fo r  
immunocytochemistry
Im m unocytochem istry was used to study the binding o f PRG4 domains to chondrocytes. 
Superficial zone chondrocytes were isolated from bovine metacarpophalangeal articular cartilage 
by pronase and collagenase digestion as described in chapter 2, section 2.2.2. Cells were then 
seeded at an initial density o f 0.8 x 106 cells/ml in DMEM supplemented with 5% [v/v] FCS and 
50pg/m l gentamicin. Cells were cultured on 100mm tissue culture dishes within the wells o f 
FlexiPerm slides (In Vitro Systems & Services GmbH, Gottingen, Germany), which were 
attached in order to divide each dish into 8 culture chambers, each with a culture volume o f 
0.5ml. Chondrocytes were incubated at 37°C with 5% CO2 for 48 hours prior to binding 
experiments, in order to allow the re-establishment o f the cell surface glycocalyx that was likely 
to have been perturbed during the enzymatic isolation o f  the cells from the cartilage matrix.
6.2.5.2 Addition o f  recombinant PRG4 domains and FLAG immunocytochemistry 
To remove serum proteins after pre-culture, each monolayer culture chamber was washed twice 
with serum free DMEM (0.5ml/chamber), incubated for 1 hour at 37°C with the same medium 
and washed a further two times. PRG4 domains and BSA for control experiments were added at 
concentrations o f 10-50pg/ml in serum free DMEM with an incubation o f 2 hours at 37°C. For 
competition experim ents with heparin, PRG4 domains (10-50pg/m l) were incubated with 
lOOpg/ml heparin (sodium salt from porcine intestinal mucosa, Sigma H3419) at 37°C for 1 hour 
before addition to chondrocytes. Cells were then washed twice with serum free DMEM and twice 
with PBS before fixation with ice-cold methanol/acetone [1:1 v/v]. Plates were allowed to air dry 
and were stored at -20°C. At this point part o f the culture dish with fixed monolayers was excised 
from the rest o f the culture dish with a hot scalpel to facilitate m icroscopy following 
immunocytochemistry. To detect bound PRG4 domains, cells were rehydrated with PBS/0.01% 
[v/v] Tween-20 (PBS-T) before the addition of alkaline phosphatase-conjugated anti-FLAG M2 
monoclonal antibody (lOfxg/ml in PBS-T). Following an overnight incubation at 4°C unbound
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antibody was rem oved by four 2 minute washes w ith PBS-T prior to addition o f  alkaline 
phosphatase substrate (Vector Red kit, Vector). Levamisole (Vector) was included in the reaction 
mixture to quench any endogenous alkaline phosphatase activity. Following development, cells 
were washed in water and increasing concentrations o f  methanol, cleared in xylene and mounted 
in DPX. Positive staining was viewed using a Nikon Labphot 2 microscope.
6.3 Results & Discussion
6.3.1 Analysis o f  recombinant N-terminal PRG4 domain interactions with other matrix 
molecules by ELISA
ELISA-based binding assays were used to examine the interactions between recombinant N- 
term inal PRG4 dom ain proteins and other m atrix molecules. These included plasm inogen 
activator inhibitor type 1 (PAI-1), fibronectin fragments and type II collagen. In all o f  these 
preliminary ELISA experiments, the candidate binding proteins were immobilised on a multiwell 
plate (solid phase) before the additions o f  recombinant PRG4 (solution phase).
6 .3 .1 .1  Analysis o f  recom binant N -term inal PRG4 domain interactions with plasm inogen  
activator inhibitor-1 (PAI-1)
Plasminogen activator inhibitor type 1 (PAI-1) is a serine proteinase inhibitor that is the primary 
inhibitor o f  both tissue- and urinary-type plasminogen activators (tPA and uPA). It has been 
im plicated in the processes o f  haem ostasis, angiogenesis, tissue rem odelling and tumour 
metastasis. PAI-1 has a brief half-life as an inhibitor because o f the spontaneous insertion o f its 
reactive centre loop (RCL) into the main p-sheet o f  the molecule (Mottonen et a l ,  1992). The 
biological activity o f  P A I-1 is stabilised by binding to the 70 kDa glycoprotein vitronectin, an 
interaction thought to be mediated by the somatomedin B (SMB) domain comprising o f the first 
44 residues o f  vitronectin (DePrada et a l ,  2002; Seiffert & Loskutoff, 1991; Okumura et a l ,  
2002). The SMB dom ain has been isolated from human serum as a separate soluble protein 
(Standker et a l ,  1996), and contains eight Cys residues arranged in four disulphide bonds, 
suggesting a com pact structure. Treatment o f  the isolated SMB domain with reducing agents 
abolishes PAI-1 binding (Seiffert et a l ,  1997), and conversion o f any o f  the eight Cys residues to 
Ala also abolishes PAI-1 binding activity (Deng e ta l ,  1996a).
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PRG4 contains two somatomedin B-like domains in exons 2 and 3 that display -45%  sequence 
homology with the SMB domain o f vitronectin (Flannery et al., 1999; Merberg et al., 1993), and 
each contains eight cysteine residues in identical positions to the SMB domain of vitronectin (for 
a diagrammatic representation see chapter 1, figure 1.15). Flannery et al. (1999) suggested that 
the SMB-type domains o f PRG4 could function as a PAI-1 binding region in a similar manner to 
the SMB domain o f vitronectin. This was investigated in this study by means of an ELISA-based 
solid phase binding assay to examine the potential interaction between the recombinant N- 
terminal PRG4 domains (described in chapters 3 and 4) and recombinant PAI-1. Different 
amounts of human recombinant PAI-1 (Calbiochem) were immobilised on an ELISA plate before 
the addition o f a constant amount o f recombinant N-terminal PRG4. After removal of unbound 
recombinant PRG4, bound PRG4 domain protein was detected by an alkaline phosphatase 
conjugated anti-FLAG monoclonal antibody.
The results from the first o f these experiments can be seen in figure 6.1. Recombinant human N- 
terminal (exons 2-5) PRG4 domain (HumN) was used in this case. The two HumN species 
described in chapter 3 were purified as two populations and used separately in identical binding 
assays. After initial purification o f  both species by FLAG immunoaffinity chromatography, the 
two species were separated by heparin-agarose affinity chromatography -  HumNl binds to 
heparin-agarose whereas HumN2 does not. Results from using the 27 kDa HumNl species are 
shown in figure 6.1 A, results using the 16 kDa HumN2 species are shown in figure 6. IB. The 
results o f the PAI-1 binding assay with the individual species, as shown in figure 6.1, 
demonstrated that both HumN 1 and HumN2 bind to immobilised PAI-1, and that binding o f both 
human recombinant PRG4 N -term inal domain species increased in relation to increasing 
concentrations o f PAI-1 im m obilised on the plate. However, this interaction appeared to be 
saturable at a PAI-1 coating concentration o f 1 (mg/well and above. Similar results were observed 
with the bovine recombinant N-terminal PRG4 domain protein species BovNl and BovN2, as 
illustrated in figures 6.2A and 6.2B, respectively. The higher absorbency values observed with 
BovN2 were produced by a longer incubation time in the developing solution.
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Figure 6.1 -  A nalysis of hum an recom binant PRG4 N -term inal dom ain (Hum N) 
in te rac tio n s  with PAI-1 by ELISA. Different amounts o f PAI-1 were immobilised before the 
addition o f  1 jig Hum Nl (A) or HumN2 (B), followed by detection of recombinant PRG4 protein 
with A P -co n ju g a ted  anti-FLAG M2 monoclonal antibody. Experiments were conducted in 
triplicate, and  bars are included to illustrate standard error.
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H um N l/B ovN l and HumN2/BovN2 contain an N-terminal FLAG epitope as assessed by 
Western blotting, and only H um N l/BovN l contain a heparin binding site (as assessed by 
heparin-agarose affinity chromatography), so it is likely that both proteins contain exons 2 and 3 
(see chapter 4, figure 4.9). Based on these predicted structures for the two recombinant N- 
terminal PRG4 domain species, an interaction between PAI-1 and the N-terminal domain o f 
PRG4 may be mediated by the two SMB-type domains present within exons 2 and 3, and thus 
does not involve the heparin binding domain.
6 .3 .1 .2Analysis o f  recombinant N-terminal PRG4 domain interactions with fibronectin  
fragments
Similar ELISA-based binding assays were used to assess the binding o f recombinant N-terminal 
PRG4 domain proteins to commercially available proteolytic fragments o f human fibronectin 
(Fn) as well as full-length bovine fibronectin. Fn is a classical example o f a protein with a 
modular structure, possessing several functional domains that can be separated by limited 
proteolysis. Separated domains retain their functionality in isolation (Ruoslahti et al., 1981), and 
may influence cellular activity independently (Woods et al., 1986). Synthesis o f fibronectin is 
upregulated in OA and RA, and proteolytic Fn fragments may potentially regulate cartilage 
metabolism (for a review see Homandberg, 1999). Homandberg and others showed that the 
addition of certain proteolytic fragments of Fn to bovine cartilage explant cultures induced the 
degradation o f cartilage, as assessed by the release of MMPs and proteoglycan into the culture 
medium (Homandberg et a l ,  1992). Intact fibronectin did not induce these effects. Levels o f 
fibronectin in OA cartilage show a marked increase near the articular surface (Rees et a l ,  1987) 
and in synovial fluid (Scott et a l ,  1981). As PRG4 is present at the articular surface (Schumacher 
et a l ,  1999) and in synovial fluid (Jay et a l ,  2000), the potential interaction between fibronectin 
fragments and PRG4 was investigated in this study. Initially, a N-terminal 70 kDa fragment o f 
human fibronectin was immobilised on an ELISA plate at increasing concentrations in the range 
of 0-2pg/well, and a constant amount (lp g ) o f recombinant N-terminal PRG4 domain was added. 
Bound PRG4 domains were detected with an AP-conjugated anti-FLAG M2 monoclonal 
antibody. Repeat experiments were conducted with the 45 kDa and 30 kDa fibronectin fragments.
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Figure 6.2 -  Analysis of bovine recombinant PRG4 N-terminal domain (BovN) interactions 
with PAI-1 by ELISA. Different amounts o f PAI-1 were immobilised before the addition o f lp g  
BovNl (A) or BovN2 (B), followed by detection o f recombinant PRG4 protein with AP- 
conjugated anti-FLAG M2 monoclonal antibody. Where experiments were conducted in 
triplicate, mean absorbency values were plotted and bars are included to illustrate standard error.
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Figure 6.3 shows the results o f these experiments with BovNl (figure 6.3A) and HumNl (figure 
6.3B). Both BovNl and HumNl appeared to interact with the immobilised 70 kDa Fn fragment, 
with interaction increasing proportionally with the amount o f Fn fragment immobilised. This 
interaction was not saturable with the protein concentrations used. It would be interesting to 
investigate the Fn fragment binding potential o f the HumN2 and BovN2 recombinant N-terminal 
PRG4 domain species. Interestingly, no discem able interaction was observed between the 
recombinant PRG4 N-terminal domain species and full-length bovine fibronectin. Similar 
experiments with 45 kDa and 30 kDa proteolytic N-terminal fragments o f human fibronectin 
have not revealed an interaction with recombinant N-terminal PRG4 proteins (see figure 6.3). 
These results are similar to work with cartilage oligomeric matrix protein, or COMP, which is 
seen to interact with the 70 kDa Fn fragment but not other isolated domains (DiCesare et al., 
2002).
6.3.1.3 Analysis o f  recombinant N-terminal PRG4 domain interactions with type II  collagen 
ELISA-based binding assays were also used to investigate the potential interaction between 
recombinant N-terminal PRG4 domains and immobilised bovine type II collagen, and the results 
are seen in figure 6.4. Type II collagen was immobilised in increasing amounts and a constant 
amount (lp g ) o f BovNl (figure 6.4A) or H um N l (figure 6.4B) was added, and bound 
recombinant protein was detected with an anti-FLAG monoclonal antibody. An interaction was 
observed, although more experiments need to be conducted to determine the strength o f this 
interaction.
6.3.1.4 Analysis o f  recombinant N-terminal PRG4 domain interactions with vitronectin 
Merberg and others, in their 1993 paper on MSF precursor protein, alluded to a potential 
interaction between PRG4 and vitronectin (Merberg et al., 1993). In this study, vitronectin from 
human plasma (Sigma) was immobilised in increasing concentrations on a microtitre plate, and 
ELISA binding assays were conducted using similar conditions to the experiments described 
above. However, under these conditions no interaction was observed between recombinant N- 
terminal PRG4 domains and immobilised vitronectin (data not shown).
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Figure 6.3 -  Analysis of bovine and hum an recom binant PRG4 N -term inal domain 
interactions with proteolytic fragm ents of hum an fibronectin by ELISA. Fibronectin 
fragments were immobilised in increasing concentrations prior to the addition of lp g  BovNl (A) 
or HumNl (B), followed by detection o f recombinant PRG4 protein with AP-conjugated anti- 
FLAG M2 monoclonal antibody. Where experiments were conducted in triplicate, mean 
absorbency values are plotted and bars are included to illustrate standard error.
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Figure 6.4 — Analysis of bovine and hum an recom binant PRG4 N -term inal dom ain 
interactions with bovine type II collagen by ELISA. Increasing concentrations (0-lpg/w ell) o f 
bovine type II collagen were immobilised before the addition of lp g  BovNl (A) or Hum Nl (B), 
followed by detection o f recombinant PRG4 protein with AP-conjugated anti-FLAG M2 
monoclonal antibody.
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6.3.2 Analysis o f  recombinant bovine C-terminal PRG4 domain interactions with other 
matrix molecules by ELISA
Similar assays to the experiments described above were used to study the interactions between 
the recombinant bovine C-terminal PRG4 domain and candidate binding proteins, but a high 
level of background binding activity was observed with the blocking reagents used, which 
included BSA, skimmed milk, ECL blocking reagent (Pierce) and deoxycholate (data not shown). 
This indicated that non-specific binding o f the recombinant C-terminal PRG4 domain to the 
blocking reagents was occurring, ruling out the use o f ELISA as a binding assay for this protein. 
Other methods were used to study the interactions o f this protein, and these are described in the 
following section.
6.3.3 Co-immunoprecipitation o f  recombinant bovine C-terminal PRG4 domain with 
fibronectin fragments
As discussed in section 6.3.1.2, Fn fragments have the ability to affect cartilage metabolism, and 
are present in the synovial fluid and at the articular surface o f osteoarthritis patients. The ability 
of Fn fragments to interact with the vitronectin-like, haemopexin domain-containing C-terminal 
region of PRG4 was investigated in this study by co-immunoprecipitation. Bovine recombinant 
C-terminal PRG4 (BovC, described in chapters 3 & 4) was incubated with the 30 kDa, 45 kDa or 
70 kDa proteolytic fragments o f human fibronectin before immunoprecipitation o f  BovC (and 
BovC-containing complexes) using anti-FLAG M2 agarose. Eluent fractions were separated by 
SDS-PAGE under reducing conditions and visualised by silver staining, and the results can be 
seen in figure 6.5. In all lanes there are two contaminating protein species running at 25 and 50 
kDa, indicated with dashed arrows, and it is likely that these contaminants are the heavy and light 
chains of the immunoglobulin proteins that have leached from the FLAG immunoaffinity resin. 
Lane 4 shows a control precipitation with BovC alone, and the two BovC species at -2 0  kDa and 
12 kDa are visible. These two species can also be seen in lanes 5, 6 and 7, where they appear to 
have been co-precipitated with the 30 kDa, 45 kDa and 70 kDa fragments o f fibronectin, 
respectively. The migration positions o f  Fn fragments are indicated with arrows. This 
demonstrates an interaction between the C-terminal domain of PRG4 and proteolytic fragments 
of fibronectin.
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Figure 6.5 -  Co-im m unoprecipitation of bovine recom binant C -term inal PRG4 domain 
(BovC) and fibronectin (Fn) fragm ents. BovC was incubated with Fn fragments before 
immunoprecipitation using anti-FLAG M2 agarose. Eluents were separated by SDS-PAGE  
(15%) under reducing conditions and proteins were visualised by silver staining. Fibronectin 
fragments were run alone, these are shown in the left panel. Migration o f  molecular size 
standards is shown to the left.
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6.3.4 Analysis o f  the interaction between recom binant PRG4 domains and HA by affinity  
blotting experiments
In chapter 2 of this study, the potential interaction between purified full-length PRG4 molecules 
and HA was examined by means of affinity blotting experiments using biotinylated HA (section 
2.3.6), and in this procedure there was no visible interaction between HA and human 
recombinant and bovine cartilage full-length PRG4 molecules. The potential interaction between 
HA and PRG4 was examined again, using purified recombinant PRG4 domains in a similar 
affinity blotting procedure with biotinylated HA. Recombinant PRG4 domains and a positive 
control (BNC A1D4) were separated on 15% SDS-PAGE gels under native and reducing 
conditions and transferred to nitrocellulose before a HA affinity blotting procedure. Under native 
conditions, the A1D4 link protein preparation, running at around 45 kDa, reacted with 
biotinylated HA. No bands were apparent for the N-terminal PRG4 domains under either native 
or reduced conditions (data not shown). A faint band at 30 kDa was seen relating to the bovine 
recombinant C-terminal domain protein (BovC) under non-reducing conditions (data not shown). 
This is the region of PRG4 most likely to interact with HA: exons 8-9 o f  PRG4 contain 
haemopexin-like domains similar to vitronectin, and haemopexin is a serum haeme-scavenging 
protein that has been shown to interact with HA (Hrkal et al., 1996). The procedure was repeated 
with different amounts of BovC (5pg and30^ig), and the results are illustrated in figure 6.6, which 
shows BovC and A1D4 proteins under native and reduced conditions. Figure 6.6A shows an 
affinity blot with biotinylated HA, figure 6.6B shows a control blot performed in the absence of 
biotinylated HA. As seen in figure 6.6, lane 3, there was a strong interaction between link protein 
(-45 kDa) and biotinylated HA under native conditions. As shown in the control blot in 6.6B, 
there appeared to be background binding activity between the streptavidin-AP conjugate and 
BovC under reducing and non-reducing conditions. However, the intensity o f staining is 
increased in the presence of biotinylated HA (figure 6.6A) under native and reduced conditions, 
which raises the possibility that there is an interaction between BovC and HA.
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Figure 6.6 -  Analysis of the interaction between recom binant bovine C -term inal PRG4 
domain (BovC) and hyaluronan (HA) by affinity blotting. In (A), proteins were separated 
under native and reduced conditions and probed with biotinylated HA. A bovine nasal cartilage 
A1D4 preparation containing link protein is used as a positive control (lane 3, 5irg/lane). In (B), 
the procedure was repeated in the absence o f  biotinylated HA as a negative control. Migration o f  
size standards is shown to the left.
2 0 1
6.3.5 An investigation into interactions between chondrocytes and recombinant PRG4 
domains using immunocytochemistry
PRG4 is homologous to megakaryocyte stimulating factor (MSF) precursor protein, and the -25 
kDa N-terminal domain o f MSF precursor has been shown to have cell proliferative effects on 
haemopoetic tissue (Merberg et al., 1993). This, together with the observation in this study of 
active heparin-binding sites in recombinant N- and C-terminal PRG4 domains, prompted an 
investigation into the potential o f  these recom binant PRG4 domains to interact with 
chondrocytes. Bovine superficial zone chondrocytes were isolated and cultured in monolayer for 
48 hours to allow for the regeneration o f cell surface proteoglycans before the addition o f 
recombinant PRG4 domains. Bound protein was detected using an anti-FLAG monoclonal 
antibody. Figure 6.7 shows experim ents using recom binant PRG4 N -term inal domain 
preparations, and figure 6.8 shows similar experiments with the bovine recombinant C-terminal 
PRG4 domain. Within both figures, negative controls are shown where PBS alone or BSA diluted 
in PBS was incubated with chondrocytes before immunocytochemistry. The control experiments 
shown in figure 6.7 are duplicated in figure 6.8, as experiments with the N- and C-terminal 
domains of PRG4 were conducted at the same time.
6.3.5.1 Immunocytochemistry o f  bovine superficial zone chondrocyte monolayer cultures after 
incubation with human and bovine recombinant N-terminal domains
All four of the available recombinant N-terminal PRG4 domain species (H um N l, HumN2, 
BovNl and BovN2) were used in this set o f experiments. As seen in figure 6.7, no staining was 
observed when recombinant N-terminal domain species were incubated with superficial zone 
chondrocytes (panels A-D), as staining was at a level that is comparable seen with the BSA- 
supplemented and untreated controls shown in figure 6.7, panels E and F. This data suggests that 
there is no interaction between the N-term inal domain o f PRG4 and superficial zone 
chondrocytes in monolayer culture.
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Figure 6.7 -  Im m unocytochem ical analysis o f bovine superfic ial zone chondrocyte  
m onolayer cultures a fte r incubation  w ith recom binan t PRG4 N -term inal dom ains.
Monolayer cultures were incubated for 1 hour in the presence o f  recombinant PRG4 N-terminal 
domains, which were diluted in a fmal volume o f 0.5ml PBS. Concentrations can be seen beneath 
each panel. Cells were fixed and immunocytochemistry was performed using an AP-conjugated 
anti-FLAG M2 monoclonal antibody to detect recombinant FLAG fusion proteins.
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6.3.5.2 Immunocytochemistry o f  bovine superficial zone chondrocyte monolayer cultures after 
incubation with bovine recombinant C-terminal domains
The results o f experiments with the recombinant bovine C-terminal domain (BovC) can be seen 
in figure 6.8. Staining was seen with BovC at 20pg/m l (figure 6.8, panel A), and this positive 
staining increased at a BovC concentration o f 50pg/ml (panel B). This suggests that under the 
conditions used there is an interaction between BovC and superficial zone chondrocytes cultured 
as a monolayer. In a duplicate set o f cell culture chambers, recombinant PRG4 domains were pre­
incubated with lOOpg/ml heparin at 37°C for 1 hour prior to their addition to the chondrocyte 
monolayers. This was performed in order to assess whether the heparin-binding ability o f the 
PRG4 domains (documented in chapter 4) had any effect on the binding o f  the recombinant 
proteins to chondrocytes in monolayer. The pre-incubation with heparin was intended to saturate 
the heparin-binding sites o f the recombinant proteins. In the experiments where BovC was pre­
incubated with heparin, staining for the FLAG epitope appears to be greatly reduced in 
comparison with experiments with BovC in the absence o f heparin (figure 6.8, panels C and D). 
This data suggests a potential interaction between the recombinant C-terminal domain o f PRG4 
and the chondrocyte, or matrix component(s) surrounding the chondrocyte, which may be 
mediated by cell surface heparan sulphate proteoglycans.
6.4 Discussion
PRG4, a protein that is known by many terms including lubricin, SZP, CACP protein and MSF 
precursor protein, is a protein/proteoglycan that is found in a number o f tissues, including at the 
surface o f articular cartilage and in synovial fluid. The determination o f the amino acid sequence 
of PRG4 led to the prediction that it is, potentially, a multifunctional, multidomain protein. 
Chapters 3 and 4 o f this study describe the production, purification and characterisation o f the N- 
and C-terminal domains o f  PRG4. These are domains that have a number o f  similarities to 
functional domains in other proteins such as vitronectin, and some o f these potential functions 
were preliminarily investigated in this chapter.
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Figure 6.8 -  Im m unocytochem ical analysis o f bovine superfic ial zone chondrocy te  
monolayer cultures after incubation with recom binant bovine PRG4 C -term inal dom ain
(BovC). Monolayer cultures were incubated for 1 hour in the presence o f  recombinant bovine 
PRG4 C-terminal domain diluted in a final volume o f 0.5ml PBS, which in some instances were 
subjected to a pre-incubation with lOOpg/ml heparin. PRG4 domain concentrations are displayed 
below each panel. Cells were fixed and immunocytochemistry was performed using an AP- 
conjugated anti-FLAG M2 monoclonal antibody to detect recombinant FLAG fusion proteins.
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Plasminogen activator inhibitor type 1 (PAI-1) is a serine proteinase inhibitor that is the primary 
physiological inhibitor o f tissue and urokinase-type plasminogen activators (tPA and uPA), and is 
an important regulator o f proteolytic events in the circulation and in the extracellular matrix (for 
a review, see Wind et a l ,  2002). PAI-1 is a conformationally labile molecule that is stabilised by 
an interaction with vitronectin. Other functions o f  PA I-1 include a modulation o f cell motility 
based on its interaction with vitronectin, a result o f  the modulation o f the interaction between 
vitronectin and the urokinase receptor uPAR caused by the binding o f PAI-1 (Okumura et a l ,
2002). PAI-1 is unstable in solution and decays into an inactive inhibitor (Ti/2 ~ 2 hours), but is 
stabilised by binding to vitronectin such that its half-life is increased by up to four-fold, longer 
when vitronectin is incorporated into the ECM (Declerck et al., 1988; M imuro & Loskutoff, 
1989). There is a bulk of evidence to suggest that this interaction is mediated by the somatomedin 
B domain o f vitronectin (Seiffert & Loskutoff 1991; Deng et al., 1996b; Seiffert, 1997; Deng et 
al., 2001; Kamikubo et al., 2002). The N-terminal portion o f PRG4 contains 2 regions that 
display sequence homology with the SMB domain o f vitronectin, and sequence analyses o f PRG4 
by Flannery (1999) and Tudor (2002) have proposed a vitronectin-like function for this region of 
PRG4. In this study, binding assays were conducted with immobilised human PAI-1 and 
solution-phase recombinant PRG4 N-terminal domain proteins, and a saturable interaction was 
demonstrated. These results describe an interaction between recombinant N-terminal domains o f 
human and bovine PRG4 and the serpin PAI-1, which may be mediated by the 2 SMB-type 
domains in exons 2 and 3 o f PRG4. More experimentation is necessary to determine whether or 
not this is the case, and work with the SMB domain o f vitronectin provides a num ber o f 
indicators in this respect. For example, mutational analyses o f the SMB domain o f vitronectin 
coupled with the use of monoclonal antibodies have pinpointed the region o f the SMB domain 
that is critical for PAI-1 binding (Royle et al., 2001), and crystal structure analysis o f the PAI-1 -  
vitronectin complex has elucidated which residues on each molecule are involved in the 
interaction (Zhou et a l ,  2003). The PRG4-PAI-1 interaction could also be studied by a 
competitive binding approach, as in the method used to examine the Vitronectin-PAI-1 
interaction: solution phase PAI-1 was bound to immobilised vitronectin and displaced by the 
addition o f solution phase vitronectin (Lawrence et al., 1997). Sedimentation equilibrium 
ultracentrifugation has been used to assess the stoichiometry o f the PAI-1 -  vitronectin 
interaction, and a high molecular weight complex has been described involving four PAI-1
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molecules and two vitronectin molecules (Podor et a l . , 2000). Jensen and others have produced a 
recombinant PAI-1 mutant that lacks vitronectin binding activity (Jensen et a l ., 2004), and it 
would be interesting to see if such a mutant also lacks PRG4 binding activity. A popular method 
of defining protein-protein interactions is BLAcore analysis (reviewed in Nedelkov & Nelson,
2003), and this could be applied to the potential PRG4-PAI-1 interaction as it has been for the 
vitronectin-PAI-1 interaction (Kamikubo et a l ., 2002). Broadly speaking, a large number of 
methods to facilitate the study of serpin-ligand interactions exists (for a review see Patston et a l.,
2004), and these techniques could be used in the context of PRG4 interactions with serpins.
Although slightly capricious at this stage, it is interesting to consider the role that a PRG4 -  PAI- 
1 interaction could play in the synovial joint. PRG4 could stabilise PAI-1 in a manner similar to 
vitronectin, and may cause its localisation to specific regions in the synovial joint: synovial fluid 
and the articular surface. From these points, PAI-1 may have an effect on the fibrinolytic cascade, 
which may in turn influence the plasmin-mediated activation of MMPs. Osteoarthritic 
synoviocytes have been shown to produce PAI-1 and other fibrinolytic factors (Matucci-Cerinic 
et a l., 1998), and there is fibrinolytic activity in the synovial membrane of OA (Matucci-Cerinic 
et a l., 1990). PAI-1 production has been documented in chondrocytes (Treadwell et a l., 1991), 
and may be influenced by various cytokines and growth factors (Campbell et a l., 1991; Campbell 
et a l., 1994), although its exact role in healthy and diseased synovial tissue is yet to be elucidated. 
Urokinase has been shown to induce arthritis (Jin et a l., 2003), and the influence of PAI-1 on 
factors such as uPA, an active component of inflamed synovial fluid, may turn out to play a part 
in joint inflammation. The plasminogen activator/plasmin system is altered in RA (for a review, 
see Busso & Hamilton, 2002), as is apparent with the accumulation of fibrin in RA joints. 
Vitronectin synthesised by rheumatoid synovial cells inhibits plasmin generation (Tomasini- 
Johanssen et a l ,  1998), which could be demonstrative of the potential effect of the Vitronectin- 
PAI-1 interaction. Increased levels of plasmin, uPA and PAI-1 have been demonstrated in OA 
chondrocyte cultures (Martel-Pelletier et a l ,  1991). The expression and secretion of PAI-1 is 
attenuated in chondrocytes treated with IL-1, an effect that can be reversed with NSAID 
treatment (Sadowski & Steinmeyer, 2002). The expression of PRG4 has been shown to be 
downregulated by IL-1 (Flannery et a l., 1999; Tudor, 2002), and decreased levels of serpins in 
synovial fluid may induce cartilage breakdown. Plasminogen added to cartilage explants
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increases degradation, which can be stopped by the addition o f serpins (Olesyszyn & Augustine, 
1996).
Recombinant bovine and human N-terminal PRG4 domains were found to interact with a 70 kDa 
proteolytic N-terminal fragment o f fibronectin as assessed by an ELISA binding assay, with 
fibronectin in solid phase and PRG4 in solution phase. The N-terminal 70 kDa fibronectin 
fragment contains both heparin- and gelatin-binding domains, although no binding was observed 
with the isolated heparin (30 kDa) or gelatin (45 kDa) domains. This is similar to the COMP- 
fibronectin interaction (DiCesare et al., 2002), and may suggest that N-terminal PRG4 binds to 
the junctions of the two fibronectin domains, or that the PRG4 binding site on the 70 kDa 
fragment is conformationally altered by proteolysis. No interaction was observe between PRG4 
and intact bovine fibronectin. The bovine recombinant C-terminal domain o f  PRG4 (BovC) was 
co-purified with the 30 kDa, 45 kDa and 70 kDa proteolytic fragments o f fibronectin in co- 
immunoprecipitation experiments using a FLAG agarose gel specific to the FLAG-tag o f BovC. 
This suggests an interaction between three N-terminal proteolytic fragments o f fibronectin and 
BovC. Fibronectin fragments are potential regulators o f cartilage metabolism. W hilst intact 
fibronectin has little effect when added to chondrocytes in vitro, proteolytic fragments have been 
found to be active, and may contribute to the protease-mediated damage to cartilage (for a review 
see Homandberg, 1999). PRG4, present on boundary surfaces o f the synovial jo in t and in 
synovial fluid, may have an anti-inflammatory effect in stopping fibronectin fragments from 
reaching cells. Co-localisation studies could be performed and other fragments o f fibronectin 
could be used, such as intact fibronectin and the 170 kDa fibronectin fragment seen in arthritic 
synovial fluid (Peters et al., 2003).
Preliminary ELISA-based binding assays demonstrated an interaction between bovine type II 
collagen and recombinant PRG4 N-terminal domain protein species. This interaction may be 
structurally important for the attachment o f PRG4 to the articular surface, and such an interaction 
would provide the firm anchor that would be necessary for PRG4 to perform as a boundary 
lubricant. Binding assays should also be performed with other macromolecular components of 
the articular surface such as decorin, biglycan and fibromodulin (Noyori et al., 1998). It may also 
be interesting to investigate a potential interaction between PRG4 and type I collagen, as another
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macromolecule that has been shown to be present at the articular surface (Eyre, 1978; Duance, 
1983).
Affinity blotting experiments with purified BovC and biotinylated HA indicate that there may 
well be an interaction between the C-terminal domain o f PRG4 and HA. This interaction was 
proposed in 1992 following the retention o f bovine synovial fluid lubricating factor (homologous 
to PRG4) with HA on a 0.22pM  filter (Jay et al., 1992). C-terminal truncating mutations of 
PRG4 are characteristic o f the disease CACP (Marcelino et al., 1999), and synovial fluid from 
patients with CACP displays a lower coefficient o f friction than a lubricin-HA solution (Jay et 
al., 2003). This has led Jay and co-workers to suggest that the loss o f lubricating ability in CACP 
patients may be associated with a loss o f PRG4-HA interaction caused by a C-terminal truncating 
mutation. PRG4 contains haemopexin-like domains in exons 8 and 9 o f PRG4 that may be 
involved in a HA interaction (Jay et a l ,  2000), and data presented here points towards this. A 
numbei of other methods could be utilised to further investigate the potential interaction between 
BovC and HA, and these are discussed in chapter 2, section 2.4. Intra-articular hyaluronate 
injections have recently been used for treatment o f osteoarthritic knee joints, although a placebo 
effect makes the benefit o f this procedure difficult to assess (for a review see Kirwan, 2001). 
Tentative discussions are taking place regarding the replacement o f PRG4 in diseased joints, and 
if a HA-PRG4 interaction exists there is scope for intra-articular injections to develop in this 
manner.
Immunocytochemical analyses have demonstrated an interaction between BovC recombinant 
PRG4 domain and bovine superficial zone chondrocytes cultured in monolayer, an interaction 
that seems to be attenuated by the addition o f heparin. However, further experimentation will 
help to elucidate the details of this potential interaction, such as the use o f chondrocytes from the 
superficial, middle and deep zones o f articular cartilage as well as other cell types. The precise 
reason for the observed interaction between the recombinant C-terminal domain o f PRG4 and 
superficial zone chondrocyte monolayer cultures still needs further investigation, as there are a 
number o f other possibilities that could explain this interaction. Other work suggests that 
superficial zone chondrocytes isolated by pronase and collagenase digestion retain some fibrous 
residual matrix in comparison to their counterparts from the deep zone (Pfister et al., 2001). This
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residual matrix contains a number o f known matrix components including type VI collagen, link 
protein, CH65, annexin V, COMP and fibromodulin. So BovC added to monolayer cultures in 
this experiment may be binding to (a) the cell surface, or (b) components o f a retained or newly 
synthesised matrix surrounding the chondrocytes. Similar culture systems and experimental 
procedures could be used to determine if  PRG4 has any metabolic effects on cells, as predicted 
by a number o f studies. M egakaryocyte stimulating factor (MSF) is in essence a -25  kDa 
proteolytic N-terminal fragment o f PRG4, and was first isolated from the urine o f patients 
undergoing bone marrow transplantation during a period o f acute thrombocytopaenia (Merberg et 
al., 1993). This protein has been shown to stimulate growth in megakaryocyte colonies from 
bone marrow fibrin clot cultures, and it would be interesting to determine whether or not the N- 
terminal PRG4 domain produced in this study has a sim ilar proliferative effect on 
megakaryocytes, or on other cell types, including chondrocytes.
Whilst the experiments described in this chapter raise a number o f interesting questions regarding 
the interactions of PRG4 with other molecules, a more detailed determination o f the structure and 
molecular weights of the recombinant PRG4 proteins used in this study would assist in the 
description of the interactions. For example, accurate molecular weights for the proteins would 
allow the calculation of KD values for each interaction. It might also be interesting to look at full- 
length PRG4 or some o f the different PRG4 splice variants known to be present within the 
synovial joint with respect to their binding capabilities, especially as different splice variants may 
possess different binding activities. Different expression constructs could be assembled that 
represent different splice variants o f PRG4 that have been seen in various tissues and cell types, 
such as synovial fluid, synoviocytes, monocytes, chondrocytes, heart, liver, lung and brain. The 
functional implications o f these different splice variants may well indicate that PRG4 is a 
modular protein, in a similar way to fibronectin. Mutational analysis o f PRG4 and domains 
thereof, used in conjunction with binding assays, could localise protein-protein binding sites. The 
PRG4 domain catabolites described in chapter 5 o f this study could also be used in binding 
assays following characterisation. In summary, the results presented in this chapter point towards 
the interaction o f the N- and C-terminal domains o f PRG4 with structural and functional 
molecules. These properties would be in addition to the well-documented boundary lubricating 
activity of the central mucinous region of PRG4 (Jay et a l , 2001a; Swann et al., 1985).
2 1 0
6.5 Chapter Summary
• Preliminary ELISA data provided in this chapter suggests that there are potential 
interactions between:
- the recombinant N-terminal domain o f  bovine and human PRG4 and human PAI-1, and 
that these interactions may be mediated by a somatomedin B domain
- the recombinant N-terminal domain o f PRG4 and the 70 kDa proteolytic fragment of 
human fibronectin, but not intact fibronectin or 45 kDa/30 kDa proteolytic fragments
- the N-terminal domain o f PRG4 and type II collagen, the major structural component of 
articular cartilage
• Co-immunoprecipitation experiments demonstrated potential interactions between the 
recombinant C-terminal domain o f bovine PRG4 and the 30 kDa, 45 kDa and 70 kDa 
proteolytic fragments o f human fibronectin.
• Affinity blotting experiments have revealed a potential interaction between recombinant 
C-terminal domain o f bovine PRG4 and hyaluronan, which may be im portant in 
pathologies that directly involve PRG4
• The recombinant C-terminal domain o f bovine PRG4 appears to interact with superficial 
zone chondrocytes from bovine articular cartilage
211
7. GENERAL DISCUSSION
PRG4 was fist described as a lubricating fraction from bovine synovial fluid (Radin et a l , 1970; 
Swann & Radin, 1972), and was later given the term Tubricin’ (Swann et al., 1985). Although 
the initial descriptions o f the lubricin occurred in the early 1970s, lubricin research has only 
seemed to gather pace in the last 10-12 years. Charles W. McCutchen, a crucial theorist in the 
field o f joint lubrication, ascribes this lull in lubricin research to the existence o f a National 
Institutes o f Health (NIH) study section “cabal in joint lubrication” (McCutchen, 1995). In a 
lecture given in 1990, McCutchen stated that “in 1984, NIH decided to end its support o f David
Swann’s research on lubricin  For NIH to support no work on lubricin is grotesque”
(McCutchen, 1990). Publications concerning lubricin started to re-appear in the early 1990s. 
Since then, lubricin has been found to be homologous to megakaryocyte stimulating factor 
precursor protein (Jay et al., 2000) and cartilage superficial zone proteoglycan (Flannery et a l ,  
1999; Jay et a l ,  2001), which are products o f the HGNC-named PRG4 (proteoglycan 4) gene. 
Sequence analyses of this gene (Merberg et a l ,  1993; Flannery et a l ,  1999) have indicated that 
the PRG4 gene product may have functions other than boundary lubrication, as vitronectin-like 
domains lie either side of the central mucin domain. The aims o f this study were to (i) investigate 
the potential multifunctionality o f the PRG4 molecule using recombinant non-mucin domains o f 
PRG4, (ii) to further characterise full length PRG4, and (iii) to determine the susceptibility o f 
PRG4 to a variety of matrix proteinases that may be present in an arthritic joint.
Broadly speaking, recent PRG4/SZP/lubricin/MSF precursor protein/CACP protein publications 
have been centred on one or more o f the following aspects:
• The boundary lubricating function o f PRG4/lubricin at the surface o f articular cartilage, 
as documented within initial papers by Swann and others, and more recently in numerous 
publications from the laboratories o f Gregory D. Jay;
Immunolocalisation of PRG4 in tissues and body fluids using monoclonal antibodies;
• Analysis of PRG4 mRNA expression in various tissues including the identification of 
splice variants;
• Sequence analyses o f PRG4;
• The effect of cytokines and growth factors on regulation of PRG4 expression;
• Description o f CACP syndrome, the disease resulting from truncated mutations o f PRG4.
2 1 2
Functional analyses o f  PRG4 have, to date, primarily been concerned with the boundary 
lubricating properties o f the molecule at the surface o f articular cartilage (Radin et al., 1970; 
Swann et al., 1972; Jay et al., 1998). The two schools o f thought with respect to lubrication by 
PRG4 are (i) that the molecule is the primary boundary lubricant in the synovial joint (Jay et al, 
2001b) and (ii) that PRG4 is a carrier for surface-active phospholipid (SAPL), which is the true 
boundary lubricant (Hills et al., 2003). Sequence analyses o f the PRG4 gene by Merberg et al. 
(1993) and Flannery et al. (1999) have ascertained that PRG4 displays some sequence homology 
to the serum adhesive glycoprotein vitronectin, indicating that PRG4 may have other functional 
properties besides lubrication. One o f the aims o f this study was to investigate these vitronectin­
like domains using different types o f  PRG4 species. Summaries o f the major papers concerning 
PRG4/SZP/MSF/lubricin/CACP protein are shown in chronological order in table 7.1, and the 
findings o f this thesis are summarised at the bottom o f the table. Figure 7 shows a schematic 
representation of the full-length PRG4 molecule, and annotations detail the potential functions o f 
the molecule as determined by this and other studies.
Data shown in this study demonstrate the heparin-binding capability o f PRG4. Full length human 
recombinant, bovine articular cartilage and bovine tendon PRG4 were able to bind to a heparin- 
agarose affinity chromatography matrix. Heparin affinity purification o f native bovine tendon 
PRG4 from the conditioned medium o f deep digital flexor tendon explant cultures represents a 
novel method for obtaining native PRG4. Both the N- and C-terminal structural domains o f 
PRG4 contain heparin-binding consensus sequences (Cardin & W eintraub, 1989), and 
experiments with recombinant PRG4 domains have shown that both these sites are functionally 
active. Heparin-binding sites within PRG4 may serve to anchor PRG4 to molecules within the 
lamina splendens o f articular cartilage as proposed by Jay and others (Jay et al., 2001b). It may 
also contribute to an interaction between PRG4 and chondrocytes: data in chapter 6 o f this study 
shows that the recombinant C-terminal region o f bovine PRG4 was able to interact with bovine 
superficial zone chondrocytes, and that this interaction was perturbed by the addition o f heparin. 
It is interesting to consider the existence o f PRG4 molecules that lack one or both o f the heparin- 
binding sites in exons 4 & 10. A PRG4 gene product has been found in synovial fluid that 
contains only exons 6-9 (Jay et al., 2000), and PRG4 mRNA lacking exons 4 & 5 has been found 
in OA chondrocytes (Flannery et al., 1999) and tendon fibroblasts (Rees et al., 2002). Further
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Table 7.1 -  Summary o f published articles/abstracts concerning PRG4
Author(s) Year Summary
Radin et al. 1970 Separation o f  a lubricating fraction from synovial fluid
Swann & Radin 1972 Purification and characterisation o f  lubricating fraction from bovine synovial fluid
Swann et al. 1981 Lubricating glycoprotein-1: purification, lubricating ability, binding to cartilage
Swann et al. 1985 Lubricin from different synovial fluids: lubricating ability and molecular structure
Jay 1992 Lubricating ability o f  purified synovial lubricating factor (PSLF)
Jay & Hong 1992 Purified synovial lubricating factor lubricates, salivary mucin does not
Jay et al. 1992 Retention o f  purified synovial lubricating factor with H A on a 0.22pm  filter
Merberg et al. 1993 Comparison o f  structural and functional aspects o f  MSF and vitronectin
Schumacher et al. 1994 SZP isolated from culture medium o f  bovine SZ cartilage explant cultures
Bahabri et al. 1998 Description o f  CACP syndrome; genetic mapping to chromosome lq25-31
Jay et al. 1998 Healon (rooster comb HA) displays less boundary lubricating ability than lubricin
Schwarz & Hills 1998 Surface-active phospholipid (SAPL) as a lubricating component o f  lubricin
Flannery et al. 1999 Hom ology o f  cartilage SZP & MSF; analyses o f  amino acid sequence & potential 
functions; inhibition o f  biosyntheis by IL-1, upregulation by T G Ff and IGF-1
Marcelino et al. 1999 Description o f  truncating mutations in CACP protein (PRG4) in CACP syndrome
Schumacher et al. 1999 Monoclonal antibodies to bovine SZP (6 -A -l & 3-A-4); immunodetection o f  SZP 
at articular surface, synovium, synovial fluid and predominantly SZ chondrocytes
Ikegawa et al. 2000 PRG4 expression in cartilage, liver, lung, heart, bone; tissue-specific splice variants
Jay et al. 2000 Homology o f  lubricin from synovial fibroblasts with exons 6-9 o f  MSF
Jay et al. 2001a Lubrication by lubricin mediated by O-linked (3(l-3)GalNAc oligosaccharides
Jay et al. 2001b Homology o f  SZP, lubricin and MSF; localisation to chromosome lq25
Schmid et al. 2001 SZP concentration in human serum ~126pg/m l, normal synovial fluid ~159pg/m l
Su et al. 2001 Cross-species SZP mAbs; SZP immunodetection in synovial fluid, plasma, serum
Rees et al. 2002 Detection o f  SZP on the surface o f  mature fibrocartilaginous bovine tendon
Schmid et al. 2002 Purified SZP binds to fibronectin, BSA, HA (ELISA binding assays)
Tudor 2002 Immunohistochemical analyses, purification & characterisation o f  PRG4
El-Garf et al. 2003 Description o f  CACP syndrome among Egyptians
Jay et al. 2003a Altered frictional characteristics o f  CACP knockout m ice joints
Jay et al. 2003b Synovial fluid from CACP syndrome patients lacks boundary lubricating ability
Klein et al. 2003 Engineering o f  articular cartilage from chondrocyte subpopulations; SZP detection
Morawietz et al. 2003 Lubricin overexpression: a factor in prosthesis loosening?
Schmid et al. 2003 Distribution o f  SZP in OA cartilage: SZP in regions o f  matrix damage
Schumacher et al. 2003 Immunolocalisation o f  SZP in m eniscus
Benya et al. 2003 Upregulation o f  SZP synthesis by TGF|3 and T A K -la  (TGF(3 activated kinase-1)
Brass et al. 2003 SZP promoter region analyses: IL-1 (3 may suppress SZP expression
Berthelot 2004 Hypothesis: could RA result from abnormal T cell response to SZP/lubricin?
Kutsumi et al. 2004 Lubricin in canine intrasynovial tendon; improves gliding o f  extrasynovial tendon
Schmidt et al. 2004 Detection o f  SZP in cartilage explants: inhibition by IL-1 a , upregulation by TGF0
Schumacher et al. 2004 Localisation o f  SZP in osteoarthritic cartilage: expression appears to be upregulated
Jones 2004 Full length PRG4: heparin binding, glycosylation profiles, purification o f  tendon 
PRG4 from explant cultures, degradation by candidate proteinases 
R ecom binant dom ains o f  PRG4: heparin binding, g lycosy la tion  profiling, 
interaction with matrix proteins (fibronectin fragments, PAI-1), possible interaction 
with HA, interaction with SZ chondrocytes, degradation by proteinases
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Exons 2-5 Exon 6 Exons 7-12
PROPOSED BIOLOGICAL FUNCTIONS
•Boundary lubrication 
(Jay et al. 2001b)
•Cytoproection/ 
anti-adhesion 
(Flannery et al. 1999; Jay 
et al. 2004. manuscript in 
preparation)
•Megakaryocyte
stimulation
(Merberg et al.. 1993)
•70kDa fibronectin 
fragment binding
•PAI-1 binding
•Heparin binding
•3-A-4 mAb epitope 
(bovtne)
•6-A-1 mAb epitope 
(bovine. Schumacher et 
al., 1999)
•Heparin binding
•Fibronectin fragment 
binding
•CACP syndrome 
(Marcelino et al. 1999)
SZ chondrocyte binding
Self aggregation
Figure 7 — Proposed functions of PR G 4/SZ P/lubricin/M SF p recu rso r pro te in /C A C P  
protein, illustrated using a schematic representation of the molecule. Functions proposed by 
this study are shown in italics. Abbreviations; Vn -  vitronectin-like domain; SMB — 
somatomedin B homology; HBR -  heparin binding region; Muc -  mucin-like repeat region; Agg 
-  potential aggregation domain (uneven number of cysteines); mAb -  monoclonal antibody.
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studies could examine the PRG4-heparin interaction more closely using techniques such as 
BIAcore analysis.
Data from lectin affinity blot experiments with full length PRG4 from three different sources 
(bovine cartilage, bovine tendon & human recombinant) have established that different full 
length PRG4 species share sim ilar patterns o f  glycosylation. In particular, both human 
recombinant and bovine cartilage PRG4 displayed affinity with the lectin PNA, which recognises 
galactose linked |3(l-3) to N -A cetylgalactosam ine, and this interaction was used in the 
purification of PRG4 using a PNA lectin-agarose affinity chromatography matrix. Sequence 
analyses of the recombinant PRG4 domains produced by this study indicated likelihood o f O- and 
N-linked oligosacchride substitutions, and these were investigated by lectin affinity blotting and 
deglycosylation experiments. Deglycosylation experiments documented the presence o f an N- 
linked oligosaccharide in the C-terminal domain o f PRG4 whilst lectin affinity blotting data 
showed that O-linked oligosaccharides are present in the N-terminal domain. These data show 
that PRG4 is glycosylated outside o f the central mucin domain.
In this study, a number of interactions between PRG4 and structural/functional molecules have 
been described by using N-terminal (exons 2-5) and C-terminal (exons 7-12) recombinant 
domains of PRG4 in binding assays. Recombinant proteins were secreted as N-terminal FLAG- 
fusion proteins using an insect cell-based expression system. The PCR cloning stage o f this 
recombinant protein expression strategy enabled the deposition o f novel PRG4 sequence to 
GenBank. Solid-phase binding assays (ELISA) have demonstrated an interaction between the N- 
terminal structural domain o f PRG4 and PAI-1, fibronectin fragments, and type II collagen. 
Immunoprecipitation experiments have demonstrated an interaction between the C-terminal 
structural domain of PRG4 and fibronectin fragments, and an interaction with HA in this region 
is also a possibility. The C-terminal region o f PRG4 also displays self-aggregation properties. 
Although preliminary in nature these results support the sequence analyses of Flannery (1999), 
who surmised that the molecule has potential matrix-binding and self-aggregating properties. The 
work would benefit from knowledge o f the 3-D structure o f PRG4, and the use o f other methods 
for determining binding kinetics. For example, the binding o f PRG4 N-terminal domain to PAI-1 
could localise PAI-1 to the articular surface, and could hold the molecule in an active
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conformation in a similar manner to vitronectin (Mimuro & Loskutoff, 1989). The vitronectin -  
PAI-1 interaction is mediated by the somatomedin B domain o f vitronectin (Seiffert & Loskutoff, 
1991), and mutational studies could be used to determine whether or not the two somatomedin B 
domains of PRG4 stabilise a similar interaction. Sulphated GAGs have an effect on the PAI-1 -  
vitronectin interaction (Seiffert, 1997), and may affect a PRG4 -  PAI-1 interaction. A number of 
methods exist for the examination o f serpin-ligand interactions, reviewed in Patston et al. (2004).
The potential for PRG4 in cytoprotection and cell proliferation (Flannery et a l., 1999) have not 
been investigated in this study, although a good place from which to start might be the use of 
recombinant PRG4 domains in culture systems to look for these effects -  immunocytochemical 
data in this study has demonstrated an interaction between superficial zone chondrocytes and the 
C-terminal structural domain o f PRG4. The addition o f fibronectin fragments to cartilage cultures 
has been shown to promote proteoglycan degradation (reviewed by Homandberg, 1999), and the 
addition of fibronectin fragment-binding PRG4 domains to this system may have modulative 
effects.
It is interesting to consider the hypothesis that different types o f PRG4 gene product perform 
different functions based on their location. As can be seen in table 7.1, the tissue distribution of 
PRG4 is widespread, and there are a number o f different PRG4 molecular weight species and 
splice variants. The synovial joint is probably the best example to use in the expansion o f this 
hypothesis, although PRG4 expression has been documented in bone, liver, heart, lung, brain 
(Ikegawa et al., 2000) and body fluids such as serum (Schmid et al., 2001). Immunolocalisation 
studies have detailed the presence o f PRG4 at the surface o f articular cartilage, in synovial 
fibroblasts (Schumacher et al., 1999), in chondrocytes of the superficial zone (Schumacher et al., 
1994), in synovial fluid (Schumacher et al., 1999), in meniscus (Schumacher et al., 2003) and on 
the surface of mature compressed tendon (Rees et al, 2002). A series o f PRG4 mRNA splice 
variants have been found to be expressed by articular chondrocytes and synovial fibroblasts (Jay 
et al., 2001b), and a PRG4 mRNA variant lacking exons 4 & 5 is expressed by osteoarthritic 
chondrocytes (Flannery et al., 1999). Several PRG4 species of different molecular weights have 
been purified from synovial joint tissue. A 345 kDa isoform can be purified from superficial zone 
chondrocyte (Schumacher et al., 1994) and tendon explant cultures (chapter 2 of this study), and
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isoforms o f 315 kDa (Schumacher et al., 1999) and 280 kDa (Jay et al., 2001b) have been 
purified from synovial fluid. Lower m olecular weight isoforms (100-150 kDa) have been 
detected in the culture medium o f superficial zone chondrocytes (Tudor, 2002). The significance 
of these different forms o f PRG4 is yet to be understood. This study has contributed to the 
understanding of this situation, as functions have been preliminarily ascribed to the N-terminal 
(exons 2-5) and C-terminal (exons 7-12) structural domains o f PRG4 by the use o f recombinant 
proteins. This approach could be augmented as and when novel forms o f PRG4 are described in 
the synovial joint: expression constructs could be made in order to produce recombinant PRG4 
molecules that mimic PRG4 species seen in vivo. It would also be interesting to investigate the 
functional properties of recombinant PRG4 proteins that are truncated in a similar way to proteins 
seen in CACP syndrome (Marcelino et a l., 1999). For example, a symptom o f CACP syndrome is 
synovial hyperplasia, so the effect o f differently truncated recombinant PRG4 variants on 
synovial fibroblasts could be investigated. The effect o f different physiological factors on the 
expression of PRG4 gene products, such as the influence o f cytokines and growth factors, is also 
an area that has not been extensively investigated. Future studies will no doubt expand on the 
data already available, that IL-1 downregulates and TGFp upregulates expression o f cartilage 
PRG4 (Flannery et al., 1999). Preliminary studies into the PRG4 promoter region have already 
been conducted using the popular luciferase reporter system (Brass et al., 2003).
The cellular source of PRG4 at various locations in the synovial joint is unclear. For example, the 
layer of PRG4 on the surface o f articular cartilage may equally be from chondrocytes or synovial 
fibroblasts. It may be that there is a population o f PRG4 that is adsorbed onto the surface o f 
articular cartilage through a cartilage-binding domain, and that there is another population o f 
PRG4 in synovial fluid that lacks this domain. However, it may be that there is a ‘floating’ 
population o f PRG4 within synovial fluid, and that a certain amount o f this material is adsorbed 
on the surface o f tissues such as synovium, meniscus and cartilage. Jay has proposed an 
interaction between PRG4 and hyaluronic acid (HA) (Jay et al., 2003b). HA is abundant in 
synovial fluid and is used as a treatment for arthritis in the form of intra-articular injections. I f  
PRG4 is depleted in diseased synovial fluid and cartilage, it may be useful within intra-articular 
injections in terms o f working towards an injection that would help to revert synovial fluid back 
to a ‘normal’ physiological composition. However, there is much debate as to the efficicacy of
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intra-articular HA injections, and the proteolytic conditions within an inflamed joint may cause 
injected PRG4 to be quickly degraded.
Although the role of PRG4 in arthritic diseases is unclear, its presence on the surface of cartilage, 
meniscus and synovium, at the boundary between jo in t tissue and synovial fluid, infers 
significance for the molecule, particularly in osteoarthritis where cartilage wears out from the 
surface downwards. In this thesis, preliminary data is present that documents the degradation of 
full length PRG4 by a number o f enzymes that could be present in the synovial joint, namely 
elastase, MMP-7, plasmin and cathepsin B. Matrix proteinase-mediated digestion o f PRG4 could 
affect the functional properties o f the molecule, and could therefore compromise the integrity o f 
the surface of articular cartilage. However, it would be capricious to speculate too much as to the 
significance of these in vitro digests in relation to the situation in vivo. Attempts in this study to 
selectively digest the non-mucin domains o f full length PRG4 with chym otrypsin were 
unsuccessful, as degradation o f the molecule as a whole occurred. This may explain the results 
seen by Jay and others (Jay et al., 2001b), where PRG4 digested with chymotrypsin displayed an 
increased coefficient o f friction in comparison to undigested PRG4. Jay et al. proposed that 
chymotrypsin digestion would remove non-mucin domains o f PRG4, and that these domains also 
contribute to the boundary lubricating properties o f PRG4. Whilst this may still be true, data in 
this study shows that chymotrypsin digests PRG4 as a whole.
Collectively, the data in this thesis provides novel information concerning the biochemical 
functions o f PRG4 gene products. With the exception o f lubrication, the specific functional 
properties o f PRG4 have not been fully investigated within the synovial joint, and these findings 
advocate a potential multifunctional role for PRG4. This work points towards the interaction o f 
PRG4 with both structural and functional molecules including heparin, fibronectin fragments and 
PAI-1. The future challenge is to relate these properties, along with the lubricating properties of 
the central mucinous region o f PRG4, to healthy and diseased tissues in which the molecule is 
present such as articular cartilage.
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10. APPEN D ICES 
A PPENDIX A -L IST  O F SUPPLIERS
Table A1 -  List of materials used in this project and their suppliers
Supplier Materials/Equipment
Anachem Ltd. 
Luton, UK
0.5ml & 1.5ml Eppendorf tubes
Applied Biosystems 
Perkin-Elmer UK 
Warrington, UK
RT-PCR reagents, sequencing reagents and machinery
Amersham Pharmacia Biotech 
St.Albans, Herts., UK
UltroSpec2000 spectrophotometer
Beckman Instruments Ltd. 
High Wycombe, UK
Chromatography columns, Western blot transfer tanks & power packs, 
agarose gel electrophoresis power packs
Bio-Rad Laboratories Ltd. 
Hemel Hemstead, UK
J-25 centrifuge, L-60 ultracentrifuge
Boehri nger-Mannheim (Roche) 
Lewes, UK
Pronase from Streptomyces griseus
Calbiochem (CN Biosciences 
Ltd.)
Human mutant plasminogen activator inhibitor-1, calpain II
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Beeston, UK
Cambio
Cambridge, UK
6X running buffer for agarose gel electrophoresis, DNA molecular 
markers
Cambrex Ltd. 
Wokingham, UK
SeaKem agarose
Coming Costar Ltd. 
High Wycombe, UK
Tissue culture plastic
Fisher Scientific 
Loughborough, UK
Acetic acid, hydrochloric acid, sodium hydroxide, methanol, ethanol, 
industrial methylated spirit, xylene
Invitrogen Ltd. 
Paisley, UK
Oligonucleotide primers, Drosophila S2 cell line, Drosophila 
Expression system (DES), pMT/BiP/V5-His A, B, C plasmid vectors, 
pCoHYGRO plasmid vector, calcium phosphate transfection kit, 
TOP 10 E. Coli, FLAG M2 agarose, FLAG M2 AP conjugate mAb, 
Precast polyacrylamide gels & running equipment. All tissue culture 
media, serum and supplements
In vitro Systems and Services 
GmBH
Gottingen, Germany
Flexiperm slides
Millipore Ltd. 
Watford, UK
All 0.22pM filters, Milli-Q Plus 185 unit, Milli-RO unit, Immobilon 
P^ transfer membrane, Centriplus YM10 centrifugal filters
Nalgene
Milton Keynes, UK
Cryovials
National Diagnostics 
Hessle, UK
Acrylagel and bis-acrylagel
Novagen (CN Biosciences Ltd.) 
Beeston, UK
Enterokinase
Oxoid
Basingstoke, UK
PBS tablets
Promega Corporation 
Southampton, UK
Restriction endonucleases, Wizard plasmid miniprep kits, Taq 
polymerase, T4 DNA ligase, anti-mouse secondary antibody (AP 
conjugate), BCIP/NBT substrate for AP
Qiagen Ltd. 
Crawley, UK
EndoFree plasmid prep kits, QIAquick gel extraction kit, RNeasy RNA 
isolation kit
R & D Systems Ltd. 
Abingdon, UK
pTAg plasmid vector
Roche Diagnostics Ltd. 
Lewes, UK
DIG Glycan differentiation kit
Schleicher and Schuell Ltd. 
London, UK
Protran BA nitrocellulose transfer membrane
Sigma-Aldrich Ltd. 
Poole, UK
General use laboratory chemicals, SOC medium, ampicillin, tri­
reagent, fibronectin, EDGLY protein deglycosylation kit, anti-rabbit 
secondary antibody (AP conjugate), trypsin, chymotrypsin, plasmin, 
elastase, cathepsins B and D, heparin (sodium salt),
Spectrum Laboratories 
Rancho Dominguez, CA, USA
Spectra/Por dialysis membrane
Techne
Burlington, NJ, USA
Technegene thermal cycler
Vector Laboratories Ltd. Levamisole, Vectastain ABC-AP kit
Wothington Biochemical Corp. 
NJ, USA
Type 13 collagenase from Clostridium histolyticum
Wyeth
Cambridge, MA, USA
Human recombinant ADAM TS-4 and -5, CHO-MegK and CHO- 
1 MegN141 cell lines, polyclonal anti PRG4 antibodies 06A10,
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APPENDIX B - VECTOR DATA
Table B1 -  Index o f vectors described in this section, together with their supplier, uses, and
figure number reference
Vector name Supplier Features Figure
pTAg R & D Systems TA cloning vector, incorporating AmpR 
and LacZ  genes to confer ampicillin 
resistance and to facilitate blue-white 
screening of transformants
B1
pMT/BiP/V5-His A, B, 
C
Invitrogen Expression vector for use in the 
D r o s o p h i l a  Expression System 
(Invitrogen). Transformants are ampicillin- 
resistant. Metallothionein promoter® and 
BiP signal sequence allow for inducible, 
secreted expression of recombinant protein
B2
pCoHYGRO Invitrogen Transformants are ampicillin-resistant. 
When co-transfected with pMT vector, can 
generate stable Drosophila S2 cell lines 
expressing recombinant proteinb
B3
aThe Drosophila metallothionein promoter is described in (Bunch et al., 1988).
bVector confers resistance to Hygromycin B, an aminocyclitol antibiotic that inhibits protein 
synthesis through a dual effect on mRNA translation (Cabanas et a l., 1978). Resistance is 
conferred by the hygromycin B phosphotransferase gene, which catalyses the phosphorylation o f 
the 4-hydroxyl group on the cyclitol ring (hyosamine), producing 7’-0-phosphoryl-hygromycin 
B which lacks biological activity (Pardo et al., 1985).
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pTAg SEQ 5' primer T7 Promoter-
GCT ATG ACC ATG ATT ACG CCA AGC TCT AAT ACG ACT CAC JEAT AGG GAA AGC 
CGA TAC TGG TTC TAA TGC GGT TCG AGA TTA TGC TGA GTG ATA TCC CTT TCG
PsH  Insert
-Mlu. J S naB L. sam H i g gg fli. I
TCG GTA CCA CGC ATG CTG CAG ACG CGT TAC GTA TCG GAT CCA GAA TTC GTG ATT J 
AGC CAT GGT GCG TAC GAC GTC TGC GCA ATG CAT AGC CTA GGT CTT AAG CAC TA TT|
Sal I 
ACC I
jbtoC.lL JdiDSL
AvrW _ M )g..
XhSLl S t e l -
jtea. l
TCT GTC GAC AAG CTT CTC GAG CCT AGG CTA GOT CTA GAC CAC ACG TGT GGG GGC 
A^A CAG CTG TTC GAA GAG CTC GGA TCC GAT CGA GAT CTG GTG TGC ACA CCC CCG
CCG AGC TCG CGG CCG CAC AAT TCA CTG GCC GTC GTT TTA CAA 
GGC TCG AGC GCC GGC GTG TTA AGT GAC CGG CAG CAA AAT GTT 
____________________________________ pTAg SEQ 3' primer___________
Figure B1 -  Vector map and polylinker details o f  the pTAg vector
f l  o ri
Kan*
C o ld
ori
LaeZ
A m p*
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Com m ents for pMT/BiP/V5-His A
3642 nucleotides
Metallothtonem promoter, bases 412-778 
Start ot transcription, base 778 
MT Forward priming site, bases 814-831 
BiP signal sequence, bases 851-904 
Multiple cloning site: bases 906-999 
V5 epitope tag bases 1003-1044 
Potyhistidine region bases 1054-1074 
BGH Reverse priming site, bases 1094-1111 
SV40 late potyadenytation signal, bases 1267-1272 
pUC origin, bases 1765-2438 (complementary strand) 
bla promoter, bases 3444-3542 (complementary strand)
AmpiclBin {bla) resistance gene OftF: bases 2583-3443 (complementary strand)
@  Invftrogerr
IfllB technologies
6xHts
pMT/BiP/V 5-His 
A, B, C
3.6 kb
* Frame-cJspeoEjent wirialioos 
X te  l and Apa I are found only in ventwne A and B
Sac It is found only n  veraxxi B
B-000612 fiSF. II n  found onfy m veroun C
Figure B2 -  Vector map and poly linker details o f the pMT/BiP/V5-His A, B, C vector
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*@ Invitrogen
life technologies
pCoHygro
Comments for pCoHygro 
4526 nucleotides
copia promoter: bases 500-746
Hygromycin resistance gene bases 781-1830
SV40 early polyadenylation sequence: bases 2146-2280
pUC origin bases 2648-3321 (complementary strand)
Ampicillin {bla) resistance gene, bases 3466-4326 (complementary strand) 
bla promoter bases 4327-4425 (complementary strand)
Figure B3 -  Vector map o f the pCoHYGRO selection vector
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APPENDIX C -  ABSTRACTS & PRESENTATIONS
ABSTRACTS
Jones A.R.C., Hughes C.E., Wainwright S.D., Flannery C.R., Little C.B. & Caterson B. (2003) 
Degradation o f PRG4/SZP by matrix proteases. Transactions o f  the Orthopaedic Research Society 
28:133
Jones A.R.C., Hughes C.E., Wainwright S.D., Flannery C.R. & Caterson B. (2003)
PRG4 N- and C-terminal domains: cloning, expression and characterisation.
Transactions o f  the Orthopaedic Research Society 29: 576
ORAL PRESENTATIONS
677th Meeting of the Biochemical Society, Cardiff University, Wales, June 2002
XVIIIth Meeting o f the Federation o f European Connective Tissue Societies, Brighton, UK, July 2002
678th Meeting of the Biochemical Society, Imperial College, London, UK, December 2002
49th Meeting of the Orthopaedic Research Society, New Orleans, USA, February 2003
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